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Synthetic cathinones represent threatening and high abuse-potential designer drugs. These
are analogs of cathinone (the β-keto analog of amphetamine (AMPH)) a naturally
occurring stimulant found in the plant Catha Edulis. Methcathinone (MCAT) was the first
synthetic analog of cathinone to be identified in 1987 by Glennon and co-workers and it
exerted its action primarily through the dopamine transporter (DAT). Most central
stimulants exert their action via monomaine transporters by causing either the release (e.g.
cathinone analogs such as MCAT) or by preventing the reuptake (e.g. cocaine) of the
neurotransmitter dopamine (DA) thus increasing the extracellular synaptosomal
concentration of this neurotransmitter. In 2010, a new class of designer cathinone-like
drugs called ‘bath salts’, initially a combination of methylenedioxypyrovalerone (MDPV),

xxvii
methylone (methylenedioxymethcathione, MDMC) and mephedrone (MEPH), soared to
popularity. It caused extremely detrimental side effects; it was exceedingly popular for its
recreational use and posed a threat to public health. At the time, their mechanisms of action
were unknown. Our group identified that MDPV produced actions distinct from other
cathinone analogs (i.e., it was identified as the first cathinone-like compound to act as a
reuptake inhibitor at the dopamine transporter (DAT)). These findings suggested that not
all cathinone-like compounds act uniformly and this insinuated that unique structural
features on the cathinone scaffold might contribute to different effects at the transporter
level. The overall goal of this project was to study the mechanisms of action of synthetic
cathinones (including ‘bath salts’) at the monoamine transporters. We investigated the
contribution of each of various structural features on the cathinone scaffold (i.e, the
terminal amine, α and β positions, and the phenyl ring). We also constructed homology
models of the human dopamine and serotonin transporters (hDAT and hSERT
respectively) to help explain differences in selectivity between the neurochemical and
behavioral aspects of DAT and SERT. Overall we found that structural features
contributed to similar or distinctive mechanisms of action and also contributed to
selectivity at monoamine transporters. Our studies provide information that can be useful
to drug and health regulatory agencies to help prevent, treat, or curb the future abuse of
such drugs.

I. Introduction

Monoamine transporters are vital to maintaining neurotransmitter homoeostasis and a
disruption of their normal functioning can result in several disease states such as
Parkinson’s disease, depression, and attention deficit hyperactivity disorder (ADHD). In
addition to being targets for the above disease states, they are also targets for
psychostimulants, such as AMPH and cocaine.1 The mechanism of stimulant action at
monoamine transporters can be exerted via two main mechanisms. For example both
AMPH and cocaine exert their stimulant action primarily via DAT but by two distinct
mechanisms. AMPH exerts its action by causing a release of dopamine (DA) into the
synapse by acting as a substrate (or releaser)2 whereas cocaine increases synaptic DA
concentrations by preventing the reuptake of synaptic DA.3

Cathinone, the β-keto analog of AMPH, is a naturally occurring stimulant in the plant
Catha edulis.4 Its N-methyl analog, MCAT, was identified in 1987 as its first and more
potent analog. It exerted its action similar to AMPH (i.e., as a releasing agent at DAT). It
was notorious for its effects in the 1980’s.5 Between the rise of MCAT and 2010 there
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were other cathinone-like compounds but none that were extremely popular, produced
striking and harmful adverse effects or had a very high abuse potential.6

In 2010 a new class of designer drugs called “bath salts” made their debut.7 Their toxic and
bizarre effects and increased abuse potential brought them to the focus. The original
constituents of

bath salts include all, or at least one, of

methylenedioxypyrovalerone,

methylenedioxymethcathinone

or

the following:
methylone,

and

mephedrone (MDPV, MDMC, and MEPH, respectively).8 At that time their mechanisms
of action were not known. Our group reported in electrophysiological assays that MDPV
was the first synthetic cathinone to exert its action similar to cocaine (i.e., by acting as a
reuptake inhibitor).9-11 These findings suggested that structural features of cathinone-like
compounds have an integral effect on transporter action. The exact mechanism of action of
synthetic cathinones at a molecular level was not exactly understood.

Since then the last few years have seen the increasing presence, reports, and misuse of at
least a few hundred newer analogs.12,13 Bath salts can today be referred to as one or a
combination of synthetic cathinones.

In the most recent report by the European Monitoring Centre for Drugs and Drug
Addiction, synthetic cathinones were the largest group new psychoactive substances
identified (i.e., 31 out of the 101 new drugs).14
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It is thus significant that the mechanisms of action of synthetic cathinones be investigated
to not only delineate their actions but also provide information to help regulate such drugs
and also provide predictions as to what the next generation of synthetic cathinones could
be.
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II. Background

A. Synthetic cathinones: A brief introduction
“Synthetic cathinones” represent a novel class of abused drugs whose widespread abuse,
especially in the last five years, globally, has called for immediate attention. Synthetic
cathinones, though recognized only recently, are analogs of cathinone (1), a naturally
occurring stimulant in the khat plant that was identified in the early 19th century.15,16
Cathinone (1) is not an entirely new entity; in fact, it is the β-keto analog of amphetamine
(AMPH; 2). Both cathinone (1) and AMPH (2) are also referred to as phenylalkylamines
(PAAs).
NH 2

NH 2
O

CH 3

CH 3

Cathinone (1)

AMPH (2)

Over the last five years a plethora of synthetic cathinones have steadily made their way
into the illicit drug market making them one of the major classes of abused drugs, and
these are now collectively termed as ‘new psychoactive substances (NPSs)’ by the United
Nations and account for the second highest percentage (25%) of NPSs reported between
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2008-2013.12,17 Their prevalent use, ease of synthesis, availability of synthetic precursors,
and abuse has caused the scheduling of various synthetic cathinones over the years by the
Drug Enforcement Agency (DEA).18-21 Synthetic cathinones constitute a broad class of
agents, though structurally similar to each other and several other related drugs of abuse in
the PAA family, requires them to be studied individually for their mechanisms of actions at
monoamine transporters, and for their pharmacological effects.22

B. Phenylalkylamine drugs of abuse
Abused

PAAs

can

be

subdivided

into

two

broad

groups:

structurally

and

pharmacologically.23,24 Structurally, the two groups are the phenylethylamines (PEAs) and
the phenylisopropylamines (PIAs) (Figure 1), where X can be any substituent, and NR1R2
can be a primary, secondary or a tertiary amine.23 Pharmacologically, from a drug abuse
perspective, they can be classified mainly as central stimulants or hallucinogens depending
upon their stimulus generalization to the stimulant AMPH (2) or the hallucinogen DOM
(1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane) (3).24 The present study deals with
central stimulants only and examples of these will be discussed.
R1

N

R2

R1

N

R2
CH 3

X

X

Phenylethylamines
(PEAs)

Phenylisopropylamines
(PIAs)

Figure 1. General structural features of phenylalkylamines23

5

NH 2
CH 3
H 3CO
OCH 3
CH 3
DOM (3)

1. Cathinone
a. Origin
(-)Cathinone (S(-)1) is a naturally occurring stimulant found in the fresh leaves of the
shrub Catha edulis. This shrub is also called khat (qat, k’at, miraa, tschat, kat, cat, ghat,
Arabian tea, Somali tea and Abyssinian tea), and belongs to the Celastraceae family,
which is a dicotyledonous evergreen shrub.25,26 Forskal, a Swedish botanist, was the first to
scientifically describe khat in Flora-Aegyptiaco-Arabia; however the first mention of khat
was as early as the 13th century in the Ethiopian king Amda Seyon’s chronicle (as reported
by Alles et al.).25 Legend has it that a Yemeni herder first ingested khat leaves after he
observed the effects of the leaves on his goat.26

The khat plant is cultivated mainly in Yemen, South Africa, Uganda, Tanzania, Rwanda,
Zimbabwe, and certain reports also suggest Turkistan and Afghanistan (as reviewed by AlHebshi and Skaug).26 Khat is a high-income yielding crop that grows on moist hillsides at
altitudes of 1670-2590 meters with no specific conditions of soil and climate, and can
survive for about 100 years. The shrub is ready for harvesting 3-5 years from planting;
before selling them in the market, their shoots at the tip are cut during dawn and then the
leaves are wrapped in banana leaves in order to preserve their freshness and are transported
6

to the market where they are sold by early afternoon (as reviewed by Al-Hebshi and
Skaug26 and Kalix and Braenden16).

Chewing of khat leaves has been considered a social and cultural tradition especially in the
Arabian peninsula; however, they are also consumed by the working class, (i.e.; farmers,
students, and laborers), to help increase their physical and mental alertness. Khat is also
consumed in other parts of the world but more so for its recreational purposes with alcohol
and other drugs (as reviewed by Al-Hebshi and Skaug26 and Kalix and Braenden16).

The khat chewing sessions, especially for men in Yemen, are called majlis al-qat where an
estimated 100-200 g of the leaves are consumed.27 In these sessions, a group of men gather
in a warm comfortable room in the afternoon and begin to chew on the khat leaves one at a
time; the young and fresh leaves are preferred for their greater effect.27 Women, too, enjoy
these khat sessions that are called tafruta but these are limited only to older and married
women and the consumption of khat is much less compared to that used by the men.27

The khat chewing experience is described as a rather interesting one, mixed with various
pleasant and unpleasant experiences. Some of the desirable effects are experienced within
the first 2 hours of the session and can be described as those filled with increased
confidence, alertness, ability to express ones views, and animated discussions; this stage is
referred to as kayf.27 Some chewers also experience a state of detachment and are lost in
their thoughts; this stage is called as sulimania.27 Towards the end of the session some
7

people experience either an increase in stamina or sometimes even depression, paranoia
and nervousness.27

b. The active constituents of khat
The first attempt to identify the active constituents of khat was in 1887 by two scientists,
Flückeriger and Gerock, who were able to identify a basic alkaloid of unknown structure
which they called katin, and they were also able to confirm the absence of caffeine in the
leaves.28 Four years later, in 1891, Mosso also identified a basic constituent which he
named celastrine; he found that it exerted sympathomimetic-like effects in frogs (e.g.
dilation of pupils) (as reported by Alles et al.).25 In 1901 Beiter identified a basic fraction
that he was able to crystallize;29 but it wasn’t until 1930 when Wolfes purified and
identified this basic fraction found by Flückeriger, Gerock, Mosso and Beiter.30 This basic
fraction was characterized and found to be (+)norpseudoephedrine and was called cathine
(4).31 It is important to note here that these early studies were performed on dried khat
leaves due to lack of efficient transportation and the state-of-the-art separation techniques
available at that time.31
NH 2
HO

CH 3

Cathine (4)

However, the belief that cathine (4) was, indeed, the main active constituent of khat was
challenged by several scientists such as Brücke, who explained that the potency of cathine
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(4) as a stimulant was too low to account for the effects of khat leaves.32 However years
later the work by Hoffman et al. in 195533 and Alles et al. in 196125 also supported cathine
(4) as the active constituent of khat.

As indicated by Kalix,15 international attention was received on the problems associated
with khat and organizations such as the League of Nations on the Traffic of Dangerous
Drugs highlighted reports which suggested the khat plant needed further investigation.15 It
was the UN Commission on Narcotics Drugs in 1971 that suggested reinvestigation of the
active constituents of the khat plant for its active constituents, and biological effects.34 This
led the United Nations Narcotics Laboratory to investigate the fresh khat leaves in its own
laboratories in Geneva. They identified and characterized a new alkaloid from the fresh
leaves as (-)-α-aminopropiophenone which they named (-)cathinone (S(-)1), the other
enantiomer, (+)cathinone (R(+)1), was absent.4 Cathinone (1) is thus referred to as a
phenylisopropanonamine. It was found that as the plant ages, or as the cut leaves wilt,
(-)cathinone (S(-)1) is rapidly converted into cathine (4) (about 80%) and to
(-)norephedrine (20%), and the amount of (-)cathinone (S(-)1) was found to be more than
two-thirds of the total phenylalkylamine content and it is for this reason that the fresh
leaves are sold based on their cathinone content.15,16
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c. Pharmacological properties of the khat alkaloids
Due to the close structural resemblance of cathinone (1) to AMPH (2), differing only in a
β-keto group (Figure 2); it was thought that cathinone (1) might have AMPH-like
sympathomimetic and stimulant effects.
NH 2
O

CH 3

S(-)1

NH 2
O

NH 2

CH 3

NH 2

CH 3

R(+)1

S(+)2

CH 3

R(-)2

Figure 2. Structural comparison of the optical isomers of cathinone (1) with those of
AMPH (2).

i. Peripheral effects
Many studies were aimed at identifying the peripheral effects of cathinone (1) and only a
few are summarized below (Table 1). In conclusion, from these studies, it was reported
that (-)cathinone (S(-)1) has peripheral effects similar to those of (+)AMPH (S(+)2) (as
reviewed by Kalix 1984 and 1985).15,16
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Table 1.
Peripheral effects of khat consumption by humans and animals: A
comparison.15,16
Effects of khat chewing in humans

Effects of cathinone in animals

Hyperthermia

Hyperthermia (rabbits)

Arrhythmia

Positive inotropic and chronotropic effects
(guinea pig atrium)

Mydriasis

Mydriasis (Monkeys)

Increased blood pressure

Increase in blood pressure
(anaesthetized rat and cat)

ii. Behavioral effects
a. Stimulant effects
Yanagita35 conducted early investigations on the central stimulant effects of cathinone (1)
in rats for their locomotor activity. It was found that (+)AMPH (S(+)2) and cathinone (1)
were equipotent in their locomotor effects.35 Since (-)cathinone (S(-)1) was the naturally
occurring constituent of khat, its stimulant effects were of interest to be evaluated. Knoll36
evaluated (-)cathinone (S(-)1) and found it be as potent as AMPH (2) in stimulating
locomotor activity in mice.36 In a study by Glennon and Showalter,37 it was found that
(-)cathinone (S(-)1) was twice as potent as cathinone (1), slightly more potent than its (+)
enantiomer (this was also found by Rosecrans et al.),38 and was ≈7-fold less potent
compared to (+)AMPH (S(+)2) at stimulating locomotor activity in mice.37 A study by
Valterio and Kalix,39 also demonstrated that (-)cathinone (S(-)1) was less potent than
11

(+)AMPH (S(+)2) by ≈4-fold and showed an inverted bell-shaped dose-response curve
that is characteristic of stimulants.

To investigate if (-)cathinone (S(-)1) activates postsynaptic DA receptors during locomotor
activity, mice were pre-treated with DA antagonists such as haloperidol, spiroperidol, and
pimozide in concentrations found to antagonize DA; locomotor activity due to (-)cathinone
(S(-)1) was blocked.39 Reserpinization only marginally affected (-)cathinone (S(-)1) and its
hypermotility was inhibited by mazindol and nomifensine.

These studies indicated that (-)cathinone (S(-)1) has comparable effects to (+)AMPH
(S(+)2) in locomotor activity tests and also resulted in the activation of postsynaptic DA
receptors.39

Cathine (4), the other constituent of khat, was found to be a locomotor stimulant but was
10 times less potent than (+)AMPH (S(+)2).40 While evaluating the pharmacological
effects of each of the enantiomers of cathinone (1) in a locomotor activity test, both
enantiomers showed a characteristic bell-shaped curve but (-)cathinone (S(-)1) was twice
as potent as its opposite enantiomer and, in a time-course of locomotor activity study, both
had the same onset time of action, and their peak effect was reached in the same time;
however, the effect of (+)cathinone (R(+)1) decayed more rapidly.41
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b. Drug discrimination
In drug discrimination studies in rats trained to discriminate racemic cathinone from
vehicle, cathinone (1) was found to be equipotent to (+)AMPH (S(+)2) and also had
parallel dose-response curves to (+)AMPH (S(+)2) which suggested a common mechanism
of action and/or common site of action between the two drugs.42 Another drug
discrimination study by Glennon et al.,43 found that (-)cathinone (S(-)1) was 3-fold more
potent than its enantiomer, and 7-fold more potent than cathine (4) in rats trained to
discriminate cathinone (1) from saline. The effects of cathinone (1) also generalized to
other simulants such as methamphetamine (METH, 5),44 cocaine,45 and methylphenidate
(6) but failed to generalize to non-stimulant drugs such as fenfluramine (7), haloperidol,
and chlordiazepoxide.46
HN

CH 3
CH 3

HN

O HN

CH 3
CH 3

H 3CO

CF3
METH (5)

Methylphenidate (6)

Fenfluramine (7)

Also, cathinone (1) and its enantiomers were found not to have DOM-like hallucinogenic
effects in a drug discrimination study where animals were trained to discriminate DOM (3)
from vehicle indicating that cathinone (1) is not a PAA hallucinogen.47
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In a conditioned place preference assay, rats trained to discriminate (-)cathinone (S(-)1)
spent more time in a non-preferred environment ((-)cathinone associated environment) and
this effect was decreased with a dopamine antagonist CGS 10746B.48

c. Stereotypy
Another behavioral effect common to khat alkaloids and AMPH (2) was stereotyped
behavior at high doses.37,49 Stereotyped AMPH-like behavior of head movements was
observed with cathinone (1) and cathine (4) in rats and these effects were more pronounced
with cathinone (1) as compared to cathine or (+)AMPH (S(+)2). When comparing
cathinone (1), (+)AMPH (S(+)2) and cathine (4) effects to apomorphine, less
verticalization was seen. These stereotyped behaviors could be reduced either by DA
antagonists such as haloperidol or by the catecholamine synthesis blocker αmethylparatyrosine.50 Apomorphine acts postsynaptically on DA receptors and these
studies indicated that cathinone (1) exerted its effects presynaptically similar to (+)AMPH
(S(+)2).50 This finding was supported by Zelger and Carlini,51 where cathinone (1)
produced AMPH-like ipsilateral movements whereas apomorphine produced contralateral
rotation in rats with unilateral lesions of the substania nigra.

d. Anorectic effects
Knoll et al.,36 first observed the anorectic effects of (-)cathinone (S(-)1) upon
intraventricular injection and these effects were more potent than AMPH (2). Later studies
found that, when rats were given i.p. injections of cathinone (1) and cathine (4), a decrease
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in body weight was observed but that cathine (4) was less potent than cathinone (1), which
was less potent compared to AMPH (2).52 However, tolerance to cathinone (1) developed
rapidly within a week and the anorectic effects were lost after about 4 weeks of continuous
drug administration, and tolerance to AMPH (2) developed within two weeks but the
anorectic effects existed even after 7 weeks of continuous drug administration, also cross
tolerance developed for both the drugs.52 Foltin and Schuster,53 also observed anorectic
effects when they studied the effects of (+)AMPH (S(+)2) and cathinone (1) when rats
were given sweetened milk. Cross tolerance and tolerance effects were also observed in
this study which caused a shift in the dose response curve to the right by about 8- to 12fold for cathinone (1) and a smaller shift by about 2-fold for (+)AMPH (S(+)2).

e. Conditioned taste aversion
Cathinone (1), similar to other psychostimulant drugs, was found to induce conditioned
taste aversion in rats that were given sweetened milk,54 and it was also found to be less
aversive than (+)AMPH (S(+)2) by 17-fold in a conditioned taste aversion test in rats; this
implied that cathinone (1) might be a more preferred drug of abuse.55

f. Effects on primates
In order to study drug dependence behavior, monkeys were trained to lever-press for
cocaine injections. When cocaine was replaced by (-)cathinone (S(-)1), it was found to be a
more potent reinforcer and the rate of lever-pressing was increased and was higher than
that for (+)AMPH (S(+)2).56 In a drug-drug choice procedure between cocaine and
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cathinone (1) where monkeys were trained to lever-press for the choice of drug, cathinone
(1) was found to be as reinforcing as cocaine.57 Yanagita,58 evaluated (-)cathinone (S(-)1)
in a continuous self-administration assay as well as a progressive-ratio self-injection test.
In the self-administration test monkeys showed cocaine-like behavior, where the monkeys
exhibited a pattern of self-administration followed by exhaustion and stopping the selfadministration and then resumed a phase of self-administration. During this cycle, the
monkeys showed anorexia, restlessness, tremors and mydriasis. In the progressive-ratio
self-injection test, the number of blank injections the monkey is wiling to take to receive
the drug provides the maximal ratios of their effects, (-)cathinone S(-)1 had lower ratios
compared to cocaine for each dose tested.58

g. Early structure-activity relationship (SAR) studies in vivo
Several cathinone analogs were studied in various behavioral assays. In a locomotor
stimulation study in mice; cathinone analogs (Table 2), including 2-methoxy (8), 4methoxy (9), 2,4-dimethoxy (10), and 4-fluoro cathinone (11) did not produce locomotor
stimulation whereas α-desmethylcathinone (12) reduced locomotor activity.37

16

Table 2. Substituted cathinones examined in early SAR studies.37,43,59
NH 2
O

R3
R1

R2

Compound number
8

R1
OCH3

R2
H

R3
CH3

9

H

OCH3

CH3

10

OCH3

OCH3

CH3

11

H

F

CH3

12

H

H

H

13

H

Cl

CH3

14

H

OH

CH3
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CH2

H

CH2

In a discriminative stimulus study of cathinone (1) and some of its structural analogs in rats
trained to discriminate cathinone (1) from saline, it was found that cathinone-like activity
was lost for the structural analogs of cathinone (1) with substitution in the 4-position (see
Table 2) with chloro (13), hydroxyl (14) and methoxy (9) groups at doses comparable to
the training dose of cathinone (1).43 Another structure-activity study compared (-)cathinone
(S(-)1), (+)AMPH (S(+)2) and four cathinone analogs: (α-desmethylcathinone (12), 2amino-1-tetralone

(15),

β-aminopropiophenone

17

(16),

and

N,N-

dimethylaminopropiophenone (17). In the drug discrimination study rats were trained to
discriminate (+)AMPH (S(+)2) from saline; (-)cathinone (S(-)1) was the only agent that
produced AMPH-like effects; and, the former was antagonized by haloperidol.59
R
N
R1

O

16: R=R1 = H
17: R=R1 = CH 3

iii. Cellular effects
a. Dopaminergic effects
Since (-)cathinone (S(-)1) was found to produce similar behavioral and peripheral effects
as AMPH (2), it was of interest to understand if it exerted its effect presynaptically through
release of catecholamines similar to AMPH (2), or if it acted by blocking the uptake of DA
into presynaptic neurons similar to cocaine.

In experiments to measure the efflux of radioactivity in rat striatial slices labeled with
[3H]DA, (-)cathinone (S(-)1) caused a reversible and a dose-dependent efflux of [3H]DA
and also in preparations pretreated with (+)AMPH (S(+)2), (-)cathinone (S(-)1) was found
to be half as potent compared to (+)AMPH (S(+)2) in retaining radioactivity.60 The effects
of (-)cathinone (S(-)1) were reversibly blocked by cocaine similar to (+)AMPH (S(+)2).
Thus (-)cathinone (S(-)1) was found to act by a mechanism similar to (+)AMPH (S(+)2) at
dopaminergic synapses.60
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b. Adrenergic effects
Since a number of sympathomimetic cardiovascular effects were observed due to khat
consumption, the effect of (-)cathinone (S(-)1) at norepinephrine (NE) storage sites was
important to investigate. In experiments where rat atrium was prelabelled with [3H]NE a
rapid increase in efflux was observed and also it was found to be half as potent as
(+)AMPH (S(+)2). The potency of (-)cathinone (S(-)1) was found to be one order of
magnitude higher than that of (+)AMPH (S(+)2) to release DA from the central nervous
system (CNS) storage sites. Pharmacological properties similar to (+)AMPH (S(+)2) were
observed upon reserpinization, where the first dose of (-)cathinone (S(-)1) caused a greater
efflux than the untreated tissue; however, rapid development of tachyphylaxis was also
observed.61 Pretreatment with cocaine and desipramine blocked the release of NE, and for
cocaine it was shown that its efflux inhibition property was not related to its local
anesthetic properties.61 Thus, it was concluded that the peripheral side effects of khat
consumption are due to the release of NE from peripheral storage sites.61

c. Serotonergic effects
AMPH (2) has been shown to release serotonin (5-HT) in a dose-dependent manner in rat
corpus striatial tissue.62 In the case of the serotonergic system it was found that the affinity
of (-)cathinone (S(-)1) was four times greater than (+)AMPH (S(+)2) for 5-HT receptors in
the rat fundus; thus, it was important to understand if cathinone (1) exerts AMPH-like
effects at the serotoninergic system.63 In rat striatial slices pretreated with [3H]5-HT, ()cathinone (S(-)1) was one-third as potent as (+)AMPH (S(+)2) in releasing 5-HT.
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Therefore the release profile of (-)cathinone (S(-)1) is the same as that for (+)AMPH
(S(+)2) (i.e,. NE > DA > 5-HT).64

When comparing the effects of (-)cathinone (S(-)1) and cathine (4), (-)cathinone (S(-)1)
was 8 times more potent than cathine (4) in releasing DA from rat nucleus accumbens
tissue, however both were equipotent in releasing epinephrine from rat atrial tissue.65 Thus,
these results suggested that (-)cathinone (S(-)1), due to its higher lipophilicity, penetrates
the blood-brain barrier better and hence has a more CNS stimulant-type effect. Therefore,
khat leaves that are fresh and have an increased (-)cathinone (S(-)1) content are preferred,
however both (-)cathinone (S(-)1) and cathine (4) have similar extent of peripheral
effects.65 While evaluating the pharmacological effects of each of the enantiomers of
cathinone (1) for their peripheral effects in guinea pigs, no difference was observed in their
potencies.41

d. Early SAR studies in vitro
A structure-activity study compared (-)cathinone (S(-)1), (+)AMPH (S(+)2) and four
cathinone

analogs

(α-desmethylcathinone

(12),

2-amino-1-tetralone

(15),

β-

aminopropiophenone (16), and N,N-dimethylpropiophenone (17)) (Table 2) for their in
vitro effects to release [3H]DA from rat caudate nucleus. In the in vitro release assay
(-)cathinone (S(-)1) was found to be the most potent compared to its analogs except for
N,N-dimethylpropiophenone (17) which had an effect of similar magnitude.59
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2. Amphetamine
a. Background
Cathinone (1) and its analogs are structural relatives of AMPH (2). Hence, a brief review
of the pharmacology and SAR of AMPH (2) is provided here for comparative purposes.
AMPH (2) is a phenylalkylamine. It belongs to the group of PIAs,23 it was initially referred
to by its chemical name alpha-methylphenylethylamine but was given the name
amphetamine by the Council on Pharmacy and Chemistry of the American Medical
Association when they wanted to include this compound as a part of New and Nonofficial
Remedies.66 AMPH (2) was first synthesized as early as 1887 by the chemist Edeleano and
he documented the volatile amine as a phenylpropylamine. In 1910 Henry and Dale
studied AMPH (2) amongst other aliphatic and aromatic amines for their sympathomimetic
effects on decerebrate cats, but it was Alles in 1927 who synthesized racemic AMPH (2) as
its sulphate salt while he was working towards identifying synthetic substitutes for
ephedrine (18), and reported on its sympathomimetic effects.67
HN
HO

CH 3
CH 3

Ephedrine (18)

His work was patented in 1932 around the same time that the Nabenhauer from Smith,
Kline and French recommended the use of AMPH (2) as a volatile base for an inhalant to
relieve nasal decongestion.67 Alles partnered with Smith, Kline and French and the
racemate of AMPH (2) as its sulphate salt was introduced as the Benzedrine Inhaler in
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1935.67 Some of the earlier uses of benzedrine was for narcolepsy, epilepsy, postencephalic Parkinsonism, fatigue and depression.66 Bradley in 1937 studied 30 children
who had severe behavioral problems (referred to as ADHD today), and observed some
positive improvements in their school performance, emotional and psychological changes.
This study formed the basis of using AMPH (2) for the treatment of ADHD.68

Two years later Smith, Kline, and French synthesized both the isomers of AMPH (2) and
marketed the (+)AMPH (S(+)2) as dexedrine.67,68 Around 72 million tablets of benzedrine
were also supplied under the name “Energy tablets” to the British and U.S armed forces to
help troops prevent fatigue and promote alertness and stimulate energy during World War
II.66 Due to its central stimulant properties it became a popular drug of abuse and was
referred to as “Bennies” around the 1940s and 1950s. Drug abusers would crack the
inhalant open and either swallow or have with coffee or alcohol the strip soaked with
AMPH (2).69 Doctors were then vigilant about prescribing AMPH (2) and the Food and
Drug Administration (FDA) controlled its use initially by making it a prescription drug.69

METH (5) is the N-monomethyl analog of AMPH (2), and the Japanese scientist
Nagayoshi first synthesized it from ephedrine (18) in 1893 a few years after the discovery
of AMPH (2); in 1919 Ogata also synthesized METH (5) from ephedrine (18) by using red
phosphorus and iodine.70
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Today it is popularly known by several names such as; meth, crystal meth, speed, ice, jib,
crank (as reviewed by Paneka et al.).70 In the most recent 2014 UNODC report the number
of clandestine laboratories synthesizing AMPH-type stimulants has increased from 12,571
to 14,322 from 2011 to 2012 and 96% of these laboratories are producing METH (5), and
the amount of METH (5) seized has increased four-fold from 24 tons in 2008 to 114 tons
in 2012.71

AMPH (2) and METH (5) are both U.S. Schedule II drugs.72 Today the main uses of
AMPH (2) clinically are to treat attention deficit/hyperactivity disorder (ADHD) and
narcolepsy,68 and METH (5) can also be used as a second-line treatment for the same.73

b. Mode of action
The primary mode of action for AMPH (2) and METH (5) is by producing a release of
DA, 5-HT and NE from their corresponding presynaptic transporters, another suggested
mechanism is via the vesicular monoamine transporter 2 (VMAT2) and, additionally,
inhibition of monoamine oxidase (MAO) (as reviewed by Seiden et al. and Paneka et
al.).70,74 A more detailed description of its actions will be discussed under the topic of
monoamine transporters.

c. Behavioral effects
AMPH (2) is a sympathomimetic agent and has effects similar to epinephrine and
norepinephrine during ‘fight or flight’. Some of the effects are central stimulation,
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euphoria, increased heart rate and blood pressure, decreased appetite, dilated pupils,
hallucinations, and increased alertness.74,75 AMPH (2) has been extensively studied in in
vivo assays such as self-administration by laboratory animals, and drugs such as cocaine
can substitute for AMPH (2) in drug discrimination studies. It also has anorectic effects
and has been shown to decrease activity in hyperactive rat models (this effect parallels
patients with ADHD).74 Chronic AMPH (2) administration leads to stereotypy and these
animal models have been used to study schizophrenia (as reviewed by Seiden et al.).74
METH (5) also produces similar effects (as reviewed by Paneka et al.).70

d. General structure activity relationship studies
The effects of PAAs can be grouped broadly into two categories; stimulants and
hallucinogens.76 The SAR of AMPH (2) contributing only to its stimulant character will be
discussed in detail.
B
A

NH 2
D

CH 3

C

E

Figure 3. SAR of AMPH (2) as central stimulants.76

A- Terminal amine
Changing the nature of the terminal amine from primary, to secondary and tertiary
decreases activity. The exception to this is METH (5), which is the N-methyl analog of
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AMPH (2) and is about two to three times more potent than AMPH. The N-ethyl (19) and
N-n-propyl (20) derivatives are half as potent and the N,N-dimethyl (21) compound was
five-fold less potent compared to AMPH. The N-ethyl (19) and N-hydroxy (22) derivatives
substituted for S(+)AMPH in S(+)AMPH-trained rats in drug discriminations studies.77

R2

N

R1
CH 3

19:
20:
21:
22:

R1 = H, R 2 = CH2CH 3
R1 = H, R 2 = CH2CH2CH 3
R1 = R 2 = CH 3
R1 = H, R 2 = OH

B- Chiral center
Both the enantiomers have been previously investigated and (+)AMPH (S(+)2) has been
found to be several-fold more potent than (-)AMPH (R(-)2) as a central stimulant, but both
enantiomers are equipotent peripherally.76

C- Side chain
The α-desmethyl analog, PEA (23) lacks central effects because it is rapidly metabolized
by MAO. Further increase in chain length from methyl results in loss in potency. (+)-αEthylamphetamine (S(+)24) did not substitute for (+)AMPH (S(+)2) in rats trained to
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discriminate

saline

from

(+)AMPH

(S(+)2).

Another

analog,

α-ethyl-N-

methylamphetamine (25) substituted for (+)AMPH (S(+)2) but was ten-fold less potent.77
NH 2

NH 2

HN

CH 3

CH 3
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Conformationally constrained analogs: When the side chain of AMPH (2) was constrained
into 2-aminoindane (26), 2-aminotetralin (27), 6-amino- and 7-amino-6,7,8,9-tetrahydro5H-benzocycloheptane (28 and 29, respectively), only 2-aminotetralin (27) was active and
was half as potent as AMPH (2).The seven carbon ring compounds did not substitute for
(+)AMPH (S(+)2), indicating that

2-aminotetralin (27) might be the most optimum

conformation to produce AMPH-like stimulant effects for the constrained analogs.78

D- β-Position
Hydroxylation at this position results in ephedrine (18) and norephedrine (30) but both
have reduced central stimulant character compared to AMPH (2).76
The presence of a β-keto group leads to cathinone (1), a central stimulant that retains
activity and potency. Another compound with a benzylic keto group is diethylpropion (31)
that has anorectic properties.

A related group of compounds that retains central stimulation properties has a benzylic
oxygen atom that forms an ether and these are, for example, the anorectics phenmetrazine
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(32), aminorex (33) and pemoline (34) (the later has been used for the treatment of
ADHD).76
H 2N
NH 2
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E- Aromatic substituents
In general an unsubstituted ring is preferred for activity. The 4-hydroxy AMPH (35) lacks
central stimulant character and this could be due to its low lipophilic character that
prevents its passage through the blood brain barrier. The 4-methoxy analog (PMA) (36)
was a weak central stimulant and is a 5-HT releasing agent.76 It was a popular drug of
abuse called ”death” around the 1970s and its use was controlled under the U.S. Controlled
Substances Act in 1973 (Schedule I).79 AMPH analogs with methyl substitution
(tolyaminopropanes; TAPs) at the para (pTAP) (37) or meta (mTAP) (38) position failed to
produce a full AMPH-like effects, and only the ortho (oTAP) (39) produced AMPH-like
effects but was ten-fold less potent compared to (+)AMPH (S(+)2) in drug discrimination
studies.80 All three analogs have weak central stimulation character.80 Fenfluramine (6), a
drug marketed initially as an appetite suppressant, and p–chloroAMPH (PCA) (40) are a
few examples of AMPH-related phenylalkylamines that act via release of neuronal 5HT.76,77

27

NH 2
CH 3

NH 2

NH 2

R
35: R = OH
36: R = OCH 3
37: R = CH 3
40: R = Cl
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When the aromatic ring is substituted with larger groups, for example the two naphthyl
analogs of racemic AMPH (2) formed by the fusion of the b-face (41) and the c-face (42),
central stimulant action was lost, implying that the larger hydrophobic groups at these
positions was not tolerated.78 The 3,4-methylenedioxy analogs of AMPH (2) and METH
(5), MDA (43) and MDMA (44), respectively, were also found to retain central stimulant
character and have been extensively studied.77 Their pharmacology and SAR and will be
discussed in greater detail later. Multiple substitutions on the phenyl ring, for example,
DOM-like compounds, result in a transition from a stimulant to a hallucinogen.76,77 A
summary of the structural requirements for AMPH-like stimulant actions or hallucinogenic
DOM-like effects is shown in Table 3.
HN CH 3

NH 2

CH 3

CH 3

O

O

O
MDMA (44)

O
MDA (43)
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Table 3. SAR for AMPH-like stimulant actions and DOM-like hallucinogenic effects of
PAAs (adapted from Foye’s Principles of Medicinal Chemistry).76
Position
A: Terminal amine

Amphetamine-like action
N-Methyl > NH2 > NHR > NR2

DOM-like action
NH2 > NHR> NR2

B: Chiral center

S(+) > (±) > R(-)

R(-) > (±) > S(+)

C: α-Methyl group

Increasing the chain length Increasing chain length
decreases potency
decreases potency
Replacement by H decreases Replacement
by
H
potency
decreases potency

D: β-Position

β-OH: reduces potency
β =O: retains activity and potency

E. Aromatic
substitution

Unsubstituted
preferred

aromatic
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β-OH:
not
well
investigated
β =O: not well investigate

ring 2,5-Dimethyl-substitution
is optimal
4-Substitution
further
modulates potency

3. N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA)
a. Background
MDMA (44) is a PAA popularly known as Adam, Molly, Ecstasy, and XTC.81,82 It’s
pharmacological property as an empathogen separates it from DOM-like hallucinogens and
AMPH-like stimulants.83 As reported by Benzehofer and Passie,84 Koellisch from Merck
first synthesized MDMA (44) in 1912 and his work was patented in 1916. Between this
time and the late 1950s Merck conducted some toxicology and pre-clinical studies and in
1960 two Polish scientists reported on the synthesis of MDMA (44) as an intermediate in
their synthesis.84 It was Shulgin who resynthesized MDMA (44) in the 1970s and selfadministered the agent (80-120 mg) and reported on its effects:
“All the next day I felt like 'a citizen of the universe' rather than a citizen of the planet,
completely disconnecting time and flowing easily from one activity to the next.” 85
“Everyone must get to experience a profound state like this. I feel totally peaceful. I have
lived all my life to get here, and I feel I have come home. I am complete.”85
He shared the effects of this drug with his friend, the psychotherapist Leo Zeff.86 MDMA
(44) helped patients in psychotherapy to deal with emotional issues by feeling a state of
openness, by increasing the ability to reach within and introspect, hence improving
communication.87 In 1980s, due to its empathogenic effects, it became a popular “club
drug” and was increasingly abused at “raves” in Europe and the United States.86 Its
popularity spread through word of mouth and also through stories published in the media.
The drug was also extremely popular amongst undergraduate students in the United
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States.87 Its use was restricted in 1985 when it was emergency scheduled in May 1985 and
was given Schedule I status.87

b. Mode of action
MDMA (44) exerts its empathogenic effects primarily as a releasing agent at the serotonin
transporter (SERT) but also at DAT and the norepinephrine transporter (NET). A detailed
description of its mechanism of action will be discussed later under the monoamine
transporters section.88,89

c. Behavioral studies
MDMA (44) is self-administered both by monkeys and baboons.90,91 It also disrupts
complex operant behavior in monkeys,92 and also decreases operant responding in mice.93
MDMA (44) produced a lowering of dose-related reward threshold in intracranial self
stimulation studies (ICSS),94 a loss of grooming and social interactions in primates,95 and
rotational activity in rats.96 It was also shown to produce antinociceptive,97 and motor
stimulation effects.98

d. Structure activity relationship studies (discussed from two book chapters: Nichols
and Oberlender, 99 and Nichols, 77 unless referenced)

31

B

A

HN CH 3
CH 3

C

D
O
O

Figure 4. SAR of MDMA (44) as an empathogen.99

A. N substitution
The N-desmethyl analog of MDMA, methylenedioxyamphetamine (MDA, 43) retains
certain pharmacological properties of MDMA (44). It is known as the “love drug” and has
a very interesting pharmacological profile. Its (+) enantiomer possesses an AMPH-like
stimulant profile due to its releasing effects on 5-HT and other catecholamines and the (-)
enantiomer exhibits a DOM-like hallucinogenic effect due to its interaction with 5-HT2
receptors.100,101 In comparison with MDMA (44), MDA produces some hallucinogenic
effects. The N-ethyl MDA analog 45 also retains MDMA-like effects in drug
discrimination studies. The N-OH MDA analog 46 could be a prodrug of MDA (43) and
this compound did not substitute for DOM or (+)AMPH (S(+)2) in drug discrimination
studies.102 The N,N-dialkyl MDA analog 47 was inactive in vivo and Shulgin reported
that it lacked effects in humans.85
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B. Chiral center
An interesting difference to highlight between MDMA (44) and hallucinogenic
phenylalkylamines is their difference in stereoselectivity. For hallucinogens the R
enantiomer is the more potent isomer (i.e., eutomer) in animals and humans.99 However in
the case of MDMA (44) the S isomer is found to be a more potent releaser of DA, 5-HT
and NE,88 and also in in vivo tests assessing different kinds of motor activities.98 Only
(+)MDMA (S(+)44) and (+)MDA (S(+)43) but not their corresponding enantiomers,
substituted for (+)AMPH (S(+)2); hence the AMPH-like effect of these enantiomers are
stereospecific.101,103
C. Side-chain modifications
Extension of the α-methyl group of MDMA (44) to α-ethyl (48) leads to a compound that
retains a pharmacological profile similar to MDMA (44) in studies in man and drug
discrimination studies in rats. The analog, however, is less effective in the release and/or
reuptake of DA compared to MDMA (44), and AMPH (2) does not substitute for it in
drug discrimination studies.
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D- Aromatic ring
Substitution on the 1,3-dioxole ring: Subsequent addition of methyl groups to the ring to
give 49 and 50 resulted in compounds which were less potent than MDA (43) in drug
discrimination studies in rats trained to discriminate MDMA (44) from saline. In in vitro
release assays for DA and 5-HT both analogs were comparatively less potent than MDA
(43). The ring-expanded analog ethylenedioxymethamphetamine (EDMA, 51) was
reported by Shulgin to be inactive at a dose twice that of the active dose for MDA (43).85

Subsequent removal of the oxygen atoms divulged that the oxygen atoms were not
important for reuptake activity of [3H]5-HT into rat whole brain synaptosomes and the
resultant carbocyclic compounds retained activity (52, 53, 54, 55).77
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Substitution on the aromatic ring: 3,4-methylenedioxy-5-methoxyamphetamine (56) was
shown to have 5-HT reuptake properties.77

4. Methyl 2-phenyl-2-piperidin-2-ylacetate (Methylphenidate)
a. Background
Methylphenidate (6) is another CNS stimulant belonging to the piperidine-substituted PAA
class of compounds. Synthesized by Ciba-Geigy Pharmaceutical Company in 1944 for the
treatment of narcolepsy, lethargy, and psychosis associated with depression amongst
others.104 Today, its U.S. FDA-approved use is mainly for the treatment of ADHD, and the
United Nations International Narcotic Control Board reports that the main consumer of
methylphenidate (6) is the U.S., accounting for 69% of the global consumption.105 Due to
its central stimulant effects it is also a drug of abuse but unlike drugs such as AMPH (2)
and METH (5), there is no clandestine synthesis of methylphenidate (6). It is abused
mainly through fake prescriptions or pharmacy thefts.105 According to the Drug Abuse
Warning network in 2011 the nonmedical emergency visits due to methylphenidate (6)
were 6395 and the National Forensic Laboratory Information System reported 2164
methylphenidate (6) seizures in 2012. Its use in the U.S has been controlled under the
Schedule II status.105 Methylphenidate (6) has four stereoisomers (Figure 5); of the four
only the dl-threo enantiomers are employed as constituent Ritalin . The dl-erythro isomers
®

have been excluded due to their hypertensive side effects and improve the therapeutic
index of pharmaceutical products containing methylphenidate (6).106
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Figure 5. Diasteriomers of methylphenidate (6).

b. Mode of action
Methylphenidate (6) exerts its stimulant effects similar to cocaine, (i.e., it is a reuptake
inhibitor) primarily at DAT but also exerts its actions at NET.107 Radiographic studies
indicated that methylphenidate (6) and cocaine share the same binding site in the human
striatum.108

c. Pharmacological effects
Methylphenidate (6) in addition to its central stimulating effects also increases alertness,
heart rate, and body temperature.105 Its behavioral/abuse conferring effects have been
evaluated in numerous rewarding, and discriminative stimulus assays in various animal
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models such as rats, monkeys and dogs as well as in human subjects (reviewed in Kollins,
et al.,109 Askenasy, et al.110 and Arnold.111).

d. Structure-activity relationship studies on the diastereomers
The dl-threo isomers ((d-(2R:2’R)-6) and (l-(2S:2’S)-6)) are the pair bestowing
pharmacological central stimulating properties. Both the threo enantiomers were evaluated
for their central and peripheral effects and the d-threo isomer (d-(2R:2’R)-6) was found to
be the more potent isomer. In locomotor stimulation assays d-threo isomer ((d-(2R:2’R)-6)
was more potent than dl ((d-(2R:2’R)-6) and (l-(2S:2’S)-6)) and l-threo isomer (l(2S:2’S)-6). The d-threo isomer (d-(2R:2’R)-6) was about ten-fold more potent than the lthreo isomer (l-(2S:2’S)-6) in reuptake studies for [3H]DA and [3H]NE. Both the isomers
were ten-fold more potent as uptake inhibitors at NET than at DAT. Neither of the isomers
produced effects on release of [3H]DA and [3H]NE. Diastolic blood pressure in
anesthetized rats was significantly potentiated only for the d-threo isomer.106

C. Monoamine transporters
Effective neurotransmitter-mediated communication is crucial for regulating both the
central and peripheral nervous systems. Monoamines DA, 5-HT and NE play vital roles in
the human body in for example, controlling mood, reward, motor function, appetite, sleep,
motivation, arousal, and attention-stress responses.1,112
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In 1961 Julius Axelrod introduced the concept of reuptake as a method of inactivating
neurotransmitters when he explained how the sympathetic nervous system took up
norepinephrine.1 At a molecular level, monoamine transporters are principally responsible
for control of extracellular (synaptic) neurotransmitter concentration via reuptake of
released monoamines into the presynaptic neuron and, hence, maintain homeostasis at the
presynaptic neuron. DAT, SERT and NET regulate the synaptic levels of DA, 5-HT, and
NE, respectively, and disruption in this normal physiological process can lead to some
serious conditions, for example, ADHD, Parkinson’s disease, anxiety, schizophrenia,
Tourette’s syndrome, and depression.112 Several synthetic compounds exert their action via
monoamine transporters, for example, cocaine and AMPH (2) act primarily via DAT,
MDMA (44) and fluoxetine act primarily via SERT, and nisoxetine and reboxetine act
primarily via NET.1 Thus, understanding monoamine transporters is not only important as
they serve as therapeutic targets, but are also targets for drugs of abuse.113
Monoamine transporters specifically belong to the solute carrier 6 (SL6) family, they
utilize Na+ as a driving force to transport substrates, and are also referred to as secondary
active transporters. In addition to Na+, Cl- is also co transported; hence, they are also given
the name Na+/Cl- neurotransmitter family and in the case of SERT, K+ ion is counter
transported. Since they transport the substrate and Na+ in the same direction, they are
synonymously referred to as neurotransmitter sodium symporters (NSSs).112 The
stoichiometry of ions differs for each of the transporters:112 NET [Na+(1): Cl-(1)]
[Na+(2): Cl-(1)] SERT [Na+(1): Cl-(1): K+ (1)].
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1. Structure
The crystal structures of the human DAT, NET and SERT remain to be elucidated. The
human DAT, NET and SERT contain 620, 617 and 630 residues, respectively.112 However
the crystal structures of the various conformations of the leucine transporter (LeuT) from
Aquifex aeolicus and the recent crystal structures of DAT from Drosophila melanogaster
(dDAT) have aided our understanding of the architecture, pharmacology, mechanism of
action of NSSs, and in addition also have helped provide an insight for substrate, inhibitor
and ion binding sites.114-118 The dDAT structure shares greater 50% sequence identity
whereas LeuT has about 20% sequence identity with human NSSs. Conservation of TMs
(transmembranes) within the monoamine transporters is higher than that of the N and Cterminals.117

Both dDAT and LeuT crystal structures displayed 12 TMs with intracellular C and Nterminals. TMs 1-5 and 6-10 are related to each other by a pseudo axis.117,119 Some of the
structural features discussed here will be those from dDAT as this structure is more
comparable to its eukaryotic counterparts.

The extracellular loop (EL) 2 has been predicted as a site for N-linked glycosylation and
disulphide bonds for NSSs. The crystal structure revealed a disulphide bond between the
two conserved cysteines. In addition, a cholesterol molecule is found wedged between
TM5, TM7, and TM1a. The authors proposed that the cholesterol plays an important role
in holding the transporter in an outward open conformation. The C-terminus sequence
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conservation is relatively poor among the NSSs, in the dDAT structure a new and unique
feature was observed in this region. There is C-terminal latch, which contains 2.5 turns
(residues 586-595). Despite of the low homology at the C-terminus, Penmatsa et al.117
identified this as a conserved feature in the NSSs. This small helix also interacts with
TM1a via its interactions with the intracellular loop 1(IL1) and this could be very
important for transporter activity since the C-terminus has been studied as a site for
phosphorylation and trafficking.117 Recent crystal structures based on dDAT show a
common binding site for substrates and inhibitors. This site is referred to as the primary
binding site (S1).116-118

2. Transport mechanisms
Several models have been proposed for the transport mechanism of monoamine
transporters.
a. Alternate access model- This model was initially proposed by Jardetzky,120 and this
model alternates between three states. First is the outward-facing conformation where the
substrate-binding pocket is open towards the extracellular side only. Second is the
occluded state where the transporter is closed from both the intra and extra cellular sides,
and the third is the intracellular-facing conformation where the substrate-binding site is
open towards the intracellular side only and this cycle repeats (reviewed in Kristensen et
al.,112 and Rudnick121). Molecular simulation studies and the LeuT structures in various
conformations have provided some credibility to explain this mode of transporter
function.114,115,119,122,123
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The proposed mechanism is that the transporter undergoes the following stages
(Figure 6)
1. Apo state that is defined by the absence of ions/substrate
2. Binding of ions promotes a more stable outward facing conformation
3. Subsequent binding of the substrate to the primary binding site (S1)
4. This induces conformational changes and promotes the closure of the extracellular
gate and formation of the inward-facing conformation.
5. Release of Na+ is promoted by water dissemination into the inner vestibule and
eventually leading to the release of the substrate.
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Figure 6. An illustration of the putative substrate translocation cycle for the DAT protein.
In the absence of bound ions or ligands, the transporter protein exists in dynamic flux
between outward- and inward-facing states. Binding of Na+ at the S1 site stabilizes a fully
outward-facing conformation with an open extracellular gate, primed to bind substrate
molecules. Substrate binding at the S1 site induces closure of the extracellular gate,
establishing an occluded conformation (closed-to-out). It has been suggested that
interaction of a second substrate molecule with the S2 site helps facilitate opening of the
intracellular gating network, giving rise to a fully inward-facing (open-to-in) conformation
capable of releasing the S1-bound substrate and ions; however, no crystallographic
evidence for simultaneous interaction of two substrate molecules with an NSS protein has
been found. Apo, an unbound, ligand-free conformational state of a protein.124
Shi et al.125 reported that binding of a second substrate molecule (leucine) simultaneously
to the primary binding site (S1) and the extracellular site S2 can facilitate the transition
from the occluded state to the inward-facing state to release ions and substrate into the
intracellular compartment (Figure 6).
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Other ligands such as tricylic antidepressants and fluoxetine have been shown to bind to
the S2 site, however there is no crystal structure with a substrate in the S2 site.126,127

b. Channel like model- Another model that explains the transport mechanism considers the
transporter to function as an ion channel due ion channel-like uncoupled ion conductance
seen with transporters.128,129

3. Cellular regulation
a. Post-translational modification- This can occur by glycosylation, phosphorylation,
ubiquitylation, and palmitoylation mediated by various kinases that interact with specific
residues on the N- and/or C-terminal.130 The three transporters possess 2-4 sites for
glycosylation on EL2.112 The roles of some of the important kinases and phosphatase are
briefly summarized (Table 4).
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Table 4. Role of kinases and phosphatases in monoamine transporters. (Table adapted
from Rammamoorthy et al.)131
Regulators
Effect at DAT
Protein kinase C Activation:
(PKC)
Regulates AMPHmediated DA efflux,
decreased
DAT
surface
proteins,
increased
DAT
endocytosis,
increased
DAT
phosphorylation,
decreased uptake of
DA.

Effect at SERT
Activation:
Increased
SERT
endocytosis
and
phosphorylation and
decreased
surface
proteins and uptake
of 5-HT.

p38MAPK

Inhibition:
Decreased
DAT
phosphorylation,
transport
and
112
activity.

Inhibition:
Inhibition:
Decreased
SERT Decreased
NET
Vmax, Km and basal Vmax and NE Km
phosphorylation with
or without changes
in SERT proteins.

CaMKII

Phosphorylation at
the N-terminal and
mediates
AMPHinduced
DAT
mediated DA efflux.

Inhibition: Decreases
AMPH-induced
SERT mediated 5HT efflux.132

Tyrosine kinase

Inhibition:
Inhibition:
Inhibition:
Decreased
DAT Decreased
5-HT Decreased
NET
Vmax and decreased uptake and Vmax.
Vmax and NE Km.
DAT proteins.

Protein
phosphatase
(PP2A)

Inhibition: Reduced
2A DA
uptake
and
increased
DAT
phosphorylation.

Inhibition: Reduced
5-HT uptake and
increased
SERT
phosphorylation.
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Effect at NET
Activation:
Decreased
NET
Vmax and surface
proteins, unaltered
NE Km. Increased
NET
endocytosis
and phosphorylation.
Movement of NET
from lipid-rafts to
non-lipid rafts.

Inhibition:
Decreased
Ca2+
induced NE uptake,
AMPH induced NET
down regulation.

Inhibition: Reduced
NE
uptake
and
increased
NET
phosphorylation.

b. Secretory pathway - Transporter oligomerization and the C-terminal play an important
role in the passage of the transporters through the endoplasmic reticulum and golgi.112

c. Regulated trafficking- The most well investigated mechanism in the NSS family is PKCdependent internalization.

In addition to the above a nonconventional conserved motif FREKLAYAIA has also been
identified in the C-terminus of all the NSSs. It has been implicated in DAT and NET
internalization.112

d. Substrate and inhibitor mediated trafficking- In the case of DAT it has been shown that
there is a decrease in DAT surface expression post the application of releasers such as
AMPH (2). However DAT reuptake inhibitors such as cocaine and methylphenidate have
been shown to increase DAT surface expression.112 There are several experiments and
theories that have tried to explain this. One of them is that a biphasic effect has been
observed after the application of AMPH (2). Initially there is a PKCβ-dependent increase
in the expression of DAT at the surface this is followed by a disruption of the soluble Nethylmaleide-sensitive factor attachment protein complex that causes DAT internalization.
Another theory is that Akt and CaMKII together cause a decrease in DAT surface
expression. For NET as well, AMPH (2) has been shown to increase internalization due to
CaMKII and syntaxin1A and also due to GTPase Rab11. In contrast to DAT and NET,
SERT surface expression has been shown to increase upon prolonged exposure to 5-HT.
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However newer studies have demonstrated an increase in surface expression of SERT at
low doses of 5-HT and a decrease in expression at higher concentrations of 5-HT.112

e. Role of lipid rafts and membrane proteins- Association of lipid/membrane rafts has been
shown to be important for transporter regulation. They can act as messengers by bringing
in close proximity the transporter to its signal transduction molecule to cause various
mechanisms.131 Flotillin-1 helps DAT interact with lipid rafts and also plays an important
role in AMPH-induced efflux, CaMKII and PKC regulation.130 Cholesterol is located
between TMs 1a, 5 and 7 in the recently crystallized (dDAT) protein and promotes the
outward facing conformation of the transporter and cholesterol diminution has shown to
reduce monoamine transporter activity.117 Membrane raft association was first suggested
for

PKC-activated

lipid

raft-mediated

internalization

of

NET

and

SERT.131

Phosphoinositide phosphatidylinositol-4,5-biphosphate (PIP2) is another lipid shown to
affect both DAT and SERT. Mutation of PIP2 binding sites on the N-termimus eliminated
AMPH-mediated efflux.130

f. Protein interactions –
i.

Syntaxin 1A is a SNARE protein and its role in the activity and cell surface
expression of monoamine transporters at their N-terminal has shown to be
important. It also plays a role in CaMKII-mediated AMPH (2) efflux in DAT and
SERT.112
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ii.

Postsynaptic Density 95/discs-large/zona occludens (PDZ) domain contains a
protein PICK1 in the C-terminal of DAT and NET. The functional importance of
the PDZ and PICK1 interaction at DAT is still not well understood. At the Cterminal of SERT, neuronal nitric-oxide synthase (nNOS) interaction at the PDZ
domain causes a decrease in SERT activity and cell surface expression.112

iii.

Hydrogen peroxide-inducible clone-5 (Hic-5) is another protein found to interact
with DAT, SERT and NET and its association with SERT has shown to cause
internalization.112

iv.

Sec24D, a part of the coat protein COPII, is an important regulator for moving the
transporter from the ER to the golgi apparatus and this motif is conserved across all
the monoamine transporters.112

v.

The dopamine D2 receptor located presynaptically has been shown to interact with
DAT and augment the surface expression of DAT and uptake of DA. The role of
the DAT/D2 interaction has been shown to be important in schizophrenia.112

vi.

α-Synuclein is a presynaptic protein that is responsible for the pathogenesis of
Parkinson’s disease. It was found to interact with all of the NTTs and studies
indicated that it regulated cell surface expression of the transporters, however its
role in the regulation as inhibitory or stimulatory is yet to be determined. Studies
this far has been unsuccessful in displaying any changes in DAT function in αsynuclein KO mice.112

vii.

Trace amine receptor (TAAR1) – Trace amines include compounds such as ptyramine and β-phenethylamine which are similar to monoamines but are present in
47

lower quantities in the brain than them. Studies have demonstrated that the uptake
of [3H]DA was inhibited in a concentration- and time-dependent due to activation
of TAAR1 and AMPH (2) and METH-mediated DA uptake was also affected by
TAAR1 regulation. TAAR1 was also shown to affect DA efflux/reuptake due to
phosphorylation and mediate DAT internalization.133

h. Transporter oligomerization- The recent crystal structures of dDAT with various
ligands have been crystallized in its monomeric form, however there are studies which
suggest that NSSs might exist as oligomers. Several studies at SERT have indicated
oligomerization; for example, fluorescence resonance energy transfer experiments in
HEK 293 cells showed oligomers of SERT. Co-immunoprecipitation studies have also
provided verification for the connection of SERT monomers and in another study
SERT dimers and tetramers retained uptake activity (reviewed by Torres et al.).1 In the
case of DAT, the cysteine residues in TM6 were observed to be important for
crosslinking and causing DAT to exist as dimers. Another mutational study of glycine
residues that form a glycophorin-like motif in TM6 further adds support that TM6 is
important for oligomerization. The role of TM2 is predicted to be important in
transporter assembly and trafficking to the cell surface (reviewed by Torres et al.).1
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4. Psychostimulant action at monoamine transporters
Drugs that are psychostimulants exert their action by increasing the synaptic levels of
monoamines. They can be grouped into two categories based on their mode of action at the
transporters.134

a. Reuptake inhibitors- Axelrod’s group first showed that catecholamine reuptake was
blocked by cocaine (reviewed in Sulzer).113 Reuptake inhibitors bind to the transporters,
but are not transported, thus preventing the uptake of monoamines from the synapse and
causing an increase in synaptic monoamine levels.3 Two popular DAT reuptake inhibitors
are cocaine and methylphenidate (6) (Table 5).

Table 5. Binding of cocaine and methylphenidate at NET, DAT and SERT107
Drug
Cocaine
Methylphenidate (6)

NET
(IC50) nM
2100
514

DAT
(IC50) nM
120
84

SERT
(IC50) nM
190
>50,000

b. Releasers- This class of drugs binds to the transporter and is transported into the
presynaptic terminal causing an increase in synaptic monoamine levels by releasing
monoamines into the synapse via reverse transport and/or channel like activity (reviewed
in Sulzer,113 and Sulzer et al.135). Psychostimulant releasers, MDMA (44),89 AMPH
(2)2,136 and METH (5)70 act via this mechanism. There are two theories that explain how
these releasers enter into vesicles. First is the weak base hypothesis- Due to the acidic
environment within the vesicles, AMPH (2) for example is a weak base (pKa 9.9) and will
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be protonated and accumulate in the vesicles, alkalinize the pH and thus reduce the energy
required to accumulate the neurotransmitters.136 This theory however has its drawbacks
and requires additional research to prove its significance at physiological concentrations
of AMPH (2).135 Another mechanism is via competition with neurotransmitters at
VMAT2 thus increasing the cytosolic pool of neurotransmitter.137 For the transporter to
engage in reverse transport either one or an integrated mechanism of two or more of the
following could be important: facilitated exchange diffusion, channel like mode of the
transporter, and in addition putative phosphorylation and protein kinases sites that also aid
in AMPH-mediated release of neurotransmitters.113,135

Another mechanism that contributes to the mode of action of AMPH (2) is inhibition of
the enzyme MAO. This enzyme is located in the presynaptic terminals and is responsible
for the metabolism of monoamines; hence, inhibition of MAO would lead to an increase
in cytosolic concentrations of neurotransmitters.138

Crystal structures of dDAT bound to releasers and inhibitors provide insight into
differences between both classes of drugs. Both classes of drugs bind to the central
binding cavity formed by TMs 1, 3, 6 and 8. Since AMPH (2) and METH (5) occupy
binding sites within the transporter similar to those observed for DA they serve as
substrates and can compete with DA for transport. Even though cocaine occupies the
same binding site as DA, Wang et al.118 suggest that due to the bulky tropane and
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aromatic groups of cocaine it can restrict the movement of transporter and latch the
transporter in an outward-open conformation.118

Table 6. Actions of a few releasers at NET, DAT and SERT,139 and VMAT2.137
Drug
(+)AMPH (S(+)2)

NET
(EC50) nM
7.07

(+)METH (S(+)5)

12.3

(-)METH (R(-)2)

28.5

SERT
(EC50) nM
1765

VMAT2 [3DA]
(EC50) nM
2.5

736

11

416

4640

34

DAT
(EC50) nM
24.8
24.5

MDMA (44)

110

278

72

27

(+)MDMA (S(+)44)

136

142

74

22

(-)MDMA (R(-)44)

560

3700

340
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D. Synthetic cathinone analogs
1. Methcathinone
a. Background
Methcathinone (MCAT, 57) or 2-methylaminopropiophenone is considered the first
synthetic analog of cathinone (1).5 MCAT (57) can be structurally related to METH (5),
analogous to cathinone (1) and AMPH (2) (Figure 7).
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Figure 7. Structural comparison of cathinone (1) and AMPH (2) analogs.

A German scientist, Eberhard, first reported its synthesis in 1915,140 and later in 1924 two
French scientists, Fourneau and Kanao, reported MCAT (57) (although it was not termed
as such at that time) as an intermediate in the synthesis of ephedrine (18) and norephedrine
(30).141 The synthesis most popularly followed is the one reported in 1928 by Hyde et
al.142

The optical isomers were first reported in 1936 in a German patent,143 and later in 1957
(-)MCAT (S(-)57) was reported as an analeptic agent in a patent by Parke Davis.144
MCAT (57) was initially referred to as ephedrone in the Soviet Union countries; it was
popularly abused in the early 1980’s under several names such as jeff, effendi, cosmos and
mul’ka.145 Its popularity, easy methods of clandestine synthesis (oxidation of ephedrine,
18) and abuse liability gained impetus in the U.S. around the late 1980’s and early 1990’s
which caused it to become a U.S. Schedule I drug.22
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b. Behavioral effects
The behavioral effects of MCAT (57) were evaluated in vivo in AMPH-trained mice, and
it was found to be twice as potent as cathinone (1) and AMPH (2).5 In locomotor activity
studies MCAT (57) was several-fold more potent than cathinone (1).5 In ICSS studies
MCAT (57) was found to produce dose-and time-dependent facilitation of ICSS (i.e., it
had an abuse-related effect).146 Also in baboons it was shown that it had cocaine-like selfadministration properties.147

In an enantiomeric potency comparison, (-)MCAT (S(-)57) was five times more potent
than its enantiomer as a locomotor stimulant in mice.148 In drug discrimination studies
using cocaine- and (+)AMPH (S(+)2)-trained rats, (-)MCAT (S(-)57) was found to be 3and 2-fold more potent, respectively, than its enantiomer and twice as potent as (+)AMPH
(S(+)2). The potency of the racemate was in between the two isomers. Thus, (-)MCAT
(S(-)57) is the more potent enantiomer.148 MCAT (57) was employed as a training drug in
drug discrimination studies and was found to be 2-fold, 4-fold, 8-fold and 2-fold more
potent than MCAT (57), (+)MCAT (R(+)57), cocaine and (+)AMPH (S(+)2), respectively,
and its stimulus was blocked by the dopamine antagonist haloperidol.148

c. Mode of action
In an in vivo experiment reported by Glennon et al,5 MCAT (57) was found to release
[3H]DA from pre-labeled rat caudate nucleus.5 Cozzi et al.149 also supported this finding,
where they evaluated the effects of MCAT (57) to release monoamines at DAT, SERT,
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NET or vesicular monoamine transporter 2 (VMAT2) and it was found that MCAT (57)
exerted its effects primarily through plasma membrane DAT versus SERT, NET and
VMAT2.149

d. Early SAR
Analogs of MCAT (57) where the chain length at the terminal amine was varied for
example,

N-monoethylcathinone

(58),

N-mono-n-propylcathinone

(59),

N,N-

dimethylcathinone (60) and (-)-N,N-dimethylcathinone (S(-)60) were evaluated in drug
discrimination studies in (+)AMPH (S(+)2)-trained rats it was observed that they were less
potent than MCAT (57) (around 2-fold).145
R2

N

O

R1
CH 3

58: R1 = H, R 2 = CH2CH2CH 3
59: R1 = H, R 2 = CH2CH 3
60: R1 = R 2 = CH 3

2. Bath salts
a. Background
During the period between the 1920’s to early 2010 reports on the abuse of synthetic
cathinones was brief. A few synthetic cathinones did make their appearance during this
period (Figure 8); most of them were initially patented for their therapeutic effect potential
were then not pursued because of their abuse potential.
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Methylenedioxypyrovalerone
1969
Methcathinone
(not identified by this name)

1928

1900-1950

EMERGENCE OF BATH SALTS
2009-2011

Bupropion, amfepramone,
metaamfepramone
1960-1980
Methylenedioxymethcathinone
1996

1950-2000

Mephedrone Cathinone was identified
1975
1929

The term
“MCAT” was
introduced
Pyrovalerone 1987
1970’s

2000-2011

A number of synthetic
cathinones, for example,
flephedrone,
naphyrone,
ethcathinone, butylone,
3-fluromethcathinone,
methedrone
2008-present

Figure 8. Timeline of a few synthetic cathinones (adapted from Prosser et al).6

In 2010 a seemingly novel group of compounds called “bath salts” made their debut in
Europe.7 These compounds were falsely marketed under names such as “plant food”,
“research chemicals” or “bath salts” and were labeled “not for human consumption” to
escape legislation. They were sold at head shops, convenience stores, gas stations and on
the Internet under alluring names such as Ivory Wave, Vanilla Sky, Explosion, and White
Rush amongst others. The use of these agents became prevalent due to their central
stimulant effects.8
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“Bath salts” initially was a combination of all or at least two of the following; methylone
(61), mephedrone (MEPH, 62), and methylenedioxypyrovalerone (MDPV, 63) (Figure 9).8

HN
O

HN
O

O

CH 3

N
O

CH 3

CH 3

O
61

CH 3

CH 3
62

CH 3

O
O
63

Figure 9. The original components of bath salts.8

Iversen reported that MEPH (62) accounted for 89% of the cathinone seizures by the UK
forensic department.7 A survey conducted by the dance magazine Mixmag in the UK in
2010 revealed that MEPH (62) was the fourth most commonly used drug.7 Iversen also
reported on the toxicology and deaths due to MEPH (62) in UK.7 Their abuse was not
limited to Europe and soon the U.S. reported cases of bath salt abuse. The DEA noted that
in 2011 the American Association of Poison Control Centers reported a total of 4137 calls
related to bath salts exposure and the National Forensic Laboratory Information Systems
(NFLIS) for the period between January 2009-June 2011 reported 1429 cases of synthetic
cathinones of which MDPV (63) accounted for (791) 55%, MEPH (62) (331) 23% and
methylone (61) (279) 20%.8 The NFLIS also reported 15 seizures of bath salts from 8
states, but by 2010 there were 560 reports from 29 states. The U.S. Customs and Border
Protection (CBP) also encountered 96 shipments just in the month of July 2011 containing
bath salts.8 Some of the routes for ingesting bath salts include snorting, swallowing tablets,
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rectal, intramuscular injections, and ingestion by bombing.8 These agents are often mixed
with other drugs such as AMPH (2), MDMA (44), caffeine, lidocaine, and other synthetic
cathinones to exacerbate or weaken their effects.8 People abusing bath salts can experience
a number of severe effects such as hallucinations, tachycardia, chest pains, blurred vision,
agitation, confusion, hypertension, hyperthermia, multi organ failure, anxiety, aggressive
behavior, psychosis, and death.150-152

b. The three components
Methylone (61) is the cathinone, (i.e., the β-keto) analog of MDMA (44) and is also named
as methylenedioxymethcathinone (MDMC). Peyton and Shulgin first synthesized MDMC
(61) in 1996 and it was patented for its effects as an antidepressant and anti-Parkinson
agent.153 In 1997, Glennon and co-workers.145 reported that in drug discriminations studies,
MDMC (61) substituted for (+)AMPH (S(+)2) and MDMA (44) but not DOM (3).145

MDMC (61) also exerts its CNS stimulant effects by acting as an AMPH-like releaser at
monoamine transporters.145 Cozzi et al.149 studied the effects of MDMC (61) on DAT,
SERT and NET, respectively.149 Upon comparing the two analogs, MDMC (61) and
MDMA (44) in in vitro and in vivo assays, MDMC (61) was found to be about half as
potent as MDMA (44).145,149

MDPV (63) was initially patented in 1969 for its central stimulant effects,154 but its abuse
potential was realized only in 2007 with a study demonstrating an extracellular increase in
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DA levels in mouse brain.155 It is structurally similar to pyrovalerone (64) developed to
treat chronic fatigue and lethargy.156

N
O

CH 3

CH 3
64

MEPH (62) is the p-methyl analog of MCAT (57) and its synthesis was first reported in
1929,157 but its rise as a designer drug of abuse only began around 2007.7

Some of the reasons there was a sudden interest, curiosity, and eruption in the use of bath
salts was because users experienced central stimulant effects, they were initially without
any legal restrictions, and they were easily available in shops and over the Internet. They
also were not detected by common screening tests and required more sophisticated
methods such as gas and mass spectrometry. Their use might be preferred over other
stimulants such as cocaine and MDMA (44), which were experiencing a decrease in
purity/availibility.158

Due to a tremendous and sudden escalation in the number and severity of bath salts abuse
cases, in October 21, 2011 MEPH (62), MDMC (61) and MDPV (63) were temporarily
placed in the U.S. Schedule I category but eventually were given permanent Schedule I
status.18-20
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c. Mode of action
When psychoactive bath salts made their debut very little was known about their
pharmacology and mechanism of action. Our laboratory in collaboration with Dr. De
Felice was amongst the first to report on their mechanism of action.11 In
electrophysiological experiments conducted on Xenopus laevis oocytes expressing hDAT,
MEPH (62) produced an inward depolarizing current,9,10 similar to that seen with releasers
such as (-)MCAT (S(-)57) and (+)METH (S(+)5) (Figure 10).9 (-)MCAT (S(-)57) was
found to be the most potent amongst the three and (+)METH (S(+)5) and MEPH (62) were
almost equipotent.9
MDPV (63), in contrast to MEPH (62), produced an outward cocaine-like hyperpolarizing
current indicating that MDPV (63) was a DAT reuptake inhibitor (Figure 11).10,11

The actions of MDPV (63) and MEPH (62) were further assessed in DA uptake
experiments in HEK cells expressing hDAT and MDPV (63, IC50= 28 nM) was found to
be 35-fold more potent than cocaine (IC50 = 995 nM) and 40-fold more potent than MEPH
(62, IC50 = 3950 nM).10

59

Figure 10. Currents generated in hDAT expressed in Xenopus oocytes at a -60 mV by the
application of 10 µM of a) (+)METH (S(+)5); b) (-)MCAT (S(-)57); c) MEPH (62) and d)
DA.9

Figure 11. Currents generated in hDAT expressed in Xenopus oocytes at -60 mV by the
application of 10 µM of MDPV (63) and cocaine.10
In an I(V) assay, MDPV (63) produced a curve similar to cocaine and was found to be a
more potent reuptake inhibitor than cocaine, and MEPH (62) produced a curve similar to
DA.10

MDPV (63) also produced similar effects to cocaine after pretreatment with MEPH (62)
but its inhibitory effects lasted for more than 30 min (Figure 12).10
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Figure 12. Panels A and B show traces of 30-secs blocker application (MDPV (63) and
cocaine 10 µM) during the persistent leak current induced by 60 secs of MEPH (62) 10 µM
at -60 mV at hDAT expressed in Xenopus oocytes.10
Bath salt components might act synergistically; MEPH (62) has a faster onset of action
than MDPV (63) causing a release of DA that MDPV (63) then blocks the uptake of
contributing to the psychoactive actions of these bath salt components.10

Baumann et al.159,160 evaluated the in vitro actions of bath salts on DAT, NET and SERT in
rat brain synaptosomes for their release and reuptake actions (Table 7).159,160 MDMC (61)
has been known from previous studies to act as a releaser.149 From the data below, MEPH
(62) and MDMC (61) act as substrates at all the three transporters and MEPH (62) was
about twice as potent as MDMC (61) at all the three transporters.159 MDPV (63) was
shown to act as a reuptake inhibitor at all the three transporters with greatest potency at
DAT vs NET and SERT (Table 7).160
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Table 7. Effects of bath salts on transporter-mediated uptake and release assays in rat brian
synaptosomes.159,160
NET

SERT

DAT

Drug
MDMC (61)

EC50 nM
152.3

IC50 nM
1031

EC50 nM
242.1

IC50 nM
1017

EC50 nM
133

MEPH (62)

62.7

487

118.3

422

49.1

MDPV (63)

13
(Emax
24%)

26

Inactive

3349

2.3
(Emax
24%)

IC50 nM
1232
762
4.1

MDPV (63), structurally, also belongs to the cathinone family similar to MEPH (62) and
MDMC (61) but it was the first synthetic cathinone shown to exert its mechanism of action
as a reuptake inhibitor at the monoamine transporters.9-11,159,160
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III. Specific aims

Cathinone (1) was identified in 1975;4 since then there have been at least a few hundred
synthetic analogs of cathinone (1) synthesized.22 Some of them are well known, and their
mechanisms of action have been investigated. For example, MCAT (57) is thought to act
primarily as a DAT releasing agent.5 Today, synthetic cathinones represent one of the
latest global drug-abuse problems and the analogs are known by multiple street names.12,17
Periodically (especially in the last 5 years) there has been an ingress of newer synthetic
cathinones. These are structurally simple, can be readily synthesized in clandestine
laboratories, and are exceedingly popular for their stimulant character. They are not
uniform pharmacologically, or in their mechanism of action. Hence studying each of them
case-by-case is imperative.22 Elucidation of the mechanism of action of drugs of abuse
will/should
•

Allow for their pharmacological classification

•

Assist in understanding their behavioral effects

•

Assist in determining potential treatments for these agents

•

Provide information to regulatory agencies (e.g. the DEA) for scheduling purposes
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Thus, the overall aim of this research is to better understand the mechanism(s) of action,
and formulate the SAR, of the designer stimulants known as “synthetic cathinones”. The
specific aims of this research can be divided into the following and each aim will be
discussed in separate chapters.

AIM I. Structure-activity relationship studies of MDPV and its effects at the
dopamine transporter.

MDPV (63) was the first synthetic cathinone to be identified as a reuptake inhibitor at
DAT.9,10

The goals of this project are to:
a. Identify what parts of the MDPV (63) molecule structurally contributes to its mechanism
of action as a reuptake inhibitor. We will “deconstruct” MDPV (63) (Figure 13), and study
MDPV (63) and its analogs by electrophysiological and affinity studies at hDAT expressed
in Xenopus laevis oocytes and HEK 293 cells respectively.
b. After determining the minimal structural features that contribute to MDPV’s activity as
a reuptake inhibitor we will “elaborate” on the structural features identified important for
activity. These compounds will be evaluated by in vitro release and uptake inhibition in rat
synaptosomes for their activity at DAT.
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Figure 13. MDPV (63) and its analogs to be investigated in AIM I.
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AIM II. Quantitative structure-activity relationship analysis, molecular modeling and
hydropathic interaction analysis of the pharmacology of p-substituted methcathinone
analogs.

MEPH (62), another bath salt component, is the p-methyl analog of MCAT (57) but was
identified by our group to be different from MCAT (57) in its behavioral and
neurochemical effects.146 Other groups have studied the p-fluoro and p-methoxy analogs of
MCAT (i.e., flephedrone (72) and methedrone (73), respectively, Table 8) and concluded
that the p-substituent influences pharmacological activity.161,162 With this evidence it was
important to understand the SAR of p-substituted MCAT analogs that are responsible for
their distinct pharmacological effects.

The goals of this project are to:
a. Synthesize 4-substituted analogs of MCAT (57) with different electronic, lipophilic and
steric properties (Table 8).
b. Evaluate these analogs by in vitro release and uptake inhibition in rat synaptosomes (for
activity at DAT and SERT) and the ICSS assay in rats for their behavioral effects.
c. To conduct quantitative structure-activity relationship (QSAR) studies by examining the
effect of electronic, lipophilic and steric parameters of the 4-position substituent of these
analogs on pharmacological activity.
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d. After identifying the parameters important for activity, to then explain the role of these
parameters by possible interactions with the transporters by constructing homology models
of hDAT and hSERT.

Table 8. MCAT (57) and its 4-position analogs to be investigated in AIM II.
HN
O

CH 3
CH 3

R

Agent
Methcathinone (57)

R
-H

Flephedrone (72)

-F

Methedrone (73)

-OCH3

4-Chloromethcathinone (74)

-Cl

4-Bromomethcathinone (75)

-Br

Mephedrone (62)

-CH3

4-Trifluoromethylmethcathinone (76)

-CF3
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AIM III. Structure-activity relationship studies on the “bath salts” component
“methylone” at dopamine and serotonin transporters.

MDMC (61) is the β-keto analog of MDMA (44). The SAR of MDMA (44) has been
studied previously;99 but, relatively little is known about the SAR of MDMC (61).
Specifically, the DEA has also sought information on PAAs that are not yet scheduled but
could be potential threats as drugs of abuse e.g. EDMA (51).163

The goals of this project are to:
a. Study the effect of ring expansion of the methylenedioxy ring of MDMA/MDMC
(Figure 14).
•

Synthesize the ethylenedioxy analogs of MDMC (61) and MDMA (44) (i.e.,
EDMC (77), EDMA (51)).

b. Study the effect of N-alkyl chain extension of MDMC (Figure 14)
•

To
(61)

synthesize
(i.e.,

N-ethyl

and

N-propyl

3,4-methylenedioxy-N-ethylcathinone

analogs

of

(ethylone,

methylone
78),

3,4-

methylenedioxy-N-propylcathinone (propylone, 79)).
c. Evaluate these analogs by in vitro release and uptake inhibition in rat synaptosomes (for
activity at DAT and SERT).

68

HN CH 3

HN CH 3

CH 3

CH 3

O

O

O

O

MDMA (44)

EDMA (51)

HN CH 3
O

HN
O

CH 3

CH 3
CH 3

O

O

O

O

MDMC (61)
HN
O

EDMC (77)

CH 3

CH 3

HN
O

CH 3

O

CH 3

O
O

Ethylone (78)

O

Propylone (79)

Figure 14. Compounds to be investigated in AIM III.

AIM IV. Investigation of the N-alkyl chain length of 4-methylamphetamine analogs:
An examination of its pharmacological effects at the DAT and SERT.

Results from Aims I, II and III will identify structural features that contribute towards
DAT/SERT selectivity and also the mechanism of actions at monoamine transporters.
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The goals of this project are to:
a. Understand how the structural features of the terminal amine contribute towards activity
and selectivity at DAT and SERT (Figure 15).
•

We will synthesize four p-methylamphetamine homologs (see Figure 15) with
varying substituents at the terminal amine (4-methyl-N-methylamphetamine (80),
4-methyl-N-ethylamphetamine (81), 4-methyl-N-propylamphetamine (82), 4methyl-N-butylamphetamine (83)).

b. Evaluate these analogs for their electrophysiological properties at hDAT and hSERT
expressed in Xenopus leavis oocytes, in vitro release and uptake inhibition in rat
synaptosomes (for activity at DAT and SERT) and the ICSS assay in rats for their
behavioral effects.

H N R
CH 3

CH 3
80:
81:
82:
83:

R
R
R
R

= CH 3
= CH2CH 3
= CH2CH2CH 3
= CH2CH2CH2CH 3

Figure 15. Compounds to be investigated in AIM IV.
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AIM V. Effects of psychoactive synthetic cathinones and amphetamine analogs at the
norepinephrine transporter.

Synthetic cathinones such as MCAT (57) and MDPV (63) have similar selectivity for at
DAT and NET compared to SERT. Our goal was to evaluate compounds investigated in
AIMS II-IV at NET and compare their activity with the results from DAT and SERT.

AIM VI. Comparison of the structural features of methylphenidate and synthetic
cathinones and investigation of the role of the carbonyl group on synthetic
cathinones: A preliminary investigation.

Methylphenidate (6) is a reuptake inhibitor at DAT and is a PAA used clinically for
ADHD.106 Given the structural similarity between methylphenidate (6) and the synthetic
cathinones, in particular MDPV (63) it was of interest to compare them.

The goals of this project are to:
a. Compare two structural features of methylphenidate (6) (i.e., the ester and the piperidine
ring) to the corresponding features of MDPV (63) (i.e., the carbonyl and pyrrolidine ring).
•

We will synthesize compounds that are hybrids of the two (84 and 85). In 84, the
ester of methylphenidate (6) was replaced by a carbonyl group, whereas 85 is an
MDPV-type analog where the carbonyl group has been replaced by an ester
(Figure 16).
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Figure 16. Compounds to be investigated in AIM VI.

b. A parallel aim was also to investigate the role of the carbonyl group on synthetic
cathinones.
•

To better understand if the sp2 nature of the carbonyl carbon atom of synthetic
cathinones is a contributor to activity, we will synthesize the methoxy analogs 86
and 87 where the hybridization state of the carbon atom is sp3 (Figure 16).

•

We will synthesize one of the bioisosteres of a carbonyl group (i.e., the oxime
analog 88) (Figure 16). Bioisosteres are compounds or groups that have similar
chemical and physical properties and produce similar biological effects.164

c. Evaluate their effects at hDAT and hSERT using electrophysiological studies.
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AIM VI. Understanding the role of a charged terminal amine: A preliminary
investigation.

AMPH (2) as well as cathinone-based drugs of abuse all have a terminal amine that is
protonated at physiological pH. Recent crystal structures of dDAT with (+)AMPH (S(+)1),
DA and METH (S(+)5) have shown an ionic interaction between an aspartate and the
terminal amine of the above PAAs.118

The goal of this project is to:
a. Investigate the role of the nitrogen atom on cathinone analogs specifically MCAT (57)
•

We will synthesize the desnitrogen analog 89 of MCAT (57) because, lacking a
basic nitrogen atom this compound cannot form the ionic interaction with
aspartates D79 in hDAT and D98 in hSERT.

HN
O

CH 3

MCAT (57)

•

CH 3

CH 3

O

CH 3

H 3C
O

+
CH 3
S
CH 3

90

89

If this ionic interaction is important for activity, then replacement of a protonated
tertiary amine with an isosteric sulfonium group could result in retention of action.
We will synthesize the sulfonium salt 90 such that it is permanently charged and
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would maintain the ionic interaction with the conserved aspartate at the substratebinding site.
b. Evaluate their effects at hDAT and hSERT using electrophysiological studies.
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IV. Outcomes

Outcomes of all the AIMS will be discussed here individually.

AIM I. Structure-activity relationship studies of MDPV and its effects at the
dopamine transporter

a. Introduction
Boehringer Ingelheim reported the synthesis of the hydrochloride salt and a few
pharmacological properties of MDPV (63) in 1969 while they were working on
heterocyclic α-substituted-ketones containing an α-pyrrolidino group.154 At that time,
MDPV (63) was not known by this abbreviation but, rather, by its IUPAC name “1-(3’,4’methylenedioxyphenyl)-2-pyrrolidinopentanone”. They reported on its therapeutic index
(875), toxicity (LD50 = 175 mg/kg) and the dose required to produce central nervous
system stimulation (0.20 mg/kg) in mice.154

In 2010 MDPV (63) made its presence quite conspicuous7 when it was identified as a
primary constituent of the psychostimulant designer drug “bath salts”.151 It became
notorious for its abusive properties that led to severe side effects.150-152 At the time it made
its debut on the drug abuse scene, its mechanism of action was still not known.
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Both MDPV (63) and MEPH (62) are synthetic cathinones and, consequently, it was
initially thought that they would have similar mechanisms of action. However we
identified that MEPH (62) produces hDAT-mediated inward currents similar to (+) METH
(S(+)5) and (-)MCAT (S(-)57) whereas MDPV (63) produces hDAT-mediated outward
currents similar to cocaine. MDPV (63) was distinctive as it was the first synthetic
cathinone to be identified as a reuptake inhibitor at DAT.9-11 Various groups have
substantiated assessment of its abuse potential. MDPV (63) produces locomotor
stimulation in rats,160,165 and mice.155,166 Its effects on the brain reward system were
observed by a decrease in ICSS.146 It was also found to be self-administrated in rats.165 In
drug discrimination studies in mice it fully substituted for MDMA (44) and METH (5) but
not morphine or the synthetic cannabinoid JWH-018.166 MDPV’s actions have been shown
to be mediated via DAT, and in a voluntary wheel-running test in rats, it produced effects
different from that of MDMA (44), an agent found to be mainly serotonergic.167

The goal of this project was to identify what structural features of MDPV (63) contribute
to its unexpected mechanism of action as a reuptake inhibitor at DAT. MDPV (63) is
structurally unique from other synthetic cathinones such as MCAT (57) and MEPH (62)
because it has a tertiary amine, in the form of a pyrrolidine ring, and an extended α-npropyl side chain.
We used one of the classical medicinal chemistry principles, (i.e., deconstruction), to
investigate MDPV (63). Deconstruction, removal of each of the molecular substituents of
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MDPV (63) one at a time, will allow us to determine their importance on the
target/biological activity; hence, it helps to identify the minimal structural features of the
molecule that contribute to its biological activity.168

MDPV (63) has four structural features that could be potential contributors to its activity
(Figure 17, highlighted in different colors); a total of seven deconstructed analogs of
MDPV were synthesized (Figure 18).

N
O

CH 3

O
O

Figure 17. Structural features of MDPV (63) to be deconstructed.

77

N

N
O

CH 3

CH 3

O
O

71

70
NH 2
O

N

CH 3

O

N
O

CH 3

CH 3

O
O

O

69

HN
O

O
O
68

O

CH 3

H 3C

O

N

CH 3

O

CH 3

65

O MDPV (63)

H 3C
O

CH 3

O

O
66

Figure 18. MDPV (63) and its deconstructed analogs.
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b. Methods
i. Synthesis – This was a joint effort by several members of our group. Dr. Kolanos
synthesized Compounds 63, 67, 69, 70, and 71, and details of their synthesis have been
described in Kolanos et al.169 The synthesis of compounds 65, 66 and 68 is described in
Scheme 1.

Scheme 1. Synthesis of compounds 65, 66, and 68a
O

X

a
O

O

O

O
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R1 = CH 3 (92)
R1 = CH2CH2CH 3 (93)
R2

Br
O

O

R1

N

R3
R1

c

b

O

O
O
R1 = CH 3 (94)
R1 = CH2CH2CH 3 (95)

O
R1 = CH 3, R 2 = R 3 = (CH 2)4 (65)
R1 = CH 3, R 2 = R 3 = CH 3 (66)
R1 = CH2CH2CH 3, R 2 = H, R 3 = CH 3 (68)

a

Reagents: (a) SnCl4, CH2Cl2, propionyl chloride (92)/ valeroyl chloride (93); (b) Br2,
AlCl3, Et2O; (c) benzene, pyrrolidine (65)/ Me2NH in MeOH (66) /MeNH2 in EtOH (68).
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ii. Two electrode voltage clamp technique (TEVC)
This assay was performed in Dr. De Felice’s laboratory at Virginia Commonwealth
University and is reported in Kolanos et al.169

Expression of hDAT in Xenopus laevis oocytes.
Oocytes were harvested and prepared from adult Xenopus laevis females following
standard procedure; 32−34 Stage V−VI oocytes were selected for cRNA injection within
24 h of isolation.

cRNA was transcribed from the pOTV vector using the mMessage Machine T7 kit
(Ambion Inc.,Austin, TX). Oocytes were injected with 50 ng of hDAT cRNA(Nanoject
AutoOocyteInjector, Drummond Scientific Co., Broomall,PA) and incubated at 18 °C for
4−8 days in Ringers solution supplemented with sodium pyruvate (550 µg/mL),
streptomycin (100µg/mL), tetracycline (50 µg/mL), and 5% dialyzed horse serum
Electrophysiology.

Two-electrode voltage-clamp (TEVC) recordings were at room temperature (23−25 °C).
Electrodes having a resistance of 1−5 MΩ were filled with 3 M KCl. Xenopus laevis
oocytes expressing hDAT were voltage-clamped to −60 mV with a GeneClamp 500 (Axon
Instruments), and the holding current was recorded using a Clampex10 (Axon
Instruments). Extracellular buffer consisted of (in mM): 120 NaCl, 7.5 HEPES, 5.4
potassium gluconate, and 1.2 calcium gluconate, pH 7.4. In a typical recording,
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extracellular buffer was perfused until stable baseline currents were obtained, followed by
experimental drugs (perfusion duration is indicated by a horizontal line on the trace).

iii. Radiolabeled [3H]DA Uptake competition assay
This assay was performed in Dr. De Felice’s laboratory at Virginia Commonwealth
University and is reported in Kolanos et al.169

Maintenance of Cells Stably Expressing hDAT (hDAT-HEK).
Cells were prepared in DMEM supplemented with 10% FBS, 2 mM L-glutamine,
penicillin (100 units/mL), streptomycin (100 mg/mL), and G418.

Radiolabeled [3H]DA Uptake Competition Assay.
hDAT-HEK cells in DMEM suspension were counted, and 200,000 cells were placed in
individual Eppendorf tubes and incubated for 15 min at room temperature (23−25 °C) with
mixtures of 1% [3H]DA.

The compounds (MDPV (63) and analogs (65-71)) were tested at a broad range of
concentrations. Ice-cold (4 °C) PBS was added to the samples, cells were centrifuged for 1
min at 2000 rpm, supernatant was removed, and cells were washed twice with PBS,
centrifuged, and supernatant was removed. Cells were solubilized with Ecoscint H
(NationalDiagnostics, Atlanta, GA), and the [3H]DA remaining was measured using a
scintillation counter. To determine IC50 values, uptake values were plotted against
81

concentration and data were fit using the Hill equation y = Vmax + (Vmin − Vmax) *
xn/(kn + xn) using Origin 8 (OriginLab Corporation, Northampton, MA).

c. Results
Results from TVEC
TVEC studies conducted on MDPV (63) and all the analogs in Xenopus laevis oocytes
expressing hDAT (clamped at -60 mV) are shown in Figure 19.

For each of the traces in Figure 19 there is first an hDAT-mediated inward (i.e.,
depolarizing current), after the initial application of 5 µM of DA. Subsequent application
of MDPV (63) or any of its analogs (65-71) (10 µM, 1 min) produced an outward hDATmediated current (i.e., a hyperpolarizing current). This was followed by a washout period
in which the current did not return to baseline after which there was an another application
of 5 µM of DA, that now produced a reduced hDAT-mediated inward current. All the
compounds tested produced qualitatively similar hyperpolarizing currents with similar
amplitudes but differed in their percentage of recovery after the second application of DA
(see Table 9 and Figure 19). MDPV (63) produced the smallest recovery whereas
compounds 66 and 69 produced a full recovery of the hDAT-mediated inward current.
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Figure 19. Currents produced MDPV (63) and its analogs 65-71 in Xenopus laevis oocytes
expressing hDAT clamped at -60 mV.169
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Table 9. Magnitude of the effect produced by MDPV (63) and its analogs 65-71 (10 µM),
and percent recovery following a subsequent application of 5 µM DA, and the IC50 values
obtained from HEK-cells expressing hDAT.
Drug

% Recovery
(±SEM)b
12.1 (1.1)

N

MDPV (63)

% Response
(±SEM)a
16.4 (2.4)

7

IC50 nM
(±SEM)
135 (±20)

65

18.0 (1.2)

91.9 (1.9)

6

3540 (±470)

66

18.7 (2.2)

102.0 (0.8)

5

22300 (±3270)

67

14.1 (1.7)

57.5 (2.4)

3

715 (±120)

68

16.9 (2.0)

75.7 (4.5)

5

1950 (±270)

69

19.2 (3.4)

102.6 (1.5)

5

27100 (±6000)

70

15.3 (1.7)

90.0 (1.6)

5

1150 (±130)

71

14.8 (2.1)

25.4 (1.7)

5

205 (±60)

a

Percent response relative to the amplitude of the inward current produced by 5 µM DA.
Percent recovery upon the application of 5 µM DA 1 min following the outward current
produced by MDPV (63) and its analogs (65-71).
b

Results from Radiolabeled [3H]DA Uptake Competition Assay
The affinities of MDPV (63) and its analogs were determined by measuring the uptake of
[3H]DA in HEK cells expressing hDAT. The IC50 values were spread over a 200-fold (see
Table 9, Figure 20) range with none of the analogs being more potent than MDPV (63,
IC50 = 135 nM). Removal of the methylenedioxy ring resulted in compound 71 (IC50 = 205
nM) with comparable affinity to MDPV (63). The AMPH analog of MDPV (i.e., the desketo analog 70), was 10-fold less potent than MDPV (63). Shortening the extended α-npropyl side chain to α-n-methyl side chain resulted in a compound (65, IC50 = 3540 nM)
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with 25-fold decreased potency, and a subsequent 6-fold decease in potency was observed
when 65 was converted to its N,N-dimethylamine analog (66, IC50 = 22,300 nM).
Deconstructing the pyrrolidine ring of MDPV (63) to the N,N-dimethylamine (67, IC50 =
715 nM), N-methyl (68, IC50 = 1950 nM), and primary amine (69, IC50 = 27,100 nM)
resulted in a systematic decrease in potency by 5-,14-, and 200-fold, respectively.
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Figure 20. Results from radiolabeled [3H]DA uptake competition assay for MDPV (63)
and its analogs 65-71 expressed in nM.
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d. Discussion
All the deconstructed analogs of MDPV (63) produced hyperpolarization. A notable
difference was the percent recovery following subsequent administration of DA (Table 9,
Figure 19). The contributions of the various structural features of MDPV (63) to affinity
can be correlated to the recovery of the current due to DA (applied after exposure to
MDPV and the analogs) (Table 9 and Figure 19). The percent recovery is highly correlated
with affinity (r = 0.916, p = 0.0014), (Figure 21). Compounds with the greatest recovery
were the ones with the least affinity.

r = 0.916

Figure 21. Relationship between pIC50 for inhibition of DAT versus % DA recovery (r =
0.916, p = 0.0014) for compounds 63, 65-71.
MDPV (63) is a compound with long-lasting effects as seen that the percent recovery is
only 12.1%. The compound without the methylenedioxy ring 71 is the only one with
affinity comparable to MDPV (63) and confers similar long lasting effects with only
25.4% recovery. The carbonyl group is a contributor to affinity but its lack does not
produce the long-lasting effect of MDPV (90% recovery, 70). The side chain shortened
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analog 65 is 25-fold less potent than MDPV (63) and this difference parallels the effect on
DA recovery, MDPV (63) 12% vs 90% for 65. Changing the nature of the terminal amine
from a bulky tertiary amine to a ring opened tertiary amine, secondary and primary amine
produced a systematic decrease in potency (spanning >200-fold), this same order is also
seen with their effects on DA recovery: MDPV (63) 12% vs 67; 57.5%, 68; 75.7%, 69
102.6%). On comparing the effects of the 5-membered pyrrolidine ring of MDPV (63)
with analogs 65, 67 and 66 we can see that these analogs are not only relatively less potent
but they also showed a higher recovery of DA compared to MDPV (63) (65: 91.9%, 66:
102%), 67: 57.5%).

The recovery currents were examined at one concentration (i.e., 5 µM) and this needs to be
further investigated in greater detail. It is important to note that our group also saw
MDPV’s long lasting effects in previous studies where the current due to MDPV (63) did
not return to baseline even after a washout period of over 30 minutes10 and in ICSS studies
it showed facilitation even beyond 300 minutes.146

All the analogs tested were reuptake inhibitors similar to MDPV (63), but with different
potencies. It can be concluded that the key structural contributors to reuptake activity at
hDAT are the tertiary amine and the extended side chain. Either of these structural features
is sufficient for high affinity, but having both of these structural features together
contributes to optimal affinity. The methylenedioxy ring is not required for activity and the
carbonyl group contributes to activity but is not essential.
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Due to the stringent legislative regulations imposed on “bath salts”, a second wave of
synthetic cathinones had already emerged by the time we completed our studies. The
primary goal of our study was to identify the structural features that made MDPV (63)
distinct from other cathinones such as MCAT (57) and MEPH (62) but an inadvertent
outcome of the present investigation was to provide information on four of the analogs (71
(α-PVP), 65 (MDPPP), 66 (bk-MDDMA) and 68 (bk-MBDP)) that were coincidentally
identified on the clandestine market at the time as potential drugs of abuse. We provided
the first study on their mechanisms of action.

Later, our group also prepared and tested the two enantiomers of MDPV (63) for their in
vitro effects in rat brain synaptosomes and their in vivo effects in ICSS assays and
established that the abuse liability of MDPV (63) is due to its S(+) isomer. In in vitro
studies S(+)63 was about 200-fold more potent than R(-)63, and about twice as potent as a
reuptake inhibitor at DAT. Stereoselective facilitation of ICSS was observed, both S(+)63
and MDPV (63) produced facilitation in ICSS but the former was marginally more potent
than the racemate. R(-)63 failed to produce any significant effects in ICSS even at doses
100 times that of the lowest effective dose of S(+)63.170

One of the analogs, α-PVP (71), encompassed the minimum structural features that
contributed to reuptake inhibition at hDAT. In our assay in HEK-cells it was nearly half as
potent as MDPV (63) (Table 9), and in rat brain synaptosomes it was 3 times less potent
than MDPV (63) as a reuptake inhibitor at DAT.171 Following the completion of our
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studies, others assessed in different behavioral assays its CNS stimulant character and
abuse potential. In locomotor stimulation assays, it displayed a locomotor stimulatory
effect in mice comparable to METH (5)172 and MDPV (63) in both mice and rats.171,173 In
self-administration assays in rats it was similar in potency and efficacy to MDPV (63),173
and showed a decrease in ICSS effects similar to METH (5).174 In drug discrimination
studies it substituted fully for both METH (5),175,176 and cocaine,176 and also showed a
decrease in conditioned place preference in a dose-dependent manner.176 In recent news αPVP (71) soared to popularity under the names of “gravel” and “flakka” in most states in
the United States and has been reported to cause some severe and bizzare effects.177 The
NFLIS has included it as one of the 25 most frequently encountered drugs for the period
between January through June 2014 and it was temporarily scheduled in March 2014.13
Psychosis,178 tachycardia, hallucination, anxiety, increased heart and respiratory rate, and
death,179,180 have also been reported due to α-PVP (71).179

Early results indicated that the α-n-propyl substituent of α-PVP (71) might be optimal for
action as a DAT reuptake inhibitor. Consequently we extended and branched the αsubstituent in order to obtain additional information concerning the role of bulk in this
region of the molecule on reuptake potency. The next part of this project was to study the
effects of the length and bulk of the extended (i.e., α-n-propyl) side chain of α-PVP (71),
and the size of the terminal amine ring (expansion of the 5-membered pyrrolidine ring)
(Table 10). This might be considered as the “elaboration” phase of this study based on
what was already known.
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Table 10. Analogs of α-PVP (71) investigated in the current study.

N
O

N
O

R

71, 96-102

R

103, 104

Compound
number
96

R
-H

97

-CH3

98

-CH2CH3

71

-CH2CH2CH3

99

-CH(CH3)2

100

-CH2(CH2)2CH3

101

-C5H9

102

-C6H11

103

-CH3

104

-CH2CH2CH3

e. Methods
i. Synthesis- Compounds 99, 101, 102, and 104 were synthesized by Dr. Kolanos and
compound 100 by Dr. Jain and their synthesis is discussed in Kolanos et al.181 Synthesis of
91

compound 96 and 103 are shown in Schemes 2 and 3. Compound 97 was synthesized in
laboratory (Scheme 3), however data was reported for it earlier in the same assay and was
hence not investigated again.

Scheme 2. Synthesis of compound 96a

Br
O

Route 1

a

N

x

b Route 2

O

Route 1

x
c

Route 3

105
a

Route 1

96

Reagents: (a) Pyrrolidine, benzene; (b) pyrrolidine; (c) Et3N, pyrrolidine, benzene.

For the synthesis of compound 96 three different routes were attempted. In Route 1
(Scheme 2) a hydrochloride salt of 96 was attempted but it was extremely sticky and could
not be recrystallized. In Route 2 (Scheme 2) pyrrolidine was used as solvent and this route
was attempted twice. In the first attempt a hydrochloride salt was tried and led to the
formation of a sticky salt, so an oxalate salt was attempted that precipitated (not a very free
flowing powder) only after were Et2O and MeOH washings. During the second attempt of
Route 2 (Scheme 2) the final product was obtained as the oxalate salt of pyrrolidine that
was characterized by NMR and had a mp (melting point) of 115-117 °C. The reaction was
then modified (Route 3, Scheme 2) such that one equivalent of Et3N and one equivalent of
pyrrolidine were used. The reaction generated Et3N as a hydrobromide salt as a side
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product that was insoluble in benzene and was removed by filteration. This route thus
prevented the use of an excess of pyrrolidine and prevented the formation of the
pyrrolidine salt.

Scheme 3. Synthesis of compounds 97 and 103a

Br
O

N
O

CH 3

CH 3

b

106

103

a

N
O

CH 3

97
a

Reagents: (a) Pyrrolidine, benzene; (b) piperidine, benzene.
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ii. In vitro uptake inhibition in rat brain synaptosomes
This assay was perfomed in Dr. Baumann’s laboratory at NIDA.

Subjects. Male Sprague−Dawley rats (Charles River, Wilmington, MA, USA) weighing
250−350 g were housed three per cage with free access to food and water and maintained
on a 12 h light/dark cycle with lights on from 7:00 a.m. to 7:00 p.m.

Animal facilities were accredited by the Association for the Assessment and Accreditation
of Laboratory Animal Care, and procedures were carried out in accordance with the
Institutional Animal Care and Use Committee and the National Institutes of Health
guidelines on care and use of animal subjects in research (National Research Council,
2011).

Procedure. [3H]Transmitters (specific activity ranging from 30 to 50 Ci/mmol) were
purchased from PerkinElmer (Shelton, CT, USA). All other chemicals and reagents were
acquired from Sigma-Aldrich (St. Louis, MO, USA). Rats were euthanized by CO2
narcosis, and brains were processed to yield synaptosomes as previously described.182 Rat
caudate tissue was used for DAT assays, whereas rat whole brain minus caudate and
cerebellum was used for SERT assays. In uptake inhibition assays, 5 nM [3H]DA and 5 nM
[3H]5-HT were used to assess transport activity at DAT and SERT, respectively.

The selectivity of uptake assays was optimized for a single transporter by including
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unlabeled blockers to prevent uptake of [3H]transmitter by competing transporters.
Uptake inhibition assays were initiated by adding 100 µL of tissue suspension to 900 µL
Krebs−phosphate buffer (126 mM NaCl, 2.4 mM KCl, 0.83 mM CaCl2, 0.8 mM MgCl2,
0.5 mM KH2PO4, 0.5 mM Na2SO4, 11.1 mM glucose, 0.05 mM pargyline, 1 mg/mL
bovine serum albumin, and 1 mg/mL ascorbic acid, pH 7.4) containing test drug and [3H]
transmitter. Uptake inhibition assays were terminated by rapid vacuum filtration through
Whatman GF/B filters, and retained radioactivity was quantified by liquid scintillation
counting. Statistical analyses were carried out using GraphPad Prism (v. 6.0; GraphPad
Scientific, San Diego, CA, USA). IC50 values for inhibition of reuptake were calculated
based on nonlinear regression analysis.

iii. Correlational Studies
QSAR studies were performed using the α-substituent volume and lipophilicity. Volume
(vol) was calculated using SYBYL-X 2.1 (Tripos Inc., St. Louis, MO). All the molecules
were sketched using SYBYL-X 2.1 and were energy minimized with the Tripos Force
Field option. Then numbers for volume were generated for the entire molecules using the
MolCAD plus option within the SYBYL program. Because 71 and 96-102 differed only in
the nature of their α substituent, differences in total volume reflect the volume of that
substituent. Lipophilicity (π) values for individual substituents were obtained from the
primary literature.183 Linear regressions and statistical analyses were performed between
both these parameters and in vitro reuptake inhibition potency at DAT (pIC50 values)
using the software Prism 5.04 (GraphPad, San Diego, CA, USA), and correlations with a p
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<0.05 were considered statistically significant. pIC50 values, volume, and π values used in
this investigation are shown in Table 11.

f. Results
Each of the compounds investigated displayed activity as reuptake inhibitors at DAT with
varying potencies (see Table 11). Removal of the extended side chain (i.e., compound 96)
(IC50= 3250 nM) resulted in a compound that was 185 times less potent than the parent
compound α-PVP (71), which had an IC50 of 17.5 nM. Decreasing the α-n-propyl side
chain of α-PVP (71) to α-n-ethyl (i.e., compound 98) made it about 4-fold less potent (IC50
= 63.3 nM) than α-PVP (71) and a further decrease in potency by about 11-fold was
observed when this extended side chain was decreased to its methyl analog (97, IC50 =
196.7 nM). However, increasing the α-n-propyl chain length of α-PVP (71) by one carbon
atom to the α-n-butyl analog (100, IC50 = 11.6 nM) increased potency marginally (about 2fold).

Another objective was to investigate the steric bulk that can be tolerated at the α-position.
The isopropyl analog (i.e., compound 99) (IC50 = 92.3 nM) was 5-fold less potent than αPVP (71) but the other two bulky substituted compounds (i.e., compounds 101 (IC50 = 17.1
nM) and 102 (IC50 = 8.3 nM)) were comparable and twice as potent to α-PVP (71),
respectively.
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Table 11. Volume and π values used in the QSAR investigation and potency of α-PVP
(71) and its analogs (96-104) as inhibitors at DAT.a
N
O

N
O

R

71, 96-102

a

R

103, 104

Compound
number

R

Volume Lipophilicity
(Å3)
(π)183

IC50 nM (SEM)

96

-H

175.39

0

3,250 ±418

97

-CH3

189.05

0.46

196.7b

98

-CH2CH3

211.61

1.02

63.3b

71

-CH2CH2CH3

229.00

1.55

17.5 ±1.7

99

-CH(CH3)2

231.20

1.53

92.3 ±11.6

100

-CH2(CH2)2CH3

246.19

2.13

11.6 ±0.6

101

-C5H9

253.22

2.14

17.1 ±2.5

102

-C6H11

270.47

2.82

8.3 ±1.1

103

-CH3

2,490 ±241

104

-CH2CH2CH3

128 ±13

Compounds had no activity at SERT at 10,000 nM. b Data reported earlier.171

Ring expansion at the terminal amine, (i.e., expanding from a pyrrolidine to a piperdine)
resulted in compounds with decreased potency. Compounds 103 (IC50 = 2490 nM) and 104
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(IC50 = 128 nM) were 10-fold less potent than their pyrrolidine counterparts 97 and 71,
respectively.

Cursory inspection of the results from the in vitro uptake studies at DAT suggested a
relationship between potency and the size of the α-substituent. Hansch analysis was
conducted between the pIC50 values of the compounds excluding 103 and 104, because
they had piperidine rings instead of pyrrolidine and the volume and lipophilic character of
the α-substituent. Statistically significant correlations were observed with both parameters;
r = 0.909, p = 0.0017 for volume and r = 0.917, p = 0.0013 for lipophilic character (Figure
22). However, the two parameters investigated were intercorrelated (r = 0.997, p < 0.0001).
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Figure 22. Relationship between pIC50 for inhibition of DAT versus substituent volume in
Å3 (upper panel; r = 0.909, p = 0.0017) and lipophilicity (π) (lower panel; r = 0.917, p =
0.0013) for compounds 71 and 96-102.
e. Discussion
In the current examination we used α-PVP (71) as a parent compound and examined the
effects of chain length and steric bulk at the α-position, and ring expansion of the
pyrrolidine ring. A systematic decrease in chain length from n-propyl (71) to ethyl (98),
methyl (100), and eliminating the chain altogether (71), resulted in a systematic decrease in
potency (to 185-fold). However homologation of the side chain resulted in a compound,
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100, that had comparable potency to α-PVP (71) indicating that reuptake activity is
optimal with increased chain length at the α-position.

Steric bulk and/or branching were also found to contribute to activity. The branched isopropyl analog 99 had activity comparable to the unbranched analog 98. Similarly, the
cyclopentyl analog 101 had comparable or improved activity to its linear analogs 71 or
100, and a further increase in steric size with the cyclohexyl analog 102 gave the most
potent compound examined in this series. All the branched/bulky analogs (i.e., 99, 101,
102) were about 2- to 24-fold more potent than 97.

The results from Hansch analysis indicated that reuptake activity at DAT was correlated
with the volume and lipophilic character of the α-position substituent. Due to the
intercorrelation between the two parameters, additional compounds will need to be
examined to better understand which of the parameters is most important for activity.

The two 6-membered ring-expanded analogs (i.e., 103 and 104) were less potent than their
5-membered pyrrolidine counterparts (i.e., 71 and 97) implying that the pyrrolidine ring
might be optimal for activity and a ring size larger than five is not as well tolerated.

We provided information that increased bulk and chain length at the α-position of MDPVlike cathinones resulted in increased potency as DAT reuptake inhibitors however access
into the transporter might be, up to some point, limited by the bulk on the nitrogen and α100

side chain. Increased lipophilicity might increase diffusion into the CNS; however, making
the compounds too bulky might hinder their entry into the transporter. Based on our results
it can be suggested that DAT probably has a hydrophobic cavity that is occupied by the
extended side chain. Also the transporter seems to accommodate a 5-membered ring better
as compared to a 6-membered ring. Additional compounds and modeling studies will need
to be conducted to provide credence.

For example, additional compounds that could be investigated to substantiate that the 5membered ring is optimal would be an α-PVP analog with a 4- (azetidine) or 3-membered
(aziridine) ring. Additional compounds to address the importance of which parameter,
volume or lipophilicity, and to determine the maximum length and bulk that can be
tolerated at the α-position, are required and warranted, and are currently being prepared in
the laboratory.

Meltzer et al.,184 were the only other group to report on the monoamine uptake activity of a
series of substituted pyrovalerophenones. Although they tested pyrovalerophenones with
substituents on the aromatic ring, and in our series we used unsubstituted analogs,
comparisons between their results and ours can be made based on their 3,4-dichloro-αPVP analog (107). With respect to 107, they found that their analogs have weak reuptake
activity at SERT compared to DAT, ring expansion to the piperidine moiety resulted in a
15-fold decrease in potency, and decreasing the side chain from n-propyl to ethyl resulted
in a compound with comparable potency.184
101

N
O

CH 3

Cl
Cl
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Other groups have also investigated some of the analogs investigated by us for their in vivo
effects. For example, compound 97 and 98 produced dose- and time-dependent stimulation
of locomotor activity,171 and 98 also showed conditioned place preference and fully
substituted for METH (5) and cocaine in drug discrimination studies.176 But, none of these
studies investigated SAR (or QSAR) in a systematic manner.

It also can be observed that MDPV-like cathinones are practically inactive at SERT and
other groups have reported this as well.160 Methylphenidate (6), which is another reuptake
inhibitor, also is practically inactive at SERT compared to DAT. It has an IC50 = 84 nM for
DAT but its inhibitory potency for SERT is >50,000 nM.107 The binding cavity (S1)
indicated in crystal structures of dDAT for nortriptyline, AMPH (S(+)2), METH (S(+)4)
and cocaine is well conserved between DAT and SERT (will be discussed in the next
chapter in greater detail). It raises curiosity then, that, even though both transporters share
a binding cavity that is highly homologous, these compounds are inactive at SERT. The
crystal structure is a snapshot of the transporter in one of its conformations; it can be
suggested, then, that it is probably the mechanism in which the two transporters provide
access to the compounds that might be different. Hypothetically MDPV-like compounds
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could bind to this common site, but they just can’t get there. This idea needs to be
supported by crystallographic or mutagenesis studies.

Overall, we have now provided the first study on the SAR/QSAR of the first synthetic
cathinone DAT reuptake inhibitor (i.e., MDPV (63)) (see Figure 23).
a

N

d

O

CH 3

O

b

c

O

Figure 23. A summary of structural features (a-d) examined for the inhibition of reuptake
at DAT. See below text for discussion.
A variety of MDPV (63) analogs was examined and it was found that various structural
features impact action as DAT reuptake inhibitors (Figure 23). In general a) a tertiary
amine is preferred, with pyrroilidine being optimal, b) an elongated or bulky chain is
preferred, with cyclohexyl being optimal, c) the 3,4-methylenedioxy group of MDPV (63)
makes minimal contribution, d) the carbonyl group contributes to activity. In order to act
as reuptake inhibitors, synthetic cathinones should bear either a tertiary amine or an
extended side chain; it would appear that the presence of both is preferred.
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AIM II. Quantitative structure-activity relationship analysis, molecular modeling and
hydropathic interaction analysis of the pharmacology of p-substituted methcathinone
analogs

a. Introduction
MCAT (57), the first synthetic cathinone analog,5 is the parent scaffold for many of the
new emerging synthetic cathinones such as those found in “bath salts”.22 It exerts its action
primarily through DAT via the release of DA.5 Its behavioral and in vitro actions were
described in detail in the Background section.

MEPH (62), one the original “bath salts” components, is the p-methyl analog of MCAT
(57). However, MEPH (62) possesses a lower in vitro selectivity for DAT over SERT,159
and in ICSS studies conducted by our collaborators, its abuse-related effects were less
efficient than that of MCAT (57).146

Most recently, others have found similar results with flephedrone (72) and methedrone
(73), two other MCAT analogs that differ in their in vitro and behavioral effects.161,162,185
Flephedrone (72) exerts its action primarily through DAT over SERT whereas methedrone
(73) demonstrates an opposite selectivity.161,162 In locomotor stimulation assays
flephedrone (72) has more pronounced effects than methedrone (73) in mice.185 Both of
these compounds were given temporary U.S. Schedule I status early last year.21
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MEPH (63), flephedrone (72), and methedrone (73) differ from MCAT (57) only in their
4-position substituent but produce distinct behavioral and neurochemical effects.

The objective of this next study was to understand the influence of the 4-position
substituent on MCAT analogs on both their behavioral and neurochemical effects. With
this purpose, we varied the nature of the 4-position substituent on MCAT (57) across three
parameters: steric, electronic, and lipophilic (Table 12) so we could conduct QSAR studies
to understand how the physicochemical nature of the 4-position substituents can influence
activity at DAT and SERT.

MCAT (57) and its analogs were evaluated for their in vitro actions on DAT and SERT
using rat synaptosomes, and their in vivo abuse potential was evaluated by an ICSS assay.
The ICSS assay is a type of a self-administration assay where the animal under study
presses a lever for an electrical impulse delivered via a microelectrode implanted typically
in the ventral tegmental area or the medial forebrain bundle. Drugs of abuse such as
AMPH (2) that are selective for DAT can facilitate low rates of ICSS that are characterized
by low frequencies of brain stimulation and this characteristic facilitation is an indication
of the abuse-related effects of the drug. On the other hand, drugs that are selective for
SERT, such as fenfluramine (7), depress ICSS rates maintained by high frequencies of
brain stimulation and this effect is a characteristic of their abuse-limiting effects.186
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Table 12. 4-Substituted MCAT analogs investigated in in vitro and in vivo assays.

HN
O

CH 3
CH 3

R

Agent

Acronym

R

Methcathinone (57)

MCAT

-H

Flephedrone (72)

4-F MCAT

-F

Methedrone (73)

4-OCH3 MCAT

-OCH3

4-Chloromethcathinone (74)

4-Cl MCAT

-Cl

4-Bromomethcathinone (75)

4-Br MCAT

-Br

Mephedrone (62)

4-CH3 MCAT

-CH3

4-Trifluoromethylmethcathinone (76)

4-CF3 MCAT

-CF3

The three parameters initially used for conducting the QSAR studies were; Taft’s constant,
lipophilicity and electronic character. Es, Taft’s constant, is a parameter that factors in both
potential energy-related steric strain effects and kinetic energy-related steric hindrance to
motion effects. It is calculated by measuring the hydrolysis rates of various esters.187,188 Es
is a general steric parameter and if a relationship between the pharmacology and Es is
obtained, other well-defined parameters such as Verloop parameters and substituent
volume can be examined. Verloop parameters incorporate length (L), minimum (B1) and
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maximum width (B5) of a substituent, and these are computationally calculated.189 The
ability of a molecule to be accessible to, and to interact with, its target depends upon its
lipophilicity, and the second parameter to be used is lipophilicity (π). Lipophilicity is the
ability of a molecule to partition itself between aqueous and organic phases and is measure
that can judge the ability of a molecule to penetrate a lipid membrane.190 Another
parameter that can influence the interaction between a molecule and its target is the
electronic character (σ) of the substituted groups on a molecule. Also known as the
Hammett σ parameter, it is one of the oldest parameters used in QSAR studies and is
experimentally derieved from the hydrolysis of substituted benzoic acids.191 It is associated
with the free energy change when a molecule binds to its target protein.191 In our study of
the 4-position (para) substitutents, σp values were used.

Verloop parameters are calculated using the STERIMOL program. Initially Verloop
devised five descriptors, this number was chosen as a compromise between the shape of
the molecule and avoiding a multitude of descriptors. The initial descriptors were length
(L) and width (B1-B4), where L is the length of the substituent along the axis of the bond
between the first atom of the substituent and the parent molecule and B1-B4 are four width
parameters calculated perpendicular to the length and also to each other.189 B1 is the
minimum width and B2-B4 is then followed in ascending order. Subsequently, Verloop
modified these parameters due to redundancy in the width parameters to include a slightly
modified length parameter, the minimum width B1 and a new parameter B5 that represents
the maximum substituent width.
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In addition, we constructed homology models both of hDAT and hSERT to examine the
results obtained from the QSAR studies. The program HINT (Hydropathic INTeractions)
was used as a means to further analyze the docking solutions. HINT calculates the
hydrophobic and polar interactions between a ligand and a protein and provides insight
into the energy contributions made between the ligand and a protein (i.e., specifically,
amino acids that might be involved in drug-receptor interactions).192

b. Methods
i. Synthesis
This, as were other projects described herein, was a collaborative effort involving other
members in our laboratory. Others in our laboratory synthesized some the compounds
employed for this study except for 4-F MCAT (72), and 4-CF3 MCAT (76) was provided
by Dr. Cozzi. Synthesis of compound 72 is outlined in Scheme 4.

Scheme 4. Synthesis of compound 72a

Br

O

O

CH 3

F
107

O
b

F
108

Reagents: (a) Br2, AlCl3, Et2O; (b) CH3NH2 in EtOH, benzene.
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CH 3

CH 3

a

a

HN

F
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ii. In vitro release in rat brain synaptosomes
This assay was performed in Dr. Baumann’s laboratory at NIDA. A detailed description of
the methods can be found in Bonano et al.193

iii. Intracranial self-stimulation in rats
This assay was performed in Dr. Negus’s laboratory at Virginia Commonwealth
University. A detailed description of the methods can be found in Bonano et al.193

iv. Correlational studies
Drs. Bonano and Glennon initially conducted the QSAR studies with Es, π, and σp and
their methods are reported in Bonano et al.193 They found that significant correlations
were obtained with Es and in vitro log DAT selectivity and in vivo ICSS facilitation. No
correlation was evident between activity and π or σp. Consequently, we investigated other
steric parameters that might better explain the role of these features towards activity.
These included volume and Verloop parameters.

For our QSAR studies, substituent volume was calculated using SYBYL-X 2.1 (Tripos
Inc., St. Louis, MO). The S isomer of each of the compounds was sketched in SYBYL and
volume values were generated for the entire molecule using the Molcad option within the
SYBYL program. Verloop’s steric parameters of length (L), minimum width (B1), and
maximum width (B5) were obtained from the literature.189 Linear regressions and
statistical analyses were performed using Prism 5.04 (GraphPad, San Diego, CA, USA)
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between each of these physiochemical parameters and in vitro log EC50 DAT, log EC50
SERT and in vitro DAT/SERT selectivity and the in vivo ICSS maximum percent baseline
facilitation, and correlations with a p <0.05 were considered statistically significant.
Values used for all parameters are shown in Table 13.

Table 13. Values used for all parameters used in the QSAR studies.
Vola

(B1)a
(Å)

(B5)a
(Å)

Esb

σ pb

πb

MCAT (57)

(Å3)
150.36

(L)a
(Å)
2.06

1.00

1.00

1.24

0

0

4-F MCAT (72)

153.78

2.65

1.35

1.35

0.78

0.06

0.14

4-OCH3 MCAT (73)

175.01

3.98

1.35

3.07

0.69

-0.27 -0.02

4-Cl MCAT (74)

164.43

3.52

1.80

1.80

0.27

0.23

0.71

4-Br MCAT (75)

169.43

3.83

1.95

1.95

0.08

0.23

0.86

4-CH3 MCAT (62)

166.89

3.00

1.52

2.04

0.00

-0.17

0.56

4-CF3 MCAT (76)

178.40

3.30

1.98

2.61

-1.16

0.54

0.88

Compound

a

Obtained from Verloop et al.189 bObtained from Wolff, M.E.194

v. Homology modeling and docking studies
Dr. Renata Kolanos constructed the homology model for hDAT and a detailed method for
its construction has been reported.195 Here, we report the construction of a SERT model.
A homology model for hSERT was constructed in a manner similar to that employed for
hDAT using the crystal structure of Drosophila melanogaster (dDAT) (PDB code 4M48)
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as a template as it shares over 50% homology with its mammalian counterparts and is a
hybrid of all three monoamine transporters DAT, SERT and NET.117

The sequence for hSERT (accession code P31645) was obtained from the SwissProtExPASY databank and was aligned with dDAT using ClustalX 2.1 (Figure 24).196 One
hundred models of hSERT were generated using MODELLER 9.10,197 and in each of these
models the first 76 residues from the N-terminus, 13 residues from the end of the Cterminus, and 7 residues from extracellular loop 2, were truncated due to lack of the
corresponding residues in the dDAT template. The two sodium ions and one chloride ion
was extracted from dDAT and incorporated into each of the hundred models. The sodium
and chloride ions have been proposed to play a role in the mechanism of action of DAT
and SERT and they might also affect the overall conformation of the transporter since the
rotameric states of the side chains of the amino acids around the ions might be
different.198,199 These ions are also in the ligand-binding pocket and could influence the
ligand-transporter interactions.117,119 Furthermore the amino acid residues forming the
binding sites for the two sodium ions and the chloride ion are highly conserved in the
dDAT, hDAT and hSERT transporters (Table 14).
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Figure 24. ClustalX-based alignment of the dDAT crystal structure, hDAT (UniProt ID =
Q01959) and hSERT (UniProt ID = P31645) primary amino acid sequences. The colored
boxes represent the transmembrane helical domains. Symbols indicate the degree of amino
112

acid conservation: ‘*’ for a fully conserved position, ‘:’ for strong conservation, ‘.’ for
weaker conservation, and no symbol for a non-conserved position.
Non-structure water molecules found in the crystal structure of dDAT were omitted from
each of the models. The S-isomer of each ligand to be docked was sketched using SYBYLX 2.1 and energy-minimized using the Tripos Force Field. The binding cavity was defined
using the nortriptyline molecule that was cocrystallized with dDAT and a 5-Å radius was
set around it. The automated docking program GOLDSuite 5.2200 was used to dock each of
the ligands to the one hundred transporter models.

Table 14. Residues interacting with the two sodium ions and the chloride ion in dDAT,
hDAT, and hSERT.

Na+1

Na+2

Cl–

dDAT
crystal
structurea
---A44
N49
S320
N352
G42
V45
L417
D420
S421
Y69
Q316
S320
S356

Current
hDAT
model
D79
A77
N82
S321
N353
G75
V78
L418
D421
S422
Y102
Q317
S321
S357

Current
hSERT
model
D98
A96
N101
S336
N368
G94
V97
L434
D437
S438
Y121
Q332
S336
S372

A total of 10 genetic algorithm-docking runs were performed for each docked ligand, and
docking simulations were performed without any constraints and were not subjected to
113

early termination. Using clustering techniques and SYBYL Programming Language (SPL)
scripts (written by Dr. Philip D. Mosier), putative modes of transporter-ligand interactions
were obtained. The most populated clusters, high Gold Scores and rational interactions
observed with the ligand and transporter, identified the most favorable transporter-ligand
complex for each of the docked ligands, and these were then energy minimized using
SYBYL-X 2.1.

HINT studies were conducted with the assistance of Dr. Mosier both on hSERT and hDAT
models. The HINT program, found within SYBYL 8.1 (Tripos Inc.) was employed.192 For
the initial partition phase, the dictionary method was used for the transporter and the
calculation method for the ligands. In the Intermolecular HintTable calculation phase, the
‘proton suppress’ button option was deactivated keeping all the other parameters to their
default values. Only the interactions involving the 4-position substituent with residues on
the transporter were analyzed and used for correlational studies.

c. Results
i. Results from in vitro assays
Results from in vitro synaptosomal release assays indicated that all the 4-positionsubstituted MCAT analogs tested were releasers both at DAT and SERT (Table 15 and
Figure 27) but with varying selectivity for the two transporters. Selectivty for DAT and
SERT of the compounds spanned a >4000-fold range with MCAT (57) demonstrating the
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highest selectivity for DAT, whereas 4-CF3 MCAT (76) displayed the least selectivity for
DAT.

% Maximum Release

125 MCAT
100
75
50
25
0
-10

DAT
SERT
-8

-6

-4

125 4-F MCAT
100
75
50
25
0
-10

-8

125 4-OCH MCAT
3
100
75
50
25
0
-6

-4

125 4-Cl MCAT
100
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50
25
0
-10

-8

-10

-8

-6

-4

-6

-4

125 4-Br MCAT
100
75
50
25
0
-6

-4

-10

-8

Drug Concentration (log M)
Figure 25. Effects of selected test agents on DAT- and SERT-mediated monoamine
release in rat brain synaptosomes. All points show mean ± SD for N=3 separate
experiments. EC50 values shown in Table 15 were derived from these concentration-effect
curves.193
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Table 15. In vitro release activity at DAT and SERT and in vivo behavioral ICSS effects
of MCAT and its analogs.
HN
O

CH 3
CH 3

R

Agent

R

DAT

SERT

EC50 (nM)

EC50

(nM)

DAT
Selectivity

ICSS
Maximum
% Baseline
Facilitation
191.9
156.3

MCAT (57)
-H
12.5±1.1
3,860±520
309
4-F MCAT
-F
83.4±1.1
1,290±220
15.4
(72)
4-OCH3
-OCH3
506±62
120±18
0.24
110.9
MCAT (73)
4-Cl MCAT
-Cl
42.2±5.2
144±22
3.40
114.9
(74)
4-Br MCAT
-Br
59.4±5.1
60.2±6.7
1.01
118.0
(75)
4-CH3 MCAT -CH3
49.1±8.3
118±26
2.41
102.5
a
(62)
4-CF3 MCAT
-CF3
2,700±300
190±30
0.07
90.9
b
(76)
a
Data published previously in Baumann et al.159 bData published previously in Cozzi et
al.201 All synaptosomal assays were conducted under similar conditions by Dr. Baumann
and, hence, data are comparable.

ii. Results from ICSS studies
Our group has reported results for MCAT (57) and MEPH or 4-CH3 MCAT (62)
previously and, in the current investigation, all the other analogs were tested and their
results are shown in Table 15 and Figure 26. All the compounds produced a dose-
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dependent change in ICSS. 4-F MCAT (72) produced a dose-dependent facilitation of low
rates of ICSS maintained by low brain frequency stimulations. 4-CF3 MCAT (76) produced
a dose-dependent depression of high rates of ICSS maintained by high brain frequency
stimulations. The remaining compounds 4-OCH3 MCAT (73), 4-Cl (74) and 4-Br MCAT
(75) produced ICSS effects that were a combination of the above two compounds, they
produced a facilitation of low rates of ICSS but at higher doses they depressed high rates
of ICSS maintained by high brain stimulation frequencies. For a detailed description of the
results see Bonano et al.193

iii. Correlational studies
Initial QSAR studies on Es, π, and σp were reported by us earlier.193 Significant
correlations obtained were with the steric constant Es and in vitro log DAT selectivity (r =
0.78, p = 0.04) and in vivo maximal ICSS facilitation (r = 0.81, p = 0.03). There was no
significant correlation between π and σp for either in vitro log DAT selectivity (r = -0.52, p
= 0.23 and r = -0.29, p = 0.53, respectively) or in vivo maximal ICSS facilitation (r = 0.66, p = 0.11 and r = -0.24, p = 0.61, respectively).193
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Figure 26. Effects of 4-F MCAT (72), 4-OCH3 MCAT (73), 4-Cl MCAT (74), 4-Br
MCAT (75), and 4-CF3 MCAT (76) on ICSS. Left panels show drug effects on full ICSS
frequency-rate curves. % MCR is %Maximum control rate. Drug doses are indicated in
legends in units of mg/kg. Filled points represent frequencies at which reinforcement rates
were statistically different from vehicle rates as determined by two-way ANOVA followed
by Holm-Sidak post hoc test, p<0.05. Right panels show summary ICSS data expressed as
percent pre-drug baseline number of stimulations delivered across all frequencies.
Upward/downward arrows indicate significant drug-induced increases/decreases in ICSS
relative to vehicle for at least one brain stimulation frequency as determined by analysis of
full frequency-rate curves. All data show mean ± SEM for five rats (4-F MCAT (72)) or
six rats (all other drugs).193
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Due to a significant correlation between the general steric parameter Es and the in vivo and
in vitro data, we performed QSAR studies using better-defined steric parameters. Results
from QSAR analyses using the 4-position substituent volume (Vol), minimum width (B1),
maximum width (B5) and length (L) are shown in Table 16.

Table 16. Results of correlational analysis between steric parameters, in vitro potencies at
DAT and SERT, and maximal ICSS facilitation. Significant correlations (p < 0.05) are
highlighted in bold.
Physicochemical log EC50 DAT
Parameter
Volume (Vol)
r = -0.803

r = 0.825

log DAT
Selectivity
r = -0.972

Maximal ICSS
Facilitation
r = -0.915

p = 0.03
r = -0.404

p = 0.02
r = 0.903

p < 0.01
r = -0.840

p < 0.01
r = -0.773

p = 0.26
r = -0.416

p < 0.01
r = 0.762

p = 0.03
r = -0.727

p = 0.04
r = -0.778

Maximum

p = 0.28
r = -0.807

p = 0.05
r = 0.720

p = 0.06
r = -0.917

p = 0.04
r = -0.814

Width (B5)

p = 0.03

p = 0.07

p < 0.01

p = 0.03

Length (L)
Minimum width
(B1)

log EC50 SERT

Log EC50 DAT was negatively correlated with volume and maximum width of the 4position substituent (i.e., a smaller volume and width of the 4-position substituent
contributes to increased potency at DAT (Figure 27)). Log EC50 SERT was positively
correlated with the 4-position substituent volume, length, and maximum width (i.e., larger
volume, length and width of the 4-position substituent contributes to increased potency at
SERT (Figure 28)). Log DAT selectivity was negatively correlated with volume, length
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and maximum width of the 4-position substituent (Figure 29) and maximal ICSS
facilitation was negatively correlated with all the parameters (Figure 30).

Figure 27. Relationships between log EC50 for DAT release and volume, maximum width,
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76).
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Figure 28. Relationships between log EC50 for SERT and volume, maximum width,
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76).
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Figure 29. Relationships between log DAT selectivity and volume, maximum width,
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76).
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Figure 30. Relationships between maximal ICSS facilitation and volume, maximum width,
minimum width and length of the 4-position substituents of MCAT (57, 62, 72-76).
iv. Molecular modeling and HINT analysis
Docking studies on the hDAT model were conducted by Dr. Kolanos and are reported in
Sakloth et al.195 The results from the paper are included here as a means for comparison of
the hDAT and hSERT models.

The homology model of hDAT (Figure 31A) is consistent with available site-directed
mutagenesis data.202-205 For hDAT, the docked MCAT solutions show extensive spatial
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overlap in the putative binding mode (Figure 31A). The models suggest that the charged
terminal amine of the MCAT analogs interacts favorably with the D79 side chain
carboxylate group, as has been reported for DA and releasing agents such as S(+)AMPH
(S(+)2).206,207 Previous mutations of this residue (i.e., D79A, D79G, D79E) suggest that it
plays a role in the binding of DA; these mutations led to the loss of the DA-reuptake
function of the transporter.204 In addition, our model shows that a hydrogen bond exits
between the backbone carbonyl group of F76 and the charged terminal amine. It already
has been shown that the mutation F76A dramatically reduced the DA uptake Vmax value.203

Other residues, including F76, V152, Y156, S422, and G426, engage in hydrophobic
interactions with the phenyl ring. Earlier studies of DAT indicated that V152, F156, and
S422 play a crucial role in the transport of DA. Mutants of hDAT (V152I, V152A and
V152M) displayed remarkably reduced DA uptake.205 Mutations of the strictly conserved
residue Y156 (Y156A and Y156C) resulted in inactive transporters.202 Also, S422 has been
implicated to bind DA through an interaction with its hydroxyl groups; a reported mutation
of this residue (S422A) resulted in decreased DA uptake.202

Our model predicts that F76, F320, and F326 interact with the α-methyl group. The Nmethyl group is directed toward a small pocket defined by F76, A77, F320, S321, and
L322. The 4-position substituent is directed toward S149. Recent studies have indicated
that, in hDAT, S149 might be important for coordination of the 4-OH group of DA.208 No
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specific interactions with the carbonyl oxygen atom of MCAT analogs were identified in
the binding site.

All the compounds adopted an analogous pose in the hSERT-binding pocket (Figure 31B).
A number of interactions were observed and the most important being the ionic interaction
of the charged amine with the side chain carboxylate group of D98. This interaction has
been observed with 5-HT in a previously published model.208 Mutagenesis studies have
indicated that this residue is important for transporter function: D98G, D98A, D98N
mutants were found to be inactive in uptake of 5-HT. Only the D98E mutation rendered
the transporter active, which suggests that the ionic interaction with D98 is important.209,210

We also observed a hydrogen bond between the backbone carbonyl of Y95 and the charged
amine. Mutation studies of this residue Y95E and Y95R rendered the transporter nonfunctional in a 5-HT uptake assay, whereas Y95F, Y95Q, Y95E decreased transporter
activity as compared to the wild type.210
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Figure 31. Superimposed poses of all seven MCAT analogs (57, 62, 72-76) in the putative
binding site of hDAT (A), and hSERT (B). Interacting amino acids within 5 Ǻ are
indicated. Unfavorable interactions of hDAT S149 with the 4-position substituents (shown
for the 4-methoxy analog (73); (C) that are not seen in hSERT due to the smaller side
chain of A169 (again, shown for the 4-methoxy analog; (D). The Connolly surface (shown
in grey in C and D) represents the channels in both transporters.
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The aromatic ring is buried in a hydrophobic pocket bound by Y95, I172, Y176, F341,
S438, and G442. In addition, our model predicts a hydrophobic interaction with the
aromatic ring of Y95 and G338 with the N-methyl group, and F341 with the α-methyl side
chain. A pocket of hydrophobic residues lined by A169, I172, A173, T439, and L443
surrounds the 4-position substituent. Residues (Y95, I172, Y176, F341, S438, G442, A169,
I172, T439, and L443) that make hydrophobic interactions in our docking studies have
been mutated previously, and the mutants showed decreased transporter activity in 5-HT
uptake assays as compared to the wild type.210

The polar, hydrophobic and total HINT scores were only calculated for the 4-position
substituent both at hDAT and hSERT (Table 17). At hDAT the total and polar scores were
negative and the hydrophobic scores, though positive, were not that high compared to
those at hSERT. Though hSERT had negative polar scores, it had higher positive total
HINT scores. A negative number in HINT studies implies unfavorable interactions and a
positive HINT score implies favorable interactions. All three HINT scores correlated only
with log EC50 at SERT (Table 18).
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Table 17. Calculated HINT scores for interaction of MCAT analogs (57, 62, 72-76) with
hDAT and hSERT.

MCAT (57)
4-F MCAT (72)
4-OCH3 MCAT (73)
4-CH3 MCAT (62)
4-Cl MCAT (74)
4-Br MCAT (75)
4-CF3 MCAT (76)

HINT Score at hDAT (4-substituent only)
Total
Polar
Hydrophobic
0
0
0
22
-11
33
-88
-231
143
-23
-154
131
2
-132
134
-13
-173
160
-5
-63
58

MCAT (57)
4-F MCAT (72)
4-OCH3 MCAT (73)
4-Cl MCAT (74)
4-Br MCAT (75)
4-CH3 MCAT (62)
4-CF3 MCAT (76)

HINT Score at hSERT (4-substituent only)
0
0
0
51
-12
63
125
-154
279
136
-102
238
135
-157
292
78
-173
251
97
-67
164

Table 18. Correlations between HINT scores and log EC50 values at hDAT and hSERT.
Statistically significant correlations (p<0.05) are highlighted in bold font.
HINT Score
Total
Polar
Contribution
Hydrophobic
Contribution

log EC50 DAT
r = 0.044

log EC50 SERT
r = -0.864

p = 0.93
r = 0.103

p = 0.01
r = 0.841

p = 0.84
r = 0.057

p = 0.02
r = -0.910

p = 0.90

p < 0.01
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d. Discussion
The aim of the current investigation was to study the behavioral and neurochemical effects
of a series of MCAT analogs (57, 62, 72-76) that differed only in their substitution at the 4position and identify what physicochemical parameters contributed to their distinct in vitro
and in vivo actions. The in vivo data revealed that all the analogs were releasers at DAT
and SERT. MCAT (57) displayed the highest selectivity (i.e., 309-fold) for DAT followed
by 4-F MCAT (72) that had 15-fold selectivity; 4-CF3 MCAT (76) and 4-OCH3 MCAT
(73) were the two compounds that displayed the least selectivity towards DAT (0.07 and
0.24-fold respectively).

The 4-Cl (74), Br (75) and CH3 (62) MCAT analogs had

intermediate selectivity for DAT (3.40, 1.01 and 2.41, respectively). ICSS data were
consistent with the in vivo data and indicated that MCAT (57) and 4-F MCAT (72)
produced an ICSS profile similar to DAT-selective agents such as AMPH (2) (a facilitation
of low rates of ICSS), and 4-CF3 MCAT (76) and 4-OCH3 MCAT (73) produced ICSS
profiles similar to those of SERT-selective agents such as fenfluramine (7) (decrease in
ICSS rates). The 4-Cl (74), Br (75) and CH3 (62) MCATs had intermediate selectivity for
DAT and SERT and produced mixed effects.

As per Hansch,211 the electronic, hydrophobic and steric features of substituents can
influence the ways in which molecules can affect biological activity, and identifying
correlations between the physicochemical properties in relation to their biological activity
can provide substantial information about the effects of substituents on biological activity.
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All the structural features of the MCAT analogs, for example the 4-position substituent,
terminal amine, aromatic ring and the α-methyl group, likely contribute to activity at DAT
and SERT. However, we focused on the 4-position substituent, as the other structural
features are constant amongst the series of MCAT analogs investigated (57, 62, 72-76).

Steric factors are important parameters in understanding drug-receptor interactions. The
binding site for the drug is made up of amino acids oriented in a particular manner such
that it provides spatial complementarity with the drug. The Taft steric parameter Es was
one of the first available parameters that integrates the effects of both steric strain and
hindrance; however, it has been criticized in the manner in which it was developed (for e.g.
it accounted for the intramolecular as opposed to intermolecular effects), and several
modifications have been developed since.212 For example, one of the modifications was by
Hancock to include the hyperconjugation effects (Esc), and Charton found that Es was
linearly related to the van der Waal’s radius for symmetrical substituents or the minimum
width for unsymmetrical ones.189,212 There are other parameters, too, that can probe the
effect of steric factors, for example molar refractivity, and Charton’s parameters.

Verloop used the STERIMOL program to computationally calculate the length, maximum
width and minimum width of substituents.189 Having first established that steric parameters
affect the activity of the 4-position substituted MCAT analogs,193 we used the above
parameters to gain greater insight. The advantage of using Verloop parameters and volume
is that they were not developed experimentally and are not subject to any experimental
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assumptions and might provide more accurate results.213 Verloop parameters also have the
advantage that they address three-dimensional issues of a compound. Since they are
calculated computationally, they can be used for any group or substituent. The way
Verloop parameters were calculated measured the dimensions of a substituent along
several axes and, collectively, these values would provide information regarding the
molecular shape especially for substituents that are nonsymmetrical. The older parameters
were all a single value defining the steric nature of a substituent and did not always
consider non-spherical molecules and were emperically derived.189

Preliminary QSAR studies indicated that large 4-position substituents contribute towards
potency at SERT whereas small 4-position substituents contribute towards potency at
DAT. Amongst the significant correlations observed between volume, maximum width,
and length, and log DAT selectivity, the correlation with the volume parameter was the
highest.

Our modeling studies gave rise to new homology models for hSERT and hDAT based on
the dDAT template. Docking studies indicated that MCAT (57) and its analogs adopt
analogous poses in the hSERT-and hDAT-binding cavity. Residues identified in our
studies to make interactions with ligands are consistent with available mutagenesis data.
The residues at the binding cavity of the 4-position substituent are relatively conserved
between both hSERT and hDAT except for S149 and V152 in hDAT and A169 and I172
in hSERT. In our docking studies the 4-position substituent is oriented towards S149 in
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hDAT and A169 in hSERT. S149 is a more polar residue as compared to the hydrophobic
A169 and makes the binding pocket less accommodating towards substituents that are
larger in size and provides an explanation towards decreased DAT selectivity for
compounds with larger 4-position substituents. And this result is consistent with the in
vitro data and QSAR data the compounds with larger 4-position substituents e.g. 4-CF3
MCAT (76) and 4-OCH3 MCAT (73) exhibit the least selectivity for DAT whereas
compounds with smaller 4-position substituents e.g. MCAT (57) and 4-F MCAT (72)
exhibit the highest selectivity for DAT. HINT studies denoted that in the case of hSERT
there are favorable hydrophobic interactions whereas at hDAT there are unfavorable polar
interactions that contribute towards potency (though not statistically significant). This
supports the docking studies that the polar residue S149 provides an unfavorable
environment in the hDAT-binding pocket for larger 4-position substituents as compared to
A169 that is a relatively smaller and more hydrophobic residue. Mutational studies
especially of A169 in hSERT and S149 in hDAT should provide evidence to support our
modeling studies, and such studies are currently underway. Once we completed our
modeling studies we became aware of a similar study conducted by Severinsen et al.214
where they studied a series of 1-phenylpiperazine analogues with varying 4-position
substituents. The residues identified by them to make key interactions with their ligands
are mostly consistent with ours (Table 19). Table 19 shows that nine of the twelve amino
acids identified by us in the hDAT model pocket were identified in the earlier study, as
well as eleven of the twelve amino acids in the hSERT model. It should be noted that their
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models were constructed using a LeuT template which has a homology of around 20%
with hDAT and hSERT.119
Table 19. Amino acid residues implicated from docking studies.
DAT (present study)
D79
F76
V152
Y156
S422
G426
F320
F326
A77
S321
L322
S149

DAT (Severinsen et al.)214
D79
F76
V152
Y156
S422
G426
F320
F326

SERT (present study)
D98
Y95
I172
Y176
F341
S438
G442
G338
A169
A173
T439
L443

SERT (Severinsen et al.)214
D98
Y95
I172
Y176
F341
S438
G442

S149
V328
A423
G153

A169
A173
T439
S149
V343
F335
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Shortly after we completed and published our studies, new x-ray crystal structures of
dDAT crystallized with psychostimulants such as AMPH (S(+)2), METH (S(+)5) and
cocaine were published.118 In order to compare our models to the published crystal
structures, the structure of dDAT co-crystallized with METH (S(+)5) was used (PDB entry
code 4XP6). METH (5) differs from our parent compound MCAT (57) by the presence of
β- keto group, in the latter, and both share a common mechanism of action.

Using SYBYL-X 2.1, 4XP6 was aligned by homology to our energy minimized MCAT
(S(+)57) ligand merged with both the hDAT and hSERT homology models. Root mean
square deviation values (RMSD) values were obtained. The degree of similarity between
two proteins can be calculated based on their RMSD score; similar structures will have low
scores in the 1-3 Å range and large values imply a greater deviation in similarity.215 The
RMSD score between dDAT complexed with (+)METH (S(+)5)

and our energy-

minimized models with MCAT (S(+)57) was 1.39 for hDAT and 1.32 for hSERT. These
low scores indicate a substantial three-dimensional similarity between our models and the
crystal structure.

In the case of both hDAT and hSERT the residues in the binding cavity are well aligned
with those of 4XP6. Our results seem consistent with what was reported for METH
(S(+)5). Wang et al.118 reported that the terminal amine of METH (S(+)5) makes an ionic
interaction with D46 and the carbonyl group of F319. In our models the terminal amine
makes the same ionic interaction with the homologous D79 and D98 and the backbone
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carbonyl of the homologous F76 and Y95 in DAT and SERT, respectively. They also
report hydrophobic edge-to-face interactions of the phenyl ring with F325. Our models
predicted the phenyl ring to be engaged in hydrophobic interactions with residues such as
F76 for hDAT and F341 for hSERT amongst others.

Although the ligands both in SERT and DAT are not perfectly superimposable with
(+)METH (S(+)5), they are in extremely close proximity (Figure 32A and B). The αmethyl and N-methyl groups of (+)METH (S(+)5) seem to align differently from our
ligands. These differences can be explained based on the fact the side chain of D46 is not
totally superimposed with D79 or D98; thus, the N-methyl group orients itself to be able to
form the ionic bond. Also due to the lack of the β-keto group, the METH (S(+)5) molecule
has a more freely rotatable bond at the β-position and could cause the α-methyl and Nmethyl groups to be oriented slightly differently.

135

S321

A

S320

L322
B

D79

D46

G322
F319

S421
S422

D46 D98A44 A96

L321

S421
S438

F43
F320
F76

Y176

F326

F325

Y124

Y124
Y156

G338

F341

I172
T439

G426 G425
V120

V120

F325

S422

S149

A169

V152
A117

A173

A117

Figure 32. Comparison of the binding pockets of MCAT (S(+)57) docked in (A) hDAT
and (B) hSERT models with METH (S(+)5) cocrystallized with dDAT. MCAT (S(+)57) is
indicated in magenta and METH (S(+)5) is indicated in green. Residues labeled in green
belong to dDAT and purple belong to hDAT and hSERT and images are an overlap of the
residues within 5Å of the ligand binding pockets of (A) dDAT and hDAT (B) dDAT with
hSERT.
Due to significant intercorrelations observed between the parameters (r > 0.9) investigated
and a narrow range of values of Verloop parameters for the 4-position substituents
additional compounds will be needed to better determine which parameter is the most
important for DAT/SERT selectivity.
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AIM III. Structure-activity relationship studies on the “bath salts” component
methylone at dopamine and serotonin transporters

a. Introduction
Methylone or methlenedioxymethcathinone (MDMC, 61), the β-keto analog of MDMA
(44) (Figure 33), is one of the original components of the psychoactive “bath salts”
mixture. Our laboratory, and others, have investigated MDMA (44) or “ecstasy”, a popular
drug of abuse, previously for its SAR, as well as its pharmacological profile, which was
discussed in the Background section.
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Figure 33. Ethylenedioxy analogs of MDMA and MDMC (51 and 77) and N-alkyl chain
extended analogs of MDMC (78 and 79) investigated in the current study.
MDMC (61), the β-keto analog of MDMA (44), has not been well investigated in terms of
its SAR. Its recreational use has made it popular and there have been reports of death due
to its toxicity.216,217 Our group first reported on its MDMA (44) and AMPH-like effects in
drug discrimination studies around 12 years before it gained recognition as a “bath salts”
component.145 Other in vivo studies were subsequently conducted after its reemergence as
“bath salts”. Our group evaluated its effects in ICSS studies,146 and others have reported on
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its effects in conditioned place preference assays,218 locomotor stimulation185,219 and
reinforcing properties as well.220 All of these studies indicated that its actions were
consistent with its abuse potential.

Ethylone (78) (Figure 33), an analog of MDMC (61), has been recently found on the
clandestine market and has been reported to cause toxic side effects and death.221,222 The
DEA has solicited information on phenylalkylamine compounds that are not scheduled that
could be potential drugs of abuse;163 one such compound is EDMA (51) (Figure 33) the
ethylenedioxy analog of MDMA.

To recapitulate, MDPV (63) and MDMC (61) share a methylenedioxy ring as a common
structural feature, but MDPV (63) has a pyrrolidine ring and an extended α-n-propyl side
chain whereas MDMC (61) has an N-methyl group and an α-methyl side chain and, from
the SAR of MDPV (63), we identified that extending the α-side chain and tertiary nature
of the terminal amine confers DAT reuptake properties.169,181

With the above backdrop, we sought to understand the effects of ring expansion from a
methylenedioxy group to an ethylenedioxy group, so we synthesized EDMC (77) and the
MDMA counterpart EDMA (51). We also wanted to investigate the length of the alkyl
chain that can be tolerated at the terminal amine such as that found in ethylone (78).
Because related agents might be identified in the future on the clandestine market and
possess abuse liability, we also synthesized propylone (79) (Figure 33).
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b. Methods
i. Synthesis
MDMA (44) was on hand, and data for MDMC (61) were reported earlier159 and is
included here as a means for comparison. The synthesis of compound 51, 77, 78 and 79 is
outlined in Schemes 5, 6 and 7, respectively.

Scheme 5. Synthesis of compounds 51a
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Reagents: (a) Ammonium acetate, nitroethane; (b) i) LiAlH4, THF ii) Et2O/HCl; (c) ethyl
chloroformate, Et3N; (d) LiAlH4, THF.
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Scheme 6. Synthesis of compounds 77a
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Reagents: (a) SnCl4, CH2Cl2, propionyl chloride; (b) Br2, AlCl3, Et2O; (c) benzene,
CH3NH2 in EtOH.
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Scheme 7. Synthesis of compounds 78 and 79a
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Reagents: (a) SnCl4, CH2Cl2, propionyl chloride; (b) Br2, AlCl3, Et2O; (c) benzene,
CH3CH2NH2 in MeOH (78)/ n-propylamine (79).
ii. In vitro release and uptake inhibition in rat brain synaptosomes
This assay was performed in Dr. Baumann’s laboratory at NIDA, and details have been
reported in Del Bello et al.223

c. Results
MDMA (44) was included as a reference compound and was found to be a non-selective
releaser at DAT and SERT consistent with earlier published results (Figure 34 and Table
20).159 Its ethylenedioxy analog, EDMA (51), was half as potent at SERT but 8-fold less
potent at DAT (Figure 34 and Table 20). EDMA (51) was more selective for SERT over
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DAT by 5-fold. MDMC (61) was slightly more selective for DAT than SERT (2-fold),
comparatively EDMC (67) was slightly more selective for SERT over DAT (1.5-fold)
(Figure 34 and Table 20). On comparing the potencies of EDMC (77) and MDMC (61)
with each other, MDMC (61) was 4- and 1.5-fold more potent at DAT and SERT. MDMA
(44) was 2-fold more (consistent with earlier published results145,149) and 4-fold more
potent than MDMC (61) at DAT and SERT respectively.

Figure 34. Effects of MDMA (44), EDMA (51) and EDMC (77) on the release of [3H]5HT at SERT and [3H]MPP+ at DAT and SERT. Data are % maximal release expressed as
mean (±)SD for n = 3-4 separate experiments performed in triplicate (Figure provided by
Dr. Baumann).
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Table 20. EC50 values for MDMA (44), MDMC (61), EDMA (51) and EDMC (77) to
release [3H]5-HT at SERT and [3H]MPP+ at DAT.
Compound

EC50 nM (±SD)a
SERT
DAT

EDMA (51)

117 (±17)
[102±3]

597 (±50)
[108±3]

MDMA (44)

61 (±9)
[98±2]

75 (±5)
[99±1]

EDMC (77)

347 (±38)
[105±3]

496 (±52)
[105±4]

MDMC (61)b

242 (±48)

133 (±11)

a

EC50 values are mean (±SEM) for n = 3-4 experiments; efficacy
values [in brackets] are % maximal release expressed as mean
(±SEM) as described in Methods.223 bEC50 values for MDMC
(61) were reported earlier159 and are included for comparison
with EDMC (77).
The N-alkyl chain-extended compounds ethylone (78) and propylone (79) show activity
different from MDMC (61) (Figure 35 and Table 21). Ethylone (78) has comparable
activity at DAT and SERT for uptake inhibition. At DAT ethylone (78) is primarily a
reuptake inhibitor since its efficacy is very low (38%) for release. At SERT, ethylone (78)
is a weak reuptake inhibitor and a partial releaser. Propylone (79) is a weak reuptake
inhibitor at both DAT and SERT, the effects at the former being slightly more potent
(Figure 35 and Table 21).

144

Table 21. EC50 values for ethylone (78) and propylone (79) to release [3H]5-HT at SERT
and [3H]MPP+ at DAT and IC50 values to inhibit the uptake of [3H]5-HT at SERT and
[3H]MPP+ at DAT.
Compound
SERT
Ethylone
(78)

Propylone
(79)

IC50 nM (±SD)
DAT

1215 (±90)

EC50 nM (±SD)
SERT
DAT

973.4 (±123)

[100]

[100]

2462 (±317)

1863 (±382)

[99]

[103]

617.4(±110)
[72]
3128(±1376)
[30]

a

1122 (±314)
[38]
975.9 (±411)
[20]

EC50 values are mean (±SEM) for n = 3 experiments; efficacy values [in brackets] are %
maximal release expressed as mean as described in Del Bello et al.223
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Figure 35. Effects of ethylone (78) and propylone (79) on release and uptake of [3H]5-HT
at SERT, and [3H]MPP+ at DAT. Data are % maximal release expressed as mean (±)SD for
n= 3 separate experiments performed in triplicate (Figure provided by Dr. Baumann).
d. Discussion
The ethylenedioxy analogs (51 and 77) seem to be better accommodated at SERT
consistent with what was reported by us earlier (see Aim II) that SERT than DAT can
tolerate larger substituents at this position compared to DAT.195 Ring expansion from the
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five-membered methylenedioxy ring to the six-membered ethylenedioxy ring results in a
small decrease in potency (less than 8-fold).

It is important to mention here that Shulgin had synthesized EDMA (51) and has selftested its effects and called it a “strange and unsatisfactory compound”. He reported that it
produced only threshold effects at a dose of 250 mg. However, the actions of EDMA (51)
have not been previously examined at DAT or SERT.85

As the length of the alkyl chain increased at the terminal amine the compounds shifted in
their activity from releasers to reuptake inhibitors. However, they seem to be weak
reuptake inhibitors if we compare them to MDPV (63), which has an IC50 of 4.1 nM in the
same assay.160 We know from our results in AIM I that an extended side chain at the αposition and the tertiary amine both contribute to the inhibitory potency at DAT. It can
then be inferred that, since ethylone (78) and propylone (79) lacked the extended side
chain at the α-position and they are secondary amines instead of tertiary amines, they
would be relatively weaker inhibitors than MDPV (63) at DAT.

In the case of SERT these compounds are weak inhibitors, implying that increased length
of the side chain at the terminal amine shifts activity from a releaser to a reuptake inhibitor.
Also compared to the analogs of MDPV (63) tested in AIM I which were inactive at SERT
(concentrations up to 10,000 nM), ethylone (78) and propylone (79) were not totally
inactive and exhibited atleast weak reuptake properties. Ethylone (78) produced releasing
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effects but with an efficacy less than 100%. Such compounds are referred to as partial
releasers. Partial releasers are defined as compounds that are “transporter substrates that
do not release the maximum releasable pool of neurotransmitter even at the highest
concentrations”.224

The present result for SERT and results from AIM I indicate that compounds lacking a
bulky/extended side chain and a tertiary amine could confer weak inhibitory properties at
SERT. Microdialysis studies have shown that transporter inhibitors produce only a small
increase in extracellular neurotransmitter concentration compared to releasers. Studies
currently being performed in Dr. Baumann’s laboratory should provide additional
information about the effects of these drugs on in vivo neurotransmitter levels and their
mechanism of action.

Compounds to test the effects of simultaneous chain extension at the terminal amine and
the α-position are currently being synthesized by others in the laboratory.

It continues to appear that newer synthetic cathinones, in this case, analogs of MDMC
(61), are making their way into the designer drug world and they could be potential
psychoactive drugs and our study provides useful information about them.
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AIM IV. Investigation of the N-alkyl chain length of 4-methylamphetamine analogs:
An examination of its pharmacological effects at the dopamine and serotonin
transporters

a. Introduction
Studies conducted thus far suggested that simple structural changes to the cathinone
molecule could result in distinct behavioral and neurochemical changes. For example,
MDPV (63) was found to be the first synthetic cathinone to show reuptake inhibition
properties,9-11 the size of the substituent at the 4-position of MCAT (57) influences their
selectivity towards DAT and SERT (AIM II),193 and in the case of MDMC (61) the length
of N-alkyl chain determines the mechanism of action and selectivity of the compounds
(AIM III).

MCAT (57) is the β-keto analog of METH (5) and, due to their close structural
resemblance, similar modifications on the METH (5) scaffold could result in either
different or similar pharmacological profiles to its MCAT analogs.

The goal of the current investigation was to determine the effect of chain extension of the
N-alkyl group of 4-methylmethamphetamine (4-MA). 4-MA was used as the parent
compound because the 4-methyl group is found in MEPH (62), and MEPH (62) was found
to be non-selective between DAT and SERT, should allow for a rational comparison of
terminal amine substituents at both the transporters (i.e., DAT and SERT).193
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We extended the chain length linearly from methyl to butyl on 4-MA (Figure 36) and
investigated these compounds for their effects in electrophysiological assays in Xenopus
laevis oocytes expressing hSERT and hDAT, for release/reuptake inhibition through DAT
and SERT in rat synaptosomes and in the ICSS assay for their abuse related/abuse limiting
effects.

H N R
CH 3

CH 3
80:
81:
82:
83:

R
R
R
R

= CH 3
= CH2CH 3
= CH2CH2CH 3
= CH2CH2CH2CH 3

Figure 36. N-Alkyl chain-extended 4-MA compounds investigated in the current study for
their in vitro and in vivo effects.
b. Methods
i. Synthesis
Rakesh Vekariya synthesized compound 80,225 and Dr. Battisti synthesized the
intermediate 121. The synthesis of 81-83 is outlined in Scheme 8.

Scheme 8. Synthesis of compounds 81-83a
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H N R

O
CH 3

CH 3
f

CH 3

CH 3

a

121

82: R = CH2CH2CH 3
83: R = CH2CH2CH2CH 3
e

NO 2
O

NH 2

CH 3

CH 3
b

a

CH 3

CH 3
116

CH 3
118

117

O
H N

H N

R
CH 3

c

R
CH 3

d

CH 3
119: R = CH 3
120: R = CH2CH 3

a

CH 3
81: R = CH 3
82: R = CH2CH 3

Reagents: (a) Nitroethane, ammonium acetate; (b) i) LiAlH4, THF ii) Et2O/HCl; (c) acetyl
chloride (119)/propionyl chloride (120), CH2Cl2, Et3N; (d) LiAlH4, THF; (e) Fe, aqueous
acetic acid; (f) glacial acetic acid, n-propylamine (82)/n-butylamine (83), NaCNBH3.
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In vivo studies required a larger scale of compounds and their initial synthesis used
LiAlH4. A scale up would require increased quantities of LiAlH4 and the second route to
synthesizing 82 was shorter.

ii. Transporter-mediated ion currents in DAT- or SERT-expressing oocytes
The procedure for this experiment is the same as that reported in Kolanos et al. for both
DAT and SERT.169 These studies were performed in Dr. De Felice’s laboratory at Virginia
Commonwealth University.

iii. In vitro release and uptake inhibition in rat brain synaptosomes
The procedure is similar to that reported by Kolanos et al.181 for reuptake inhibition (aim I)
and the procedure is similar to that reported by Bonano et al.193 for release assays. These
studies were performed in Dr. Baumann’s laboratory at NIDA. Details can also be found in
AIM I.

iv.

Intracranial self-stimulation in rats

The procedure is similar to that reported by Bonano et al.193 These studies were performed
in Dr. Negus’s laboratory at Virginia Commonwealth University.
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c. Results
i. Results from TVEC assay
An application of DA (5 µM) in Xenopus laevis oocytes expressing hDAT and clamped to
-60 mV showed a characteristic inward (i.e., depolarizing) current. This was followed by
the application of each of the 4-MA analogs (10 µM) (Figure 37). Only N-methyl 4-MA
(80) showed an inward depolarizing current that is characteristic for compounds that act as
releasing agents (Figure 37). The N-ethyl (81), N-propyl (82) and N-butyl 4-MA (83)
analogs produced an outward hyperpolarizing current that is characteristic for agents that
are reuptake inhibitors; however, the compounds differed in the magnitude of their
hyperpolarizing effects.

Application of 5-HT (5 µM) in Xenopus laevis oocytes expressing hSERT and clamped to
-60 mV showed a characteristic inward current. This was followed by the application of
each of the 4-MA analogs (10 µM). All compounds produced inward currents with varying
magnitudes (Figure 37). N-Methyl (80) and N-ethyl 4-MA (81) produced inward currents
that were twice as large as those produced by 5-HT. The N-propyl analog, 82, produced a
current that was comparable to the 5-HT current and the N-butyl analog, 83, analog
produced a diminished inward current (Figure 37).
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Figure 37. Effect of N-substituted 4-MA analogs on membrane currents in oocytes
transfected with hDAT (A-D) or hSERT (E-H) (Figure provided by Dr. De Felice’s
laboratory). N-Me (N-methyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4MA, 82), and N-Bu (N-butyl 4-MA, 83).
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ii. Results from monoamine release and uptake inhibition in rat-brain synaptosomes
All the compounds produced dose-dependent effects for monoamine release and/or of
reuptake (Figure 38 and Table 22). N-Methyl 4-MA (80) displayed both inhibitory and
release effects at DAT and SERT (Figure 38 and Table 22) and was more potent for its
release than reuptake properties by 22-fold at DAT and 2.5-fold at SERT (Figure 38 and
Table 22). Also N-Methyl 4-MA (80) was non-selective for its release effects at DAT and
SERT (Figure 38 and Table 22). N-Ethyl 4-MA (81) displayed both inhibitory and
releasing effects that were almost comparable; it was more selective at DAT over SERT by
about 5-fold (Figure 38 and Table 22). However, it was less efficacious at DAT (58%) and
less potent at SERT by 2- to 3-fold than its N-methyl analog 80 (Figure 38 and Table 22).
N-propyl 4-MA (82) was only 20% as efficacious as a releaser but displayed an inhibitory
action at DAT, but with lower potency as compared to its N-methyl (i.e., 80) and N-ethyl
analog (i.e., 81) (Figure 38 and Table 22). However at SERT, the N-propyl analog had
comparable potency for release and reuptake effects (Figure 38 and Table 22). The N-butyl
analog, 83, produced sub-maximal effects at DAT for release and exhibited diminished
inhibitory potency (Figure 38 and Table 22). At SERT, the compound was inactive as a
releaser and produced sub-maximal effects (36%) as a reuptake inhibitor (Figure 38 and
Table 22).

155

A

Monoamine release
B

Monoamine uptake inhibition
C

D

Concentration (log M)
Figure 38. Effects of N-alkyl 4-MA analogs on monoamine release and uptake in rat brain
synaptosomes. Top panels (A-B) show drug effects on monoamine release. Abscissae:
drug concentration in log M. Ordinates: Percent release of [3H]MPP+ (A) or [3H]5HT (B).
Bottom panels (C-D) show drug effects on monamine uptake inhibition. Abscissae: drug
concentration in log M. Ordinates: Percent uptake inhibition of [3H]DA (C) or [3H]5-HT
(D). EC50 and IC50 values determined from these curves are reported in Table 22. N-Me
(N-methyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4-MA, 82), and N-Bu (Nbutyl 4-MA, 83). All points show mean (±SEM) of three determinations (figure provided
by Dr. Baumann’s laboratory).
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Table 22. EC50 values to promote monoamine release or IC50 values to inhibit monoamine
uptake for N-substituted 4-MA analogs. All values were derived from data shown in
Figure 38. An EC50 or IC50 value is shown only if the maximal effect was ≥50%. If the
maximal effects was <50%, the maximum effect is shown.

Drug

EC50 (nM±SEM)

DAT
909.6±66

SERT
170.9±41

794.9±125

166.0±29

N-Propyl 4-MA (82)

550.4±132
102.2±16
(Emax= 62%)
20%
650.2±90

3064±366

983.6±219

N-Butyl 4-MA (83)

29%

13660±360

36%

N-Methyl 4-MA (80)
N-Ethyl 4-MA (81)

DAT
41.3±5

SERT
67.4±14

IC50 (nM±SEM)

0%

iii. Results from ICSS studies
All of the examined analogs produced dose-dependent changes in ICSS that differed in
their DA-mediated abuse-related effects and potencies (Figure 39). N-Methyl 4-MA (80)
produced facilitation of low rates of ICSS maintained by low brain frequencies at a dose of
0.32 mg/kg and, at higher doses of 1 mg/kg, produced mixed effects consisting of
facilitation of ICSS at low brain frequencies and depression of high rates of ICSS
maintained by higher frequencies. N-Ethyl 4-MA (81) produced mixed effects at a dose of
1 mg/kg and depression of ICSS effects maintained by high brain frequencies at a dose of
3.2 mg/kg. The N-propyl (i.e., 82) and N-butyl analog (i.e., 83) produced dose-dependent
decreases in ICSS effects for intermediate to high brain frequencies at doses of 10 and 0.32
mg/kg respectively.
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N-Methyl 4-MA

N-Methyl 4-MA

N-Ethyl 4-MA

N-Ethyl 4-MA

N-Propyl 4-MA

N-Propyl 4-MA

N-Butyl 4-MA

N-Butyl 4-MA

Figure 39. Effects of N-alkyl 4-MA analogs on ICSS in rats. Left panels A-D show full
ICSS frequency-rate curves. Abscissae: Brain stimulation frequency in log Hz. Ordinates:
Percent maximum control response rate (%MCR). Filled points show drug effects
significantly different from VEH treatment as determined by two-way ANOVA followed
by a Holm-Sidak post hoc test (p<0.05). For all panels, there were significant main effects
of frequency (p<0.001) and dose (p<0.001) (details not shown). Frequency-dose
interactions were also significant (all p<0.001) as follows: N-Me 4-MA, F(36,180)=9.91,
N-Et 4-MA, F(36,180)=6.38, N-Pr 4-MA, F(36,180)=7.01, N-Bu 4-MA, F(36,180)=2.93.
Right panels E-H show summary data for the total number of stimulations delivered across
all brain-stimulation frequencies. Abscissae: Drug dose in mg/kg. Ordinates: Total
number of stimulations per component expressed as percent baseline (% Baseline Total
Stimulations). Upward/downward errors indicate that ICSS rates were significantly
increased/decreased for at least one brain-stimulation frequency as determined by analysis
of full frequency-rate curves in the left panels. All points and bars show mean±SEM in six
rats (figure provided by Dr. Negus’s laboratory).
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d. Discussion
The effects on selectivity and mechanism of action of N-alkyl substituted 4-MA analogs
have not been previously investigated at DAT and SERT. It would to appear that as the
length of the N-alkyl chain is increased there is a change in action from a strong releaser to
a weak reuptake inhibitor at DAT, but at SERT an increased side chain length shows nonselective properties as both a releaser and a reuptake inhibitor.

At hDAT, electrophysiological studies suggest that the length of the N-alkyl chain on 4MA analogs influences their current. Only N-methyl 4-MA (80) showed the
electrophysiological signature of a releasing agent (i.e., an inward current) whereas the
other analogs showed outward hyperpolarizing currents, the signature of reuptake
inhibitors, the magnitude of which diminished as the N-alkyl chain length increased from
ethyl (81) to propyl (82) to butyl (83).

In vitro data support the above, with N-methyl 4-MA (80) being the most potent as a
releaser at DAT. As chain length was increased to N-ethyl (i.e., 81), the compound was
non-selective as a releaser or a reuptake inhibitor but its efficacy was only 62% as a
releaser at DAT. This implies that the compound is a “partial releaser” and a weak
reuptake inhibitor at DAT. There are two possible explanations for this. First, the
difference in activity might be due to a difference in activity between the two enantiomers,
with one isomer being more potent as a releaser or reuptake inhibitor, or the isomers could
have opposite mechanisms of action. The isomers are currently being investigated. A
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second explanation for this hybrid activity is related to the transport mechanism. N-Propyl
4-MA (82) and N-butyl 4-MA (83) show weak reuptake inhibition properties. These
inhibitory effects result in a decrease in potency as chain length is increased at the N-alkyl
position with N-butyl 4-MA (83) being 150-fold less potent than its corresponding Nmethyl analog.

At SERT, all analogs showed inward depolarizing currents of differing magnitudes, and
increased chain length at the terminal nitrogen atom resulted in a loss in activity. For
example, N-butyl 4-MA (83) was inactive as a reuptake inhibitor and had decreased
efficacy (36%) for release. As chain length was decreased to N-propyl (82) and N-ethyl
(81) the compounds were efficacious both for release and reuptake and have comparable
potencies for both actions. A plausible explanation for their dual action of the above two
compounds is a difference in the activity of the two enantiomers or the mechanism of
transport. Isomers will need to be examined

The ICSS assay provides a useful tool to assess the abuse liability of a compound.186 In the
current study it was observed that as chain length was increased there was a decrease in the
DA-mediated abuse related effects with the potency order being N-methyl (80) > N-ethyl
(81) > N-propyl (82) > N-butyl (83).

Previous studies conducted by others on analogs of METH (5) (without the 4-methyl
substituent) also produced results analogous to those observed herein, both in in vivo and
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in vitro assays. van der Shoot first studied the effects of chain extension on the terminal
nitrogen of AMPH (2) in mouse locomotor assays and found that as chain length increased
from methyl to n-butyl, locomotor stimulation properties decreased.226 These assays were
conducted on racemates. In vitro assays performed on the above AMPH analogs, displayed
results very similar to ours, with N-ethyl AMPH being less potent than METH (5) as a
releaser at DAT by about 3.5-fold and N-propyl and N-butyl AMPH were DA reuptake
inhibitors (N-butyl analog demonstrating a 2.5-fold decrease in activity).224

Cathinone (1) is the β-keto analog of AMPH (2) and the SAR for both display some
parallels but there have been exceptions.145 On comparing the AMPH series with the
corresponding cathinone analogs we see that the SAR shows some differences. MEPH
(62), the cathinone analog of N-methyl 4-MA (80), both showed activity as releasers at
DAT and SERT. N-Ethyl-4-methylcathinone (MEC, 122) is a SERT substrate and a DAT
blocker;227 its AMPH analog, 81, displayed activity both as a releaser and a reuptake
inhibitor at DAT but had a higher efficacy as a DAT reuptake inhibitor than as a releaser
but was equipotent and efficacious at SERT for both reuptake and inhibition.
HN
O

CH 3
CH 3

CH 3
122
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It can be observed that simple structural changes contribute to somewhat different actions
at DAT and SERT and that these differences can, perhaps, be attributed to their mechanism
at the transporter (i.e., their could be differences in the binding site or the manner in which
they make their entry into the transporter-binding site (a more detailed discussion is
provided in the Summary chapter)).
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AIM V. Effects of psychoactive synthetic cathinones and amphetamine analogs at the
norepinephrine transporter

a. Introduction
The norepinephrine transporter (NET) is a target for therapeutic drugs such as the
norepinephrine reuptake inhibitor reboxetine for depression,228 and atomoxetine for the
treatment of ADHD.229 NET is also a target for psychostimulant drugs such as cocaine and
AMPH (2).230,231 The activity of synthetic cathinones at NET is more similar to DAT
compared to SERT (Table 23).

Table 23. A comparison of the in vitro effects of MCAT (57), MEPH (62), and MDPV
(63) at DAT, NET and SERT in rat brain synaptosomes.
Compound
MCAT (57)193

DAT
EC50 =12.5 nM

NET
EC50 = 22 nM

SERT
EC50 = 3860 nM

MEPH (62)159

EC50 = 49.1 nM

EC50 = 62.7 nM

EC50 = 118 nM

MDPV (63)160

EC50 = 2.3 nM
(Emax = 24%)
IC50 = 4.1 nM

EC50 = 13 nM
(Emax = 24%)
IC50 = 26 nM

EC50 = Inactive
IC50 = 3349 nM

Since release/inhibition at SERT and DAT result in effects that are distinct from each
other, it was essential to study the effects of synthetic cathinones at DAT and SERT.
However, the contribution of NET to the action of these psychoactive compounds could
not be ignored.
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We investigated compounds discussed in AIMS II-IV for their in vitro actions to
release/reuptake inhibition of [3H]MPP+ in rat synaptosomes.

b. Effects of the 4-position substituent of MCAT on release/reuptake inhibition in rat
synaptosomes
Compounds described in AIM II (Table 24) were tested for their ability to promote release
of [3H]MPP+ in rat brain synaptosomes. The in vitro potencies ranged over 40-fold with
MCAT (57) being the most potent and 4-CF3 MCAT (76) being the least potent (Table 24).

A QSAR analysis was first performed between Es, π, σp and log EC50 NET (Table 25). A
significant correlation was observed only with Es (r = 0.772, p = 0.04) (Figure 40 and
Table 25). A further QSAR analysis with Verloop parameters and volume was performed
which resulted in significant correlations with B5 (r = -0.817, p = 0.02) (Figure 40, Table
25) and volume (r = -0.878, p = 0.01) (Figure 40, Table 25), indicating that the 4-position
substituent size could influence the in vitro releasing action at NET. It appears that the
activity observed at NET is similar to that observed for DAT, (i.e., the in vitro releasing
activity decreases with an increased size of the substituent at the 4-position). A significant
correlation was also observed between log EC50 NET and log EC50 DAT (r = 0.906, p =
0.0050, n = 7) (Figure 40). A homology modeling study of NET should provide further
insight.
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Table 24. In vitro release activity at NET (method similar to that reported in Del Bello et
al.223)
HN
O

CH 3
CH 3

R

Agent

R

Methcathinone (57)

-H

NET
EC50 nM
22±4

Flephedrone (72)

-F

62±10

Methedrone (73)

-OCH3 1 111±24

4-Chloromethcathinone (74)

-Cl

44±9

4-Bromomethcathinone (75)

-Br

100±16

Mephedrone (62)

-CH3

63±17

4-Trifluoromethylmethcathinone (76)

-CF3

900±300
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A

B

C

D

Figure 40. Relationships between (A) Es, (B) volume, (C) maximum width (B5) of the 4position substituents of MCAT and log EC50 NET, and (D) relationship between log EC50
DAT and log EC50 NET for 57, 62, 72-76.
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Table 25. Results of correlational analysis between steric parameters, electronic and
lipophilic parameters with in vitro potencies at NET for 4-substituted MCAT analogs (57,
62, 72-76). Significant correlations (p <0.05) are highlighted in bold.
Physicochemical log EC50 NET
Parameter
Taft (Es)
r = 0.772
Lipophilicity (π)

p = 0.04
r = -0.472

Electronic (σ)

p = 0.29
r = -0.3601

Volume (Vol)

p = 0.43
r = -0.878

Length (L)

p = 0.01
r = -0.677

Minimum width
(B1)

p = 0.1
r = -0.676

Maximum

p = 0.1
r = -0.817

Width (B5)

p = 0.02

c. SAR studies for methylone
We tested the effects of ring expansion from methylenedioxy to ethylenedioxy and
increased

chain

length

at

the

N-alkyl

position

using

methylone

or

methylenedioxymethcathinone (MDMC, 61) as the parent scaffold. In vitro assays in rat
synaptosomes indicated that the ethylenedioxy analogs (51, 77) are less potent than their
corresponding methylenedioxy analogs (44, 51) by 4.5 and 2-fold respectively (Table 26).
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Both the ethylenedioxy analogs EDMA (51) and EDMC (67) are equipotent in their
actions at NET.

As the length of the N-alkyl chain increased, potency for releasing effects decreased (Table
26). Ethylone (78) produced submaximal effects for release (Table 26) and reuptake
inhibition (IC50 = 5820 nM, efficacy

(≈100%). Propylone (79) was inactive for its

releasing effects but produced very weak reuptake properties (IC50 = 28,540 nM, efficacy
less than 50%).

At NET, the ethylenedioxy ring is tolerated but the methylenedioxy ring is preferred and
an increased chain length at the N-alkyl position shifts the activity of the compound from a
releaser to a weak reuptake inhibitor.

168

Table 26. EC50 values for EDMA (51), MDMA (44), EDMC (77), MDMC (61), ethylone
(78) and propylone (79) to release [3H]MPP+ at NET.
Compound

NET
EC50 nM (±SD)a

EDMA (51)

325 (±61)
[91 (±2)]

MDMA (44)

72 (±13)
[95 (±3)]

EDMC (77)

327 (±54)
[84 (±4)]

MDMC (61)b

152 (±33)

Ethylone (78)

4251(±1622)
[64%]
IC50 = 5820(±1244)
[≈100%]

Propylone (79)

0%
IC50 = 28540(±12580)
[less than 50%]

a

EC50 values are mean (±SEM) for n = 3-4 experiments; efficacy
values [in brackets] are % maximal release expressed as mean
(±SEM) as described in Methods.223 bEC50 values for MDMC
(61) were reported earlier159 and are included for comparison
with EDMC (77).
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d. SAR studies for N-alkyl 4-MA analogs at NET
N-alkyl 4-methyl amphetamine analogs were investigated for their effects to release
[3H]MPP+ and inhibit the uptake of [3H]NE in rat brain synaptosomes. It can be observed
that releasing effects are optimal when the N-alkyl chain is either a methyl (80) or ethyl
(81) group (Figure 41, Table 27). However, N-methyl 4-MA (80) is about 3-fold more
potent than N-ethyl 4-MA (81) (Table 27). N-propyl (82) and N-butyl 4-MA (83) both
displayed weak inhibitory effects for reuptake inhibition and sub maximal effects for
release (Figure 41, Table 27). Similar to what was observed in AIM IV for DAT, the
increased N-alkyl chain length on 4-MA transitions the compound from a full releaser
>>partial releaser>>weak reuptake inhibitor.
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Monoamine release

A

Monoamine reuptake

B

Concentration (log M)

Figure 41. Effects of N-substituted 4-MA analogs on NET monoamine release and uptake
in rat brain synaptosomes. All points show mean±SEM of three determinations. Top panel
(A) shows drug effects on monoamine release. Abscissae: drug concentration in log M.
Ordinates: Percent release of [3H]MPP+ (A). Bottom panels (B) show drug effects on
monamine uptake inhibition. Abscissae: drug concentration in log M. Ordinates: Percent
uptake inhibition of [3H]NE (B). EC50 and IC50 values determined from these curves are
reported in Table 27. All points show mean±SEM of three determinations. N-Me (Nmethyl 4-MA, 80), N-Et (N-ethyl 4-MA, 81), N-Pr (N-propyl 4-MA, 82), and N-Bu (Nbutyl 4-MA, 83). All points show mean (±SEM) of three determinations (figure provided
by Dr. Baumann’s laboratory).
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Table 27. EC50 values to promote monoamine release or IC50 values to inhibit monoamine
uptake for N-substituted 4-MA analogs. All values were derived from data shown in
Figure 41. An EC50 or IC50 value is shown only if maximal effect was ≥50%. If maximal
effects were <50%, then maximum effect is shown.

Drug

NET EC50
(nM±SEM)

NET IC50
(nM±SEM)

N-Methyl 4-MA (80)

66.9±8.4

438.3±41.6

N-Ethyl 4-MA (81)

182.4±19.9

685.4±78.8

N-Propyl 4-MA (82)

742±171.9
(Emax= 56%)
23%

2916±321.3

N-Butyl 4-MA (83)

6009±1188.9

Overall the SAR at NET for its releasing action can be summarized as (Figure 42): a) the
length of the N-alkyl chain that can be accommodated is N-ethyl but N-methyl is optimal
b) smaller substituents such as –F, and CH3 contribute to optimal activity at the 4-position
and c) a carbonyl group is tolerated at the β-position. We have not studied the effects of
chain extension at the α-position in NET, but we expect an activity similar to DAT (AIM
I).
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Figure 42. Summary of the SAR investigated at NET.

An overall correlation analysis was conducted (Figure 43) between the log EC50 DAT and
log EC50 NET (r = 0.755, p = 0.002, n = 14) and log EC50 SERT and log EC50 NET (r =
0.090, p = 0.8, n = 14) for 14 compounds (except propylone (79), N-propyl 4-MA (82),
and N-butyl 4-MA (83) since their EC50 were not calculated due to poor efficacy).
It is striking that there are two outliers (compounds 76 and 78) in the correlation between
log EC50 DAT and log EC50 NET. These two compounds have a slight difference in
activity at DAT and NET, 4-CF3 MCAT (76) is 3-fold more potent at DAT then at NET
and ethylone (78) at DAT and NET is primarily a weak reuptake inhibitor, however they
differ in their efficacies for release, 38% at DAT and 64% at NET.
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A

B
Ethylone (78)

4-CF3 MCAT (76)

Figure 43. Correlation analysis between (A) log EC50 DAT and log EC50 NET (r = 0.755,
p = 0.002, n = 14), and (B) log EC50 SERT and log EC50 NET (r = 0.090, p = 0.8, n = 14)
for 14 compounds. Compounds included for the above correlation are 44, 51, 57,61, 62,
72, 73, 74, 75, 77, 76, 80, 81, and 78.
It can be concluded that effects at NET are similar to those observed at DAT. Koldsø et
al.208 reported on the similarities of the DAT, NET and SERT substrate-binding cavities
based on homology models constructed using the LeuT template. They report that the
sequence identity in the substrate-binding pocket of hSERT to hDAT and hNET is 57%
and 68%, respectively, and the sequence identity between hNET and hDAT is 86%.208
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Sequence identity refers to the extent to which two sequences have the same residues at the
same position in an alignment. Schlessinger et al.232 also constructed a homology model of
NET and described the substrate-binding site as small and hydrophobhic.232 It was reported
by our group that the substrate-binding cavity of hDAT was small and relatively more
polar whereas hSERT has a more hydrophobic and relatively larger substrate-binding
pocket.195 Koldsø et al.233 recently published a homology model of NET based on the new
dDAT crystal structure with DA in the binding cavity, and NE docked similarly to DA in
the substrate-binding site. These findings are consistent with our in vitro correlations of
activity at DAT and NET.

A homology modeling study on NET would provide additional information regarding their
binding modes and provide a comparison with those at DAT and SERT. These studies are
planned to be conducted.
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AIM VI. Comparison of the structural features of methylphenidate and synthetic
cathinones and investigation of the role of the carbonyl group on synthetic
cathinones: A preliminary investigation

a. Introduction
Methylphenidate (6, Ritalin ) is a known medication for ADHD (additional information
®

discussed in the Background), and others have studied its SAR previously for reuptake
inhibition at DAT, NET and SERT.234-237 Its selectivity for monoamine transporters is in
the order DAT > NET >> SERT and its binding affinities (IC50) at DAT, NET and SERT
were 84, 514 and >50,000 nM, respectively as reported by one study.107 However, it has
not been investigated for comparison with synthetic cathinones. Its mechanism of action,
(i.e., DA reuptake inhibition), is the same as that of the psychoactive drug MDPV
(63).9,10,107 It was of interest to understand and compare the structural features of the two.
Methylphenidate (6) has three structural features that are distinct from MDPV (63); 1) it
has a methyl ester group instead of a carbonyl group at the benzylic position (β-position),
2) it lacks the extended α-alkyl chain, and 3) it has a 6-membered piperidine ring instead
of a 5-membered pyrrolidine ring (Figure 44). It might be noted, however, that
methylphenidate (6) is a secondary amine, and the amine substituent is also a portion of the
α-alkyl substituent.
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The aim of the current investigation was two-fold:
1. To compare the two structural features of methylphenidate (6) (i.e., the ester and the
piperidine ring) to the corresponding features of MDPV (63) (i.e., the carbonyl and
pyrrolidine ring) (Figure 44). We synthesized compounds that were hybrids of the two (84
and 85). In 84, the ester of methylphenidate (6) was replaced by a carbonyl group, whereas
85 is a MDPV-type analog where the carbonyl group has been replaced by an ester. Also,
85 lacks an α-substituent in order to avoid problems with diastereoisomerism. It has
already been shown (AIM I) that an α-H is less than optimal. However, if 85 shows
activity, this will provide an impetus for examining specific optical isomers in the future.

O HN

N
O

H 3CO

CH 3

O
O

MDPV (63)

Methylphenidate (6)

Figure 44. Structural comparison of MDPV (63) and methylphenidate (6).
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2. To investigate the role of the carbonyl group on synthetic cathinones.
a. To better understand if the sp2 nature of the carbonyl carbon atom of synthetic
cathinones is a contributor to activity, we synthesized the methoxy analogs 86 and 87
where the hybridization state of the carbon atom is sp3.

b. We synthesized one of the bioisosteres of a carbonyl group (i.e., the oxime analog 88).
Bioisosteres are compounds or groups that have similar chemical and physical properties
and produce similar biological effects.164

b. Methods
i. Synthesis
Dr. Jain synthesized compound 85 and Dr. Kolanos synthesized compound 88; their
synthesis is described in Scheme 11 and 12, respectively. The synthesis of 84, 87, and 88 is
shown in Scheme 9 and 10, respectively.

Scheme 9. Synthesis of compound 84a
HN
O
a

N
H

COOH

123
a

84

Reagents: a) i) PCl5, CH2Cl2 ii) AlCl3, benzene.
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Scheme 10. Synthesis of compound 85a
O

O
H 3C

H 3C

O

CH2

O

a

125

124

O
H 3C

O

N

H 3C

O

b

N

O

c

85

126

( 119 )

a

Reagents: (a) HCHO, K2CO3, DMF; (b) pyrrolidine, DMF; (c) i) 10N HCl, ii) MeOH,
HCl. EtOH.
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Scheme 11. Synthesis of compounds 86 and 87a
Br
H 3C

a

N

O
H 3C

b

127

O

128
86
c

H 3C
H 3C

CH 3

N

O

87
a

Reagents: (a) KBr, KBrO3, conc. H2SO4, MeOH; (b) (CH3)2NH2 in MeOH, benzene; (c)
Et3N, pyrrolidine, benzene.
Scheme 12. Synthesis of compound 88a
HN

Br
O

O

CH 3

CH 3
HCl
CH 3

CH 3
CH 3

b

a

106

OH HN
N

57

a

88

Reagents: (a) i) CH3NH2 in EtOH, benzene, ii) HCl/Et2O (b) NH2OH.HCl, pyridine,
EtOH.
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ii. Electrophysiological studies
These studies were conducted in Dr. De Felice’s laboratory at Virginia Commonwealth
University and the procedure is similar to that reported in AIM I. Compounds were
investigated for their electrophysiological properties at a concentration of 10 µM in
Xenopus oocytes expressing hSERT and hDAT.

c. Results and discussion
Hybrid compounds 84 and 85 were strong reuptake inhibitors at hDAT. Compound 84
retained the piperidine ring from methylphenidate (6) but has the cathinone feature (i.e.,
the carbonyl group). Compound 85 retains the ester side chain of methylphenidate (6) and
has the pyrrolidine ring feature of MDPV (63). Preliminary data suggest that at hDAT, for
reuptake inhibition, the ester and carbonyl functional groups are both tolerated. At hDAT,
84 was a potent hyperpolarizing agent at 10 µM. Compound 85 showed a similar effect,
but the action was less pronounced. At hSERT, these compounds didn’t produce any
effects at 10 µM but 85 was a weak inhibitor at a very high concentration of 50 µM. A
further examination of the in vitro quantitative effects of 84 and 85, particularly with
methylphenidate (6) for comparison, will provide additional information regarding their
potencies and confirm which structural features are the most important for activity at
hDAT and hSERT. Nevertheless, these preliminary findings establish a tantalizing
structural link between methylphenidate (6) and the cathinones. In addition, although it
was not known whether these hybrid molecules would be effective at DAT, it was
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hypothesized that if they were, they would act as reuptake inhibitors. That is, 84 possesses
an α-alkyl chain that is larger than methyl, where as 85 is a tertiary amine.

Synthetic cathinones having tertiary amines are known to confer hDAT reuptake inhibition
properties (AIM I). Compounds 86 and 87 both have tertiary amines and are both strong
reuptake inhibitors at hDAT, suggesting that the methoxy functional group can be tolerated
at this position. Compound 86 however shows a more pronounced effect compared to 87
since it has the pyrrolidine ring. A comparison of the corresponding carbonyl analogs
would provide information as to whether the methoxy or the carbonyl group is a greater
contributor to potency. At hSERT both showed moderate to weak activity at 10 µM. The
α-chain extended analogs of 86 and 87 should result in more potent DAT reuptake
inhibitors.

Previous studies in AIM I suggested that the extended side chain at the α-position is a
contributor to activity as a DAT reuptake inhibitor, however 84, 85, 86 and 87 lack this
extended side chain but act as DAT reuptake inhibitors. A comparison of compounds with
the extended side-chain at the α-position should indicate the importance of an extended
side-chain at the α-position for such compounds as hDAT reuptake inhibitors.

The corresponding secondary amine analog of 87 (i.e., compound 129) was also
synthesized. Currently we have no biological data but we expect that in comparison to 86
and 87 it would either be a releaser.
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Compound 88 differs from MCAT (57) in the bioisosteric replacement of the carbonyl
group with an oxime. MCAT (57) produced its action selectively through DAT, however
oxime analog 88 showed no release activity but extremely weak reuptake inhibition
activity at hDAT at 10 and 50 µM. Whereas at hSERT it displayed releasing action at 50
µM which was blocked by fluoxetine. This suggests that bioisosteric replacement of the
carbonyl group with an oxime can convert a DAT selective compound to a SERT selective
compound and also change activity at DAT from a releaser to a reuptake inhibitor. Other
bioisosteres for the carbonyl group might show different/similar effects at DAT and SERT.

This is a preliminary investigation and additional in vitro and in vivo studies will provide
information regarding the potencies of these compounds. Furthermore, based on these
preliminary data, optimization of structural features selective for DAT vs SERT and vice
versa is now being considered.
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AIM VII. Understanding the role of a charged terminal amine: A preliminary
investigation

a. Introduction
Recent crystal structures of DA, AMPH (S(+)2), METH (S(+)5), and cocaine
cocrystallized with dDAT all showed an ionic interaction of the terminal amine with D46
in the substrate-binding pocket (primary binding site or S1).118 Since this aspartate is
conserved across DAT, NET and SERT, formation of an ionic bond could be an important
contributor to their mode of interaction and, perhaps, mechanism of action for monoamine
release/reuptake inhibition.

The goal of this study was to understand the role of the nitrogen atom in contributing
towards activity at DAT and SERT. We chose MCAT (57) as our parent compound since it
is the chief scaffold for newer synthetic cathinones on the clandestine market:

1. We synthesized the desnitrogen analog 89 of MCAT (57) because, lacking a basic
nitrogen atom, this compound cannot form the ionic interaction with D79 in hDAT and
D98 in hSERT.
2. Amines at physiological pH will be protonated and will likely form an ionic interaction
with the conserved aspartate residue. If this ionic interaction is important for activity, then
replacement of a protonated tertiary amine with an isosteric sulfonium group could result
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in retention of action. The sulfonium salt 90 was synthesized such that it is permanently
charged and would maintain the ionic interaction at the substrate-binding site.
CH 3
O

CH 3

H 3C + CH 3
S
O
CH 3

90

89

b. Methods
The synthesis of 89 and 90 is shown in Scheme 13 and 14 respectively.
i. Synthesis
Scheme 13. Synthesis of compound 89a
CH 3
H 3C

O

O

CH 3
Cl
130

a

CH 3

a

89

Reagents: (a) AlCl3, benzene.
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Scheme 14. Synthesis of compound 90a
Br
O

CH 3
a

106

a

H 3C + CH 3
S
O
CH 3

90

Reagent: (a) (CH3)2S.

ii. Electrophysiological studies
These studies were conducted in Dr. De Felice’s laboratory at Virginia Commonwealth
University and the procedure is similar to that reported in AIM I. The compounds were
investigated for their electrophysiological properties at a concentration of 10 µM in
Xenopus oocytes expressing hSERT and hDAT.

c. Results and discussion
The desnitrogen analog of MCAT, 89, exhibited weak reuptake properties at hDAT; the
removal of the nitrogen atom converted the compound from a potent releasing agent to a
weak reuptake inhibitor. At hSERT the compound was inactive.

From this preliminary investigation we learnt that, at hDAT, the nitrogen atom is an
important contributor to release activity, and at hSERT the nitrogen atom is essential for
activity.
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However, for reuptake inhibition at hDAT, the nitrogen atom may not be essential. Meltzer
et al.236 reported in a study of methylphenidate (6) analogs that lacked the nitrogen atom,
for example compound 131 where the nitrogen atom was replaced by an sp3 hybridized
carbon atom, possessed DAT reuptake properties and was 9-fold less potent compared to
methylphenidate (6) in radiolabelled binding assays using [3H]WIN 35,428. This suggested
that the nitrogen atom might not be required for reuptake activity but contributes to
potency. However, these analogs were substituted at the 3- and 4-positions with Cl and
these functionalities might be potential contributors to activity. To test the contribution of
the chloro groups on our parent molecule we prepared and evaluated analog 132 and it
showed no activity at 10 µM at hDAT. At a higher concentration (50 µM) it produced
weak effects as a reuptake inhibitor. This indicated that the chloro groups were not
contributing significantly to activity at hDAT. A comparison of the potencies of 89 and
132 will give a better indication regarding the contribution of the 3,4-dichloro groups.
Also, removal of nitrogen atom on a DAT reuptake inhibitor such as α-PVP might better
substantiate the role of nitrogen for reuptake inhibitors.

CH 3

O
O

H 3CO

CH 3

Cl

Cl
Cl

Cl
131

132
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The sulfonium analog 90 produced no effects at 10 µM but at higher concentrations (50
µM) it produced a weak effect for reuptake inhibition at hDAT and hSERT.

It can be implied that the ionic interaction made by a protonated nitrogen atom is optimal
for activity. Though a sulfonium group, in theory, is capable of making an ionic interaction
it has an atomic size of 1 Å whereas nitrogen has an atomic size of 0.65 Å.238 Due to this
size difference the sulfonium analog (90) might not be well accommodated in the
substrate-binding site, contributing to its weak action. Another possibility is that
equilibrium between protonated and unprotonated forms of cathinone analogs play a role
in these actions.

Others in our laboratory239 have examined the quaternary amine analogs of MDPV (63), a
DA reuptake inhibitor, and MEPH (62), a DA releasing agent, (i.e., 133 and 134,
respectively).

N + CH

N
O

O

CH 3

O

3

O

CH 3

CH 3

O
O

63

HN CH 3

CH 3

O

62

133

CH 3
H 3C N + CH 3
O
CH 3

CH 3
134

It was found that the quaternary analog of MDPV (63), 133, is a weak reuptake inhibitor at
hDAT and a strong reuptake inhibitor at hSERT. MDPV-like analogs were shown to be
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exclusively selective for DAT over SERT in AIM I. Compound 133 was the first
cathinone-like SERT reuptake inhibitor to be identified. MEPH (62) is a non-selective
releasing agent at DAT and SERT but converting it to its quaternary analog 134, showed
strong reuptake activity at DAT and a weak reuptake activity at SERT. This suggests that
compounds that have a permanent charge (i.e., quaternary amine analogs) can be
accommodated at DAT and SERT.

After this current AIM was completed, a paper by Sandtner et al.240 was published and they
reported on the quaternary analog of MDA, 135. They reported similar results, compound
135 was a reuptake inhibitor at DAT and SERT and they provided an explanation for their
reuptake activity based on its difference in binding mode compared to MDA (43).
According to their results 135 cannot make strong electrostatic interactions with Na+ and
the conserved aspartate in the primary binding site due to its low surface charge density
and this could contribute to its reuptake action.
CH 3
H 3C N + CH 3
CH 3

O
O
135

Overall, our preliminary investigation suggests that the nitrogen atom is an important
contributor to releasing activity at hSERT and hDAT. It also suggests that an ionic
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interaction at the substrate-binding site might be more important for releasers than for
reuptake inhibition action. This requires further investigation.
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V. Summary

Monoamine transporters have similar mechanisms of action however they differ in their
selectivity towards compounds that exert their mechanism of action through them. We
studied synthetic cathinones (β-keto analogs of PAA) and a few AMPH analogs at DAT,
SERT and NET and identified structural features that contributed to their action and
selectivity.

Below is a summary of the SAR studies conducted at DAT and SERT (Figure 45) (a
summary of the actions at NET were discussed in AIM V and they are similar to the SAR
described for DAT).
C

A

R 2 N R1
B
D

Figure 45. Structural features on the phenylalkylamine scaffold investigated at DAT and
SERT.
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Structure-activity relationship summary at DAT
A. Terminal amine
For reuptake inhibition
•

Nature of the amine: Tertiary > secondary > primary, R1 = R2 = CH3 > R1 = H, R2 =

CH3 > R1 = R2 = H
•

Ring: 5-membered > 6-membered

•

Aliphatic chain: methyl > ethyl > n-propyl > n-butyl

•

Absence of nitrogen confers weak reuptake properties

•

Quaternary amines are tolerated

Bulky and tertiary amines seem optimal for activity

For release
•

Aliphatic chain: methyl > ethyl > n-propyl > n-butyl. As chain length increases

compound transitions from a full releaser to a partial releaser to a weak reuptake
inhibitor.
Presence of nitrogen required for activity

•

B. α-position
For reuptake inhibition
•

Aliphatic chain: n-butyl > n-propyl > ethyl > methyl > H

•

Bulk: cyclohexyl > cyclopentyl > i-propyl

192

Optimal reuptake activity with both an extended/bulky side chain and a tertiary amine
however the analog where R1 is cyclized to the α-position also shows reuptake activity.

For release
•

Activity optimal with methyl group

C. β-position
For reuptake inhibition
•

C=O > H

•

Methoxy and methyl ester tolerated

•

Oxime confers weak action

For release
•

H > C=O

D. Phenyl ring
For reuptake inhibition
•

Methylenedioxy ring at the 3- and 4-position is tolerated but unsubstituted ring is
also sufficient
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For release
•

Optimal activity when unsubstituted but smaller sized substituents such as –F are
tolerated at the 4-position.

Structure-activity relationship summary at SERT
A. Terminal amine
•

Bulky and tertiary amines are inactive at SERT, except for quaternary amines, they
confer reuptake properties

•

Aliphatic chain: methyl > ethyl > n-propyl > n-butyl (for release and reuptake
inhibition).

•

Presence of nitrogen required for activity

B. α-position
•

Linear chain and bulk result in inactive compounds

•

Release and inhibition optimum with methyl

C. β-position
•

H > C=O for release

•

Oxime confers releasing action

D. Phenyl ring
•

Favors larger substituents such as 4-methoxy and trifluromethyl and 3,4ethylenedioxy for release activity

Transporters are dynamic proteins and all the regions could affect transporter function. It
has been suggested that ligands can influence different transporter conformations and
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stabilize different conformational states that contribute towards distinctive activity.124,241,242
It can be observed from our studies that structural features on synthetic cathinones can
influence transporter activity and selectivity. Ligand selectivity for a transporter can be
dependent on one or more of these factors, such as entry of the ligand through the
extracellular pathway, its binding site, binding pose and interaction with other proteins.243

MDPV-like reuptake inhibitors discussed in AIM I were exclusively selective for DAT
versus SERT. The hypothesis discussed in AIM I was that there could be a difference in
the way that ligands enter the transporter that accounts for the MDPV-like compounds to
be inactive at SERT. This hypothesis is supported by recent studies published by Andersen
et al.243 for a group of DAT-and NET-selective inhibitors. In this study they compared the
non-conserved residues in the primary binding site (S1) and residues lining the
extracellular pathway (mainly EL4 and S2 sites) for hDAT and hNET. They reported that
for hDAT, residues outside the binding sites confer selectivity for the compounds
investigated (bupropion (136), cocaine, rimcazole, JHW 007, GBR 12,909) (i.e., residues
lining the extracellular pathway (mainly EL4 and S2 sites) that lead to the primary binding
site (S1 site)).

HN
O

CH3
CH3
CH3
CH3

Cl
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They hypothesize that a “selectivity filter” formed by specific residues in the extracellular
pathway could confer selectivity. It is important to mention that one of the hDAT
inhibitors that were investigated was a cathinone analog (i.e., bupropion (136)). It is then
tempting to speculate that perhaps the entry through the extracellular pathway might be an
important contributor to inhibitor selectivity for cathinone-like compounds. A possible
hypothesis based on the Andersen et al.243 study is that the “selectivity filter” is different
for DAT and SERT. Either it is made of residues that are non-conserved between DAT or
SERT or the “selectivity filter” is located at different positions in DAT and SERT and thus
both transporters could confer some differences in the ligands it can provide access to.
Therefore, compounds such as MDPV-like inhibitors cannot pass through this filter on
SERT and are not given access to the transportor thus rendering them inactive. A similar
study such as that reported by Andersen et al.243 with cathinone-like molecules would
address differences in inhibitor selectivity for DAT, NET and SERT.

It is important to recognize here that other proteins such as cholesterol could also
contribute to the transporter action. Cholesterol has been proposed to play a role in
stabilizing the outward conformation of dDAT.117 However its role in the binding of
substrates and inhibitors has yet to be investigated.

Results from AIM II suggested that differences in the selectivity of compounds could be
addressed based on their interactions and binding modes at their binding site. We identified
through homology modeling and docking studies that MCAT (57) and its 4-position
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substituted analogs bind to the primary binding site (S1). Selectivity of their actions for
DAT versus SERT was dependent on the size of the 4-position substituent that could be
explained based on differences in the binding pocket of the transporters. hDAT
accommodates compounds with small substituents at the 4-position (e.g. MCAT (57) and
4-F MCAT(72) due to a small, more, polar, binding pocket around the 4-position, whereas
hSERT accommodates larger 4-position substituents (e.g. 4-OCH3 MCAT (73) and 4-CF3
MCAT (76)). Shortly after our work was published the crystal structures of dDAT with
AMPH (S(+)2), DA, and METH (S(+)5) identified this same binding site. We also predict
that this is the reason why the six-membered ethylenedioxy analogs (i.e, EDMA (51)) and
EDMC (77) investigated in AIM III were less potent than their five-membered
methylenedioxy analogs (i.e., MDMA (44) and MDMC (61)) at SERT versus DAT.

In AIMS III and IV we observed how minimal structural changes on the N-alkyl chain for
cathinone and AMPH-like compounds could change the activity of the compounds from a
full releaser to a partial releaser and eventually a weak reuptake inhibitor. Partial releasers
differ from full releasers such that they do not release the maximal pool of releasable
neurotransmitter even at the highest concentrations. Compounds that are fully efficacious
(100%) for release have smaller structural features than reuptake inhibitors and are
somewhat similar un structure to endogenous substrates, for example N-methyl 4-MA (80).
As the structural features are expanded/enlarged compounds start to lose their efficacy for
release and show partial release and weak reuptake activity; for example, ethylone (78) is a
partial releaser and a weak reuptake inhibitor at SERT and N-ethyl 4-MA (81) is a partial
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releaser and a weak reuptake inhibitor at DAT. It is important to note here that these
compounds were tested as their racemates; studies currently being conducted on their
enantiomers (prepared by others in our laboratory) should address whether each
enantiomer has different or similar effects. Compounds that act as releasers are transported
through the transporter, whereas inhibitors are not, such that they latch the transporter in a
conformation that prevents the reuptake of the endogenous neurotransmitter. The exact
mechanism of action of “partial releasers” is, however, still under investigation, but some
of the theories regarding their mechanism of action are:

1. Rothman et al.244 studied a few phenylalkylamine partial releasers and reported the
mechanism of their partial release could be attributed to the fact that these compounds have
a slower rate of efflux than full releasers and they are slower in elevating extracellular DA
and 5-HT levels in microdialysis studies. They suspect that partial releasers bind to the
transporter, but modify the transporter conformation in such a way that could affect reverse
transport.

2. A review by Reith et al.224 reported that partial releasers could bind to a probable S3 site
below the primary binding site.

3. Sandtner et al.240 explained that the partial releasing activity of 47 at SERT can be
explained based on its binding mode. They identified that 47 binds in two modes, the first
similar to 5-HT and the other was a reverse mode. They hypothesized that by adopting
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substrate- and inhibitor-like binding modes at all concentrations, 47 would always inhibit a
fraction of 5-HT even at saturation concentrations. Due to this, it shows activity as a partial
releaser and a weak reuptake inhibitor. If the individual enantiomers of our compounds
(e.g. N-ethyl 4-MA (81)) show differing activity (i.e., if one is a reuptake inhibitor and
other a releaser) then a possible explanation could be based on the hypothesis presented by
Sandtner et al.240
H 3C

N CH 3
CH 3

O
O
47

4. Shi et al.125 have proposed that simultaneous binding of another substrate molecule to
the extracellular S2 and the primary binding site (S1) can trigger the release of substrate
and ions to the intracellular compartment. If the enantiomers of N-ethyl 4-MA (81), for
example, have the same activity a proposed hypothesis for our compounds could be related
to the above mechanism. For example, for N-ethyl 4-MA (81) the second molecule of Nethyl 4-MA (78) might not simultaneously bind and facilitate the conformational change
for inward movement of the transporter. Thus, due to this, the transporter might retain a
conformation that results in weak reuptake activity and this conformation would probably
interfere with reverse transport and result in slow efflux of the corresponding monoamine.
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We have not constructed a homology model of hNET thusfar, but AIM V suggested that
synthetic cathinones have similar activity at DAT and NET. These similarities could be
attributed to their higher sequence identity compared to that between DAT and SERT.

AIMS VI and VII are only preliminary investigations and additional studies and
compounds are required to obtain conclusive results. However, it was suggested that the
nitrogen atom of cathinone analogs is an essential feature for release properties as
compared to reuptake activity. A plausible explanation for this could be that one of the key
interactions releasers need to make to be transported through the transporter is with the
conserved aspartate. But, for reuptake inhibitors, this interaction might not be key to the
transporter conformation required for reuptake action. Another plausible explanation could
be related to the weak base hypothesis for monoamine release. According to this
hypothesis amines such as AMPH (2) and cathinone (1) are weak bases and have a pKa of
9-11. At physiological pH they are protonated and disrupt the acidic pH in the synaptic
vesicle to cause the release of monoamines. If this hypothesis were true then compounds
lacking the nitrogen (e.g. 89 and 90) would not be able to act via this mechanism to release
DA/5-HT/NE; this implies that a nitrogen atom would be vital for release action.

Overall it can be observed that synthetic cathinones are not uniform in their actions and
selectivity and require a case-by-case study at monoamine transporters as previously
suggested.145 Each compound should also be investigated on a case-by-case basis for their
action at the transporter level.
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The rapid growth of NPSs is a tremendous concern to public health; synthetic cathinones
constitute a majority of these, and it was thus crucial to understand their mechanisms of
action. Our work has been very timely and informative. We studied the first generation of
“bath salts” and subsequent generations (even before they were found on the clandestine
market), and have also provided predictions for newer cathinone analogs. We were
successful in classifing drugs based on their mechanism of action, delineating structural
features that could be potential contributors to selectivity, explained how differences in
transporter action and selectivity might account for differences in activity.

When this project was initiated in 2010 there were only three main ‘bath salts’ components
(i.e., methylone (61), mephedrone (62) and MDPV (63)), and only and the availability of
the prokaryotic LeuT crystal structure as a template (around 20% homology to DAT,
SERT and NET) to conduct studies at the transporter level. Five years later there are a few
hundred synthetic cathinones and the availability of crystal structures of the eukaryotic
dDAT co-crystallized with psychostimulants such as cocaine and (+)AMPH (S(+)2). It
might be parenthetically noted that our first hSERT model (not described here) was
constructed on the basics of the LeuT crystal structure. Once the dDAT structure was
reported, a new model (i.e., that described herein) was constructed. Years of continued
contribution of research in the field of cathinone and AMPH-like molecules gets us one
step closer to fundamentally understanding these drugs at the cellular level. Our research
has provided some of the integral pieces of the yet-to-be-fully-assembled puzzle towards
understanding the actions of synthetic cathinones at monoamine transporters.
201

VI. Follow-up studies

Discussed in this chapter are compounds that were synthesized after we had received data
on our initial AIMS. That is, this study was not one of the original Aims.These compounds
were intended to either provide further direction to the overall project, engage or extend
some of the results we obtained, or act as leads to new projects. It should be noted that
most of the compounds await biological testing. Hence, most of these are follow-up
studies; biological data are sparse and are currently being obtained.

a. Role of increased bulk at the α-position of cathinone analogs
Studies in AIM I suggested that one of the features that contributed to reuptake activity at
DAT is the presence of bulk at the α-position. In vitro potency (pIC50 DAT) was
significantly correlated with the volume and/or lipophilicity of the α-substituent (r > 0.9).
However, volume and lipophilicity were highly intercorrelated (r > 0.9); so, we needed to
synthesize additional analogs to determine which of the two parameters was most
important. One of the analogs that we synthesized was compound 137, that has a very
bulky adamantyl group at the α-position and, although it has a secondary amine, due to the
increased bulk at that position we expect that the compound would be a reuptake inhibitor
at DAT and inactive at SERT.
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Scheme 15. Synthesis of compound 137a
I

138
Route 1
a

X

X

Route 2
b

Route 3
O

O

c

OH

O

d

Cl
140

139

141

Br
e

O

HN
f

CH 3

O

142

137

a

Reagents: (a) Acetophenone, FeBr2, DMSO, t-BuOK; (b) 1-phenyl-1trimethylsiloxyethylene, BF3.etherate; (c) thionyl chloride; (d) AlCl3, benzene; (e) Br2,
AlCl3, Et2O; (f) CH3NH2 in water, KI, K2CO3, DMF.
Initially, to synthesize intermediate 141 a literature procedure for the same compound was
followed (Route 1, Scheme 15).245 The reaction mixture was divided into two parts; to the
first, fraction column chromatography was attempted but did not yield the compound.
Instead, what was isolated were only fractions of yellow oils. Since 141 was reported to be
a solid246 these fractions were not characterized. To the other part, what was observed was
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that upon the addition of MeOH a solid precipitated that had a melting point above 200°C
(the mp of 141 is reported as 66-67 °C).246 This reaction has been reported to follow a
radical nucleophilic reaction, and a possible explanation for this reaction not working is
that there could be a problem with forming the radical.

Another attempt (Route 2, Scheme 15) was one reported that used 1-fluroadamantane.246 1Fluroadamnatane was not easy to synthesize and procedures for its synthesis required
electrochemical methods247 or required the use of reagents such as IF5 and a specialized
reaction vessel.248 Since 1-iodoadamantane (138) was readily available, the reaction was
attempted using it as a starting material (Route 2, Scheme 15). This reaction was also
unsuccessful and the product was an uncharacterized yellow oil. A possible explanation for
the reaction failure could be the use of 1-iodoadamantane (138) instead of 1fluroadamantane since the reactivity of the former would be less.

The third route that was attempted (Route 3, Scheme 15) was devised based on similar
compounds previously synthesized in the laboratory. This route, though, had two steps
more than Routes 1 and 2; however, it provided compound 137. Compound 137 is yet to
be evaluated.
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b. Role of the 4-position substituent of MCAT to release/inhibit uptake of
monoamines in rat brain synaptosomes

In AIM II it was concluded that the steric nature (i.e., size = bulk/volume) of the 4-position
substituent of MCAT (57) analogs influenced their neurochemical and behavioral
actions/potency at DAT and SERT. We found that the in vivo and in vitro data were highly
correlated with the size of their 4-position substituent; however, the parameters used in our
study (B1, B5, L, and volume) ranged only over a narrow range and were highly
intercorrelated (r > 0.9; see AIM II). To address the above we synthesized two additional
agents: 4-t-butylmethcathinone (4-t-Bu MCAT (143)) and 4-benzylmethcathinone (4-Bz
MCAT (144)). Their syntheses are outlined in Scheme 16.

Scheme 16. Synthesis of compounds 143 and 144a

Br

O

X= C(CH 3)3 (145)
X= CH2C6H 5 (146)

O

CH 3

a
X

HN
O

X= C(CH 3)3 (147)
X= CH2C6H 5 (148)

CH 3

CH 3
c

b
X

CH 3

X
X= C(CH 3)3 (149)
X= CH2C6H 5 (150)

X
X= C(CH 3)3 (143)
X= CH2C6H 5 (144)

a

Reagents: (a) Propionyl chloride, AlCl3, CH2Cl2; (b) Br2, AlCl3, Et2O; c) CH3NH2 in
EtOH, benzene.
These compounds were tested for their in vitro effects in rat synaptosomes (Figure 46,
Table 28). 4-Bz MCAT (144) was essentially inactive at both DAT and SERT (Figure 46
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and Table 28). 4-t-Bu MCAT (143) showed weak activity at DAT for release (efficacy less
than 50%) and reuptake, and was inactive at SERT (Figure 45 and Table 28).

The Verloop parameters for the 4-position substituents of 143 and 144 and their volume
are shown in Table 28.

Table 28. Verloop parameters, volume and in vitro data at DAT and SERT.
B1

B5

4-t-Bu MCAT 218.17 4.11 2.59
(143)
4-Bz MCAT 234.46 3.63 1.52
(144)
*
Inactive at concentrations up to 1 µM

2.97

DAT
EC50
nM
941.9

6.02

**

Compound

**

Vol

L

>10,000 nM
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SERT
EC50
nM
*

DAT
IC50
nM
2207

SERT
IC50
nM
**

**

**

**

Figure 46. Effects of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) on monoamine release
and uptake in rat brain synaptosomes. Top panels show drug effects on monamine uptake
inhibition. Abscissae: drug concentration in log M. Ordinates: Percent uptake inhibition
of [3H]MPP+ or [3H]5-HT. Bottom panels show drug effects on monoamine release.
Abscissae: drug concentration in log M. Ordinates: Percent release of [3H]MPP+ (A) or
[3H]5-HT (B). EC50 and IC50 values determined from these curves are reported in Table 28.
All points show mean (±SEM) of three determinations (Figure provided by Dr. Baumann’s
laboratory).
Both compounds were docked and analyzed in homology models of hDAT and hSERT
using methods described in AIM II. The transporter models chosen for hDAT and hSERT
were the same as those as in AIM II and docking solutions obtained through clustering
techniques for that transporter model were analyzed.
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At hDAT*, the docking studies showed that 4-t-Bu MCAT (143) and 4-Bz MCAT (144)
occupied the same binding site as MCAT (57) but with different orientations (Figures 47A,
B and D). Similar interactions were observed both for 4-t-Bu MCAT (143) and 4-Bz
MCAT (144) (Figures 47A and B). For both compounds the terminal amine made an
interaction with the D79, an additional bifurcated hydrogen bond interaction was also
observed with the backbone carbonyl of F320 and S321. Another hydrogen bond was
observed between the carbonyl group and the side chain of S422. The N-CH3 group was
oriented in a manner such that it made a hydrophobic interaction with F76. The phenyl ring
was oriented in a manner such that it made a π-π interaction with Y156 and an edge to face
interaction with F326 for 4-t-Bu MCAT (143) and for 4-Bz MCAT (144) only the edge to
face interaction with F326 was seen. A hydrophobic pocket lined by I148, F326, F155,
S149, V152, G153, Y156, G425, G426, A423 and G153 surrounded the 4-t-Bu substituent.
The 4-Bz group is large and was oriented differently in a hydrophobic pocket and was
surrounded by I484, A489, V145, A480, I148, V152, S149, S429, I484, I146, F326, G153,
G425, G426 such that it formed a π-π interaction with F326.

*

The docking studies were performed with the assistance of Dr. Kolanos.
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N82

A

B

L322

A81
A77
A81

S321

S321

D79

D79

L322

L80

F76
G323
L80

F76
S422

L329
L329

V328
Y156

A423

S422

F320

F320
G425

A480

F326

A423

F326
G426

V152

Y156

V152
V328

S429

G327

G425
I148

G153

G426
S149

S149

V145

I148

I146
F155

G153

C

D

F326
S149

Figure 47. Docking studies of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) at the putative
binding site of hDAT. A) Putative binding mode of 4-t-Bu MCAT (143), B) Putative
binding mode of 4-Bz MCAT (144), C) Unfavorable interactions due to S149 and F326,
D) Superimposed poses of MCAT (57, green), 4-t-Bu MCAT (143, magenta), and 4-Bz
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MCAT (144, purple). Pink and green circles in A-C are sodium and chloride ions
respectively. Interacting amino acids are within 5Å are indicated for A an B.
4-Bz MCAT (144) is inactive at DAT as a releasing agent or reuptake inhibitor at a
concentration of 1 µM and a possible explanation is that the 4-Bz substituent of 144 is too
large to be accommodated in the hDAT binding-pocket. Figure 46C indicates that the 4benzyl substituent is too close to S149 and F326 and this probably leads to unfavorable
interactions that contribute towards the compound being inactive at DAT. Crystal
structures of dDAT complexed with cocaine and AMPH (S(+)2) show that reuptake
inhibitors and releasers both occupy the same binding-site.118 The reuptake inhibitor 4-t-Bu
MCAT (143) is proposed to occupy the same binding site as MCAT (57).

At hSERT, 4-t-Bu MCAT (143) and 4-Bz MCAT (144) are oriented differently (Figure
48A, B and C). The docking pose of 4-t-Bu MCAT (143) showed that the terminal amine
formed a cation-π interaction with Y95 and an additional hydrogen bond with the
backbone of Y95. The carbonyl group additionally made a H-bond with the side chain of
Y95. Hydrophobic residues F335, F341 and Y176 surrounded the phenyl ring and residues
S497, G458, Y175, F335, V501, Q498, T497, and I179 surrounded the 4-t-Bu substituent.
The docking pose of 4-Bz MCAT (144) did not indicate a lot of interactions except for a
cation-π interaction with Y95. Residues R104, A401, W103, Q493, G100, N101, G332,
A331, F335 and S336 surrounded the diphenylmethane group. 4-t-Bu MCAT (143) and 4Bz MCAT (144) did not form an interaction with D98 and adopted a binding pose different
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than that of MCAT (57) (Figure 47C). This could perhaps be the reason why these
compounds are inactive at hSERT.
A

V343
Y95

L344

N368

B

A96

L337

G94

S438
Y95

V97
F334

N368

V97

F341

D437

S336
D98

Y175
D98
L337

N101

F341

I172

S438
N101

V501
G100

W103

F335

S336

G100

F334

G498
F335

I333

L99

T497

Q493

Y176

I172
W103

Q332
A401

Q493

A331

Y175
I179

R104

Q494

C

Figure 48. Docking studies of 4-t-Bu MCAT (143) and 4-Bz MCAT (144) at the putative
binding site of hSERT. A) Putative binding mode of 4-Bz MCAT (144), B) Putative
binding mode of 4-t-Bu MCAT (143), C) Superimposed poses of MCAT (57, green), 4-tBu MCAT (143, magenta), and 4-Bz MCAT (144, purple). Pink and green circles in A-C
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are sodium and chloride ions respectively. Interacting amino acids are within 5Å are
indicated for A an B.
Table 29. Calculated HINT scores for interaction of MCAT analogs with hDAT and
hSERT.

4-t-Bu MCAT (143)
4-Bz MCAT (144)
4-t-Bu MCAT (143)
4-Bz MCAT (144)

HINT Score at hDAT (4-substituent only)
Total
Polar
Hydrophobic
52
-352
404
146
40
186
HINT Score at hSERT (4-substituent only)
-170
-351
181
-175
-215
40

At hDAT, based on HINT scores (Table 29) and docking studies, we cannot conclusively
explain the in vitro activity of 4-t-Bu MCAT (143) and 4-Bz MCAT (144). Perhaps 4-Bz
MCAT (144) is so large that it does not even enter the transporter whereas 4-t-Bu MCAT
(143) enters the transporter but is too large to be transported and possess release properties.

In the hSERT model, the compounds were oriented in a completely different manner than
MCAT (57) and, together with negative HINT scores (Table 29), suggest, perhaps, why
these compounds are inactive. Future studies involving molecular dynamics should address
how these molecules interact with the transporter.

c. Hybrid compounds
AIM II indicated that the presence of a methoxy group at the 4-position of MCAT (i.e.,
methedrone, 66) confers selectivity for SERT over DAT. AIM I indicated that pyrrolidinecontaining compounds, for e.g. 97, are reuptake inhibitors at DAT and inactive at SERT.
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Our aim was to convert a DAT selective compound, to a compound possessing hybrid
properties for both DAT and SERT. Hybrid compounds should produce effects different
from dual releasers and reuptake inhibitors since they would increase extracellular DA/5HT levels at a different rate.224 Such compounds could also have some therapeutic
potential.224 Compound 151 has the pyrrolidine feature for DAT selectivity and the 4methoxy substituent that confers SERT selectivity. We expect compound 151 to be a
reuptake inhibitor at DAT and a weak reuptake inhibitor (or a partial releaser) at SERT. Its
synthesis is shown in Scheme 17. Compound 151 is yet to be pharmacologically
investigated.

HN
O

CH 3
CH 3

OCH 3
Methedrone (66)

N
O

N

O

CH 3

CH 3
OCH 3

97
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151

Scheme 17. Synthesis of compound 151a
N

Br
O

O

CH 3

O
b

a

a

CH 3

CH 3

OCH 3

OCH 3

OCH 3

152

153

151

Reagents: (a) Br2, AlCl3, Et2O; b) pyrrolidine.

d. Role of the pyrrolidine ring on AMPH-like compounds
It is known that PAA-like compounds can act as releasers and tthat he presence of a
pyrrolidine ring on the cathinone scaffold confers reuptake properties. According to
Heinzelman and Aspergren, PAAs with tertiary amines confer interesting pharmacological
properties.249 They also described that some pyrrolidine-containing PAAs have
sympathomimetic effects (bronchodilation).249 Patents by G.M.B.H reported on the central
stimulation properties of several pyrrolidine-and piperidine-containing PAAs.250,251
However the mechanism of action of pyrrolidine-containing PAAs has not been reported;
hence, we prepared analog 154 to investigate its action at monoamine transporters.

The synthesis of this compound was attempted by two routes (Scheme 18). The first route
of catalytic hydrogenation was attempted since 97 was previously synthesized and was on
hand. However this route has not been reported for the synthesis of 154. Route 1 (Scheme
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18) was attempted twice, first on a small scale (0.14 g), which gave a product that was a
mixture of two uncharacterized compounds. Purification by distillation was not attempted
because only 0.04 g of the crude product was obtained. In the second attempt a larger
quantity of 97 was used (0.30 g) which gave a mixture of uncharacterized crude product
(0.15 g) that could not be successfully purified by Kugelrohr distillation.
The second route attempted (Route 2, Scheme 18) was reported for compound 154250 and
successfully yielded 154 (Scheme 18).
Compound 154 is yet to be pharmacologically evaluated.
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Scheme 18. Synthesis of compound 154a

N
O

CH 3

97

Route 1

CH 3CHO

+

X

N

b

N
H

a

c

N
H 3C

CH 3

CN

Route 2
155

154

a

Reagents: (a) Pd/C, CH3COOH, HClO4; (b) KCN, Et2O; c) benzylmagnesium chloride,
Et2O.

e. Effect of the α-side chain of MCAT for monoamine release action
AIM I indicated that decreased side chain length at the α-position on MDPV-like reuptake
inhibitors resulted in loss of potency. The effect of decreased side chain at the α-position
on MCAT (57) has not been investigated at DAT, SERT and NET. For AMPH-like
releasers such as PEA (23), a lack of central effects has been reported.77 Hyde et al.142
reported that 156 caused an increase in blood pressure however its mechanism of action
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remains uninvestigated.142 We therefore synthesized the desmethyl analog of MCAT (57)
(i.e., compound 156) to investigate its effects at monoamine transporters.
Scheme 19. Attempted synthesis of compound 156a
Cl
O

153
c

Route 3

X
Br
O

HN

a

X

CH 3

O

b
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O

X

Route 1

Route 2
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152

Route 4

105

Xd
Br

O

105
a

Reagents: (a) CH3NH2 in EtOH, benzene (b) CH3NH2 in EtOH, CH3CN; (c) CH3NH2 in
EtOH, benzene; (d) CH3NH2 in EtOH, toluene.
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The synthesis of 156 was attempted by different routes. Route 1 has been reported for
similar compounds142 and was attempted due to the availability of 105 in the laboratory. In
route 1 (Scheme 18) an attempt was made to form the hydrochloride salt first since it was
reported142 but it was sticky and did not precipitate. Consequently, an oxalate salt was
attempted but it too was sticky.

Route 2 was reported for the same compound.252 The reaction mixture was divided in two
portions before the work up. The first portion was worked up according to the procedure
for this route and an attempt was made to form the hydrochloride salt, but it was sticky and
did not precipitate. The second portion was worked up as reported in Hyde et al.142 (work
up for the same compound is reported) and that gave a precipitate that had a mp >230°C
which, likely was methylamine hydrochloride (lit.253 mp 231-233 °C).

Route 3 has been reported for the same compound.142 The reaction led to a tarry product
that was washed with CHCl3 as reported in the procedure and additional charcoal filtering
yielded the product. The yield was poor (less than 1% yield without recrystallization). To
scale up the reaction it was attempted yet another time however the melting point was low
and not sharp (201-208 °C) and the compound obtained was not clean (as seen on TLC)
and due to the low yield (less than 1%) compound could not be purified further.

The procedure for Route 4 was not reported and toluene was used as a solvent. The work
up of this reaction followed the procedure described by Hyde et al.142 for the same
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compound and resulted in a solid mp 198-200 °C but due to extremely low yields ( less
than 1%) it could not be characterized by NMR.

The above reactions gave difficulty in forming the salt or resulted in the formation of tarry
products and hence resulted in very low yields. Another synthetic route,254

reported for

similar compounds was attempted (Scheme 20) to synthesize 156.254 Even though this
route had two steps more in the final step of the hydrochloride salt is formed in situ and
hence it would be a solution to the salt formation problem. Compound 156 was then
successfully obtained by this method (Scheme 20).
Compound 156 has yet to be investigated.
Scheme 20. Synthesis of compound 156a
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Reagents: (a) Trifluroacetic anhydride, CH2Cl2; (b) oxalyl chloride, benzene, pyridine; (c)
i) AlCl3, benzene ii) conc. HCl, i-PrOH.
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VII. Experimentals

Melting points (mp) were measured on a Thomas-Hoover melting point apparatus using
glass capillary tubes and are uncorrected. 1H NMR spectra were recorded on a Varian 400
MHz spectrometer using tetramethylsilane (TMS) as an internal standard. Peak positions
are given in parts per million (d). Elemental analysis was performed by Atlantic Microlab
Inc. (Norcross, GA) for the elements indicated and the results are within 0.4% of
calculated values.

Infrared spectra were obtained on a Thermo Nicolet iS10 FT-IR. Flash chromatography
was performed on CombiFlash Companion/TS (Telodyne Isco Inc., Lincoln, NE) using
packed silicagel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica
Flash Column, Teledyne Isco Inc., Lincoln, NE). All reactions were monitored by thinlayer chromatography (TLC) on silica gel GHLF plates (250 m, 2.5 x 10 cm; Analtech
Inc., Newark, DE).
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1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-N-methylpropan-2-amine

Hydrochloride

(51). A solution of 112 (0.30 g, 1.13 mmol) in anhydrous THF (12 mL) was added in a
dropwise manner to a stirred suspension of LiAlH4 (0.13 g, 3.40 mmol) in anhydrous THF
(12 mL) at 0 °C under an N2 atmosphere. After completion of the addition, the reaction
mixture was heated at reflux for 3 h, and then quenched at 0 °C by the dropwise addition of
Et2O (50 mL), H2O (3 mL) and 15% NaOH (0.50 mL). The mixture was stirred, filtered
and the filtrate was dried (Na2SO4). The solvent was evaporated under reduced pressure to
give a yellow oily residue that was dissolved in absolute EtOH (5 mL) and converted to its
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization
from i-PrOH afforded 0.03 g (11%) of 51 as a white solid: mp 150-151 °C; 1H NMR
(DMSO-d6) δ 1.25 (d, J = 6.5 Hz, 3H, CH3), 2.54 (s, 3H, CH3), 2.52-2.5 (m, 1H, CH),
3.08-3.13 (m, 1H, CH), 3.26-3.30 (m, 1H, CH), 4.22 (s, 4H, CH2), 6.66 (dd, J = 8.2, 1.9
Hz, 1H, ArH), 6.74 (d, J = 1.9 Hz, 1H, ArH), 6.80 (d, J = 8.2 Hz, 1H, ArH), 8.86 (s, 3H,
NH3+, D2O ex); Anal. Calcd for (C12H17NO2·HCl) C, 59.14; H, 7.44; N, 5.75. Found: C,
58.91; H, 7.42; N, 5.53.

1-(Benzo[d]-1,3-dioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one Hydrochloride (65). This
compound is reported in the literature and was synthesized according to the literature
procedure.255 Pyrrolidine (0.24 mL, 2.90 mmol) was added to a stirred solution of 94 (0.37
g, 1.45 mmol) in anhydrous benzene (3 mL) at room temperature under an N2 atmosphere.
The reaction mixture was allowed to stir at room temperature for 6 h followed by heating
at reflux for 2 h. The reaction mixture was allowed to cool to room temperature, Et2O (5
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mL) was added, and the mixture was washed with H2O (3 x 5 mL). The organic portion
was dried (MgSO4) and solvent was removed under reduced pressure. The obtained residue
(0.29 g) was converted to the hydrochloride salt using a saturated solution of HCl/Et2O
which upon recrystallization from absolute EtOH/Et2O afforded 0.14 g (40%) of 65 as a
white powder: mp 244-246 °C (lit.255 mp 242-243 °C); IR (Diamond, cm-1) 3378 (N-H),
1672 (C=O), 1456 (CH2O), 1254 (C-O); 1H NMR (DMSO-d6) δ 1.52 (d, J = 7.0 Hz, 3H,
CH3), 1.96 (m, 4H, CH2), 2.98–3.12 (m, 1H, CH2), 3.12–3.26 (m, 1H, CH2), 3.50–3.60 (m,
1H, CH2), 3.60–3.70 (m, 1H, CH2) 5.39 (m, 1H, CH), 6.23 (s, 2H, CH2O), 7.18 (d, J = 8.2
Hz, 1H, ArH) 7.56 (d, J = 1.6 Hz, 1H, ArH), 7.73 (dd, J = 8.2, 1.7 Hz, 1H, ArH), 10.50 (s,
1H, NH+).

1-(Benzo[d]-1,3-dioxol-5-yl)-2-(dimethylamino)propan-1-one Hydrochloride (66). This
compound is reported in the literature and was synthesized according to the literature
procedure.256 Dimethylamine (2M in MeOH, 1.16 mL, 2.32 mmol) was added to a stirred
solution of 94 (0.30 g, 1.16 mmol) in anhydrous benzene (3 mL) at room temperature
under an N2 atmosphere. The reaction mixture was allowed to stir at room temperature for
4 h followed by heating at reflux for 3 h. The solvents were evaporated under reduced
pressure. The residue was dissolved in Et2O (5 mL) and the solution was washed with H2O
(3 x 5 mL). The organic portions were combined, dried (MgSO4), and the solvent was
evaporated under reduced pressure. The obtained residue (0.20 g) was converted to the
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization
from absolute EtOH/Et2O to afford 0.05 g (20%) of 66 as a white powder: mp 253-255 °C
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(lit.256 mp 252-254 °C) (MeOH/EtOH); 1H NMR (DMSO-d6) δ 1.47 (d, J = 7.1 Hz, 3H,
CH3), 2.83 (br s, 6H, CH3), 5.29 (q, J = 14.2, 7.08 Hz, 1H, CH), 6.19 (s, J =1.0 Hz, 2H,
CH2), 7.4 (d, J = 8.2 Hz, 1H, ArH) 7.53 (s, J =1.6 Hz, 1H, ArH), 7.73 (dd, J = 8.3, 1.8 Hz,
1H, ArH), 10.33 (s, 1H, NH+).

1-(Benzo[d]-1,3-dioxol-5-yl)-2-(methylamino)pentan-1-one Hydrochloride (68). This
compound is reported in the literature and was synthesized according to the literature
procedure.257 Methylamine (33% in EtOH, 0.35 mL, 2.80 mmol) was added to a stirred
solution of 95 (0.20 g, 0.70 mmol) in anhydrous benzene (2 mL) at room temperature
under an N2 atmosphere in a sealed tube. The reaction mixture was allowed to stir at room
temperature for 36 h. The solvent was then evaporated under reduced pressure and the
residue dissolved in EtOAc (5 mL) and washed with H2O (5 mL). The H2O layer was
extracted with EtOAc (3 x 2 mL). The organic portion was dried (MgSO4), and solvent
was evaporated under reduced pressure. The obtained residue (0.15 g) was converted to the
hydrochloride salt which upon recrystallization from absolute EtOH/Et2O afforded 0.04 g
(24%) of 68 as a white powder: mp 224-225 °C (lit.257 mp 221-225 °C ); 1H NMR (DMSOd6) δ 0.80 (t, J = 7.2 Hz, 3H, CH3), 1.03–1.30 (m, 2H, CH2), 1.76–1.80 (m, 2H, CH2), 2.54
(s, 3H, CH3), 5.11 (t, J = 5.4 Hz, 1H, CH), 6.19 (s, 2H, CH2O), 7.13 (d, J = 8.2 Hz, 1H,
ArH) 7.53 (d, J =1.6 Hz, 1H, ArH), 7.71 (dd, J = 8.2, 1.7 Hz, 1H, ArH), 9.14 (s, 1H, NH+).

1-(4-Fluorophenyl)-2-(methylamino)propan-1-one Hydrochloride (72). This compound
is reported in the literature and was synthesized according to the literature procedure.258
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Methylamine (33% in EtOH, 6.30 mL, 51.60 mmol) was added to a stirred solution of 108
(3.00 g, 12.19 mmol) in anhydrous benzene (30 mL) at room temperature under an N2
atmosphere. The reaction mixture was allowed to stir at room temperature for 20 h. The
solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (15
mL) and the solution was washed with H2O (3 x 5 mL). The organic portions were
combined and acidified with 2M HCl (20 mL, pH=1). The aqueous portion was basified
with 3M NaOH (20 mL, pH=14), and extracted with EtOAc (15 mL). The combined
organic portions were washed with H2O (3 x 5 mL), dried (MgSO4), and evaporated to
dryness under reduced pressure to yield a residue that was converted to the hydrochloride
salt which upon recrystallization from absolute EtOH afforded 0.07 g (20%) of 72 as a
white powder: mp 223-224 °C (lit.258 mp 222 °C); 1H NMR (DMSO-d6) δ 1.44 (d, J = 7.2
Hz, 3H, CH3), 2.60 (s, 3H, CH3), 5.16 (q, J = 14.6, 7.2 Hz, 1H, CH), 7.46 (t, J = 8.8 Hz,
2H, ArH), 8.12 (dd, J = 5.4, 2.1 Hz, 2H, ArH), 9.22 (s, 1H, NH+).
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(methylamino)propan-1-one Hydrochloride
(77). This compound is reported in the literature (no physical data).257 Methylamine (33%
in EtOH, 1.62 mL, 13.08 mmol) was added to a stirred solution of 115 (0.88 g, 3.27 mmol)
in anhydrous benzene (12 mL) at room temperature under an N2 atmosphere in a sealed
tube. The reaction mixture was allowed to stir at room temperature for 36 h. The reaction
mixture was filtered and the solvent was then evaporated under reduced pressure and the
residue dissolved in Et2O (25 mL) and washed with H2O (3 x 5 mL). The organic portions
were combined and acidified with 2M HCl (10 mL). The aqueous portion was basified
with saturated NaHCO3 (25 mL), and extracted with Et2O (3 x 10 mL). The combined
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organic portions were washed with brine (3 x 5 mL), dried (Na2SO4), and evaporated to
dryness under reduced pressure to yield a residue

(0.15 g) as a free base that was

converted to the hydrochloride salt which upon recrystallization from absolute EtOH/Et2O
afforded 0.04 g (6%) of 77 as a buff-colored powder: mp 218-219 °C; 1H NMR (DMSOd6) δ 1.43 (d, J = 7.1 Hz, 3H, CH3), 2.57 (s, 3H, CH3), 4.33 (m, 4H, CH2O), 5.07 (m, 1H,
CH), 7.05 (d, J = 8.4 Hz, 1H, ArH), 7.56 (dd, J = 5.7, 1.9 Hz, 2H, ArH), 9.28 (s, H, NH+).
Anal. calcd for (C11H15NO2 x HCl) C, 55.93; H, 6.26; N, 5.43. Found: C, 56.01; H, 6.12;
N, 5.33.
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(ethylamino)propan-1-one

Hydrochloride

(78). Ethylamine (2M in MeOH, 10.50 mL, 21.00 mmol) was added to a stirred solution of
94 (1.14 g, 4.43 mmol) in anhydrous benzene (15 mL) at 0 °C in a sealed tube. The
reaction mixture was allowed to stir at room temperature for 24 h and then the solvents
were evaporated under reduced pressure. The residue was dissolved in Et2O (25 mL) and
the organic layer was washed with H2O (3 x 15 mL) and separated. The organic layer was
acidified with 1M HCl (25 mL, pH=1), and then the aqueous portion was separated and
basified with 1M NaOH (30 mL, pH=14) and extracted with Et2O (3 x 20 mL). The
organic portions were combined, dried (Na2SO4), and evaporated under reduced pressure
to yield 1.46 g of the free base which was converted into the hydrochloride salt using a
saturated solution of HCl/Et2O which upon recrystallization from absolute EtOH/i-PrOH
afforded 0.66 g (25%) of 78 as a buff-colored solid: mp 223-226 °C; 1H NMR (DMSO-d6)
δ 1.25 (t, J = 7.2 Hz, 3H, CH3), 1.44 (d, J = 7.1 Hz, 3H, CH3), 2.83-3.04 (m, 2H, CH2),
5.11 (q, J = 14.2, 7 Hz, 1H, CH), 6.19 (s, 2H, OCH2), 7.13 (d, J = 8.2 Hz, IH, ArH), 7.56
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(d, J = 1.7 Hz, 1H, ArH), 7.73 (dd, J = 8.3, 1.8 Hz, 1H, ArH), 9.20 (br s, 2H, NH2+); Anal.
Calcd for (C12H15N·HCl·0.2H2O) C, 55.16; H, 6.33; N, 5.36. Found: C, 55.28; H, 6.42; N,
5.24.
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)-2-(propylamino)propan-1-one Hydrochloride
(79). Propylamine (0.72 mL, 28.86 mmol) was added to a stirred solution of 94 (1.14 g,
4.43 mmol) in anhydrous benzene (6 mL) at 0 °C in a sealed tube. The reaction mixture
was allowed to stir at room temperature for 18 h followed by heating at 45 °C for 6 h. The
solvents were evaporated under reduced pressure. The residue was dissolved in Et2O (15
mL) and the organic layer was washed with H2O (2 x 5 mL) and separated. The organic
portion was acidified with 1M HCl (25 mL, pH=1), the aqueous portion was separated and
washed with Et2O (2 x 10 mL) and then basified with 1M NaOH (20 mL, pH=14) and
extracted with Et2O (3 x 10 mL). The organic portions were combined, dried (Na2SO4),
and evaporated under reduced pressure to yield 0.43 g of the free base which was
converted into the hydrochloride salt using a saturated solution HCl/Et2O which upon
recrystallization from absolute EtOH/i-PrOH afforded 0.21 g (18%) of 79 as a buff-colored
solid: mp 202-203 °C; 1H NMR (DMSO-d6) δ 0.92 (t, J = 7.4 Hz, 6H, CH3), 1.45 (d, J =
7.1 Hz, 3H, CH3), 1.75-1.65 (m, 2H, CH2), 2.96-2.67 (m, 2H, CH2), 5.13 (d, J = 7 Hz, 1H,
CH), 6.19 (s, 2H, CH2), 7.13 (d, J = 8.2 Hz, 1H, ArH), 7.56 (d, J = 1.7 Hz, 1H, ArH), 7.72
(dd, J = 8.3, 1.8 Hz, 1H, ArH), 9.00 (s, 1H, NH+), 9.60 (s, 1H, NH+); Anal. Calcd for
(C13H17N·HCl) C, 57.46; H, 6.68; N, 5.15. Found: C, 57.42; H, 6.79; N, 5.09.
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N-Ethyl-1-(p-tolyl)propan-2-amine Hydrochloride (81). In a three-necked flask
equipped with a CaCl2 guard tube a solution of 119 (0.62 g, 3.24 mmol) in anhydrous THF
(15 mL) was added in a dropwise manner to a stirred suspension of LiAlH4 (0.18 g, 4.86
mmol) in anhydrous THF (20 mL) at 0 °C under an N2 atmosphere. After completion of the
addition, the reaction mixture was heated at reflux for 18 h. The reaction was worked up at
0 °C by the addition of Et2O (50 mL), and then by the dropwise addition of H2O (1 mL),
15% NaOH (1 mL) and H2O (3 mL). The mixture was stirred, filtered and the filtrate was
washed with water (10 mL) and dried (Na2SO4). The solvent was evaporated under
reduced pressure to give 0.20 g of a yellow oily residue that was converted to its
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization
from i-PrOH/Et2O afforded 0.08 g (12%) of 81 as a white solid: mp 160-161 °C; 1H NMR
(DMSO-d6) δ 1.31 (d, J = 6.5 Hz, 3H, CH3), 1.47 (t, J = 7.2 Hz, 3H, CH3), 2.72-2.74 (m,
2H, CH2), 2.78-2.84 (m, 1H, CH), 3.28-3.15 (m, 2H, CH2), 3.56 (s, 3H, CH3), 7.36 (s, 4H,
ArH), 9.26 (br s, 2H, NH2+); Anal. Calcd for (C12H19N·HCl·0.1H2O) C, 66.87; H, 9.45; N,
6.50. Found: C, 66.84; H, 9.30; N, 6.37.

N-Propyl-1-(p-tolyl)propan-2-amine Hydrochloride (82). Method A: In a three-necked
flask equipped with a CaCl2 guard tube a solution of 120 (0.42 g, 2.05 mmol) in anhydrous
THF (20 mL) was added in a dropwise manner to a stirred suspension of LiAlH4 (0.12 g,
3.07 mmol) in anhydrous THF (10 mL) at 0 °C under an N2 atmosphere. After completion
of the addition, the reaction mixture was heated at reflux for 17 h, and then quenched at 0
°C by diluting with Et2O (20 mL), and dropwise addition of H2O (1 mL), 15% NaOH (1
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mL) and H2O (3 mL). The mixture was stirred, filtered and the filtrate was washed with
water (2 x 10 mL), separated and dried (Na2SO4). The solvent was evaporated under
reduced pressure to give 0.30 g of a yellow oily residue that was converted to its
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization
from i-PrOH/Et2O afforded 0.10 g (21%) of 82 as a white solid: mp 183-184 °C; 1H NMR
(DMSO-d6) δ 0.93 (t, J = 7.4 Hz, 3H, CH3), 1.08 (d, J = 6.5 Hz, 3H, CH3), 1.68 (q, J = 7.5,
2H, 15 Hz, CH2), 2.28 (s, 3H CH3), 2.56-2.53 (m, 1H, CH), 2.91-2.87 (m, 2H, CH2), 3.10
(d, J = 13 Hz, 1H, CH), 3.33-3.29 (m, 1H, CH), 7.36 (s, 4H, ArH), 9.26 (br s, 2H, NH2+,
D2O ex.); Anal. Calcd for (C13H21N·HCl) C, 68.55; H, 9.74; N, 6.15. Found: C, 68.37; H,
9.67; N, 6.11.

Method B:
In a 3-neck flask, glacial acetic acid was added slowly to a stirred solution of npropylamine (52.0 mL, 641.25 mmol) in MeOH (100 mL) in an ice bath until pH ≈ 6.
Once all the glacial acetic acid was added, 121 (1.00 g, 6.75 mmol) was added, followed
by the portionwise addition of NaCNBH3 (1.25 g. 19.91 mmol). The ice bath was removed
and the contents were allowed to stir at room temperature for 20 h. The reaction mixture
was then basified by the addition of saturated aqueous solution of NaOH (300 mL,
pH=14), and extracted with Et2O (4 x 50 mL). The combined organic portion was washed
with H2O (3 x 50 mL), dried (Na2SO4), and evaporated to dryness under reduced pressure
to yield 1.20 g of a yellow oil which was converted to its hydrochloride salt using a
saturated solution of HCl/Et2O which upon recrystallization from absolute EtOH/Et2O
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afforded 0.60 g (36%) of 82 as a white solid: mp 180 °C; 1H NMR (DMSO-d6) δ 0.93 (t, J
= 7.5 Hz, 3H, CH3), 1.10 (d, 3H, CH3), 1.74-1.64 (m, 2H, CH2), 2.28 (s, 3H, CH3), 2.59 (q,
J = 12.9, 10.5 Hz, 1H, CH), 2.91-2.86 (m, 2H, CH2), 3.39-3.20 (m, 2H, CH2), 7.13 (s, 4H,
ArH), 9.05 (br s, 2H, NH2+).

N-Butyl-1-(p-tolyl)propan-2-amine (83). In a 3-neck flask, glacial acetic acid was added
slowly to a stirred solution of n-butylamine (60 mL, 641.25 mmol) in MeOH (100 mL) in
an ice bath until pH ≈ 6. Once all the glacial acetic acid was added, 121 (1.00 g, 6.75
mmol) was added, followed by the portionwise addition of NaCNBH3 (1.25 g. 19.91
mmol). The ice bath was removed and the contents were allowed to stir at room
temperature for 20 h. The reaction mixture was then basified by the addition of a saturated
aqueous solution of NaOH (250 mL, pH=14), and extracted with Et2O (3 x 50 mL). The
combined organic portion was washed with H2O (3 x 20 mL), dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield 1.50 g of a yellow oil which was
converted to its hydrochloride salt using a saturated solution of HCl/Et2O which upon
recrystallization from absolute EtOH/Et2O afforded 0.70 g (42%) of 83 as a white solid:
mp 206-208 °C; 1H NMR (DMSO-d6) δ 0.91 (t, J = 7.4 Hz, 3H, CH3), 1.09 (d, J = 6.5 Hz,
3H, CH3), 1.38-1.33 (m, 2H, CH2), 1.60-1.68 (m, 2H, CH2), 2.28 (s, 3H, CH3), 2.59 (q, J =
10.4, 13. 0 Hz, 1H, CH), 2.90-2.94 (m, 2H, CH2), 3.09-3.30 (m, 2H, CH2), 7.14 (s, 4H,
ArH), 8.85 (br s, 2H, NH2+, D2O ex); Anal. Calcd for (C14H23N·HCl·0.15 H2O) C, 68.77;
H, 10.02; N, 5.73. Found: C, 68.67; H, 10.13; N, 5.84.
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Phenyl(piperidin-2-yl)methanone Hydrochloride (84). Pipecolic acid (123) (0.50 g, 3.87
mmol) was added to a suspension of PCl5 (0.81 g, 3.87 mmol) in anhydrous CH2Cl2 (15
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to warm to room
temperature and stirred for 3 h. The solvent was evaporated under reduced pressure. The
residue was dried under high vacuum for 1 h and washed with toluene and acetone to yield
pipecolic acid chloride as a yellow-colored solid (0.66 g): mp 131-137 °C; IR (Diamond,
cm-1) 1768 (COCl). Pipecolic acid chloride is known259 but was synthesized according a
procedure for a similar compound.260 AlCl3 (1.56 g, 11.61 mmol) was added to a
suspension of the above acid chloride in anhydrous benzene under an N2 atmosphere and
stirred at room temperature for 18 h followed by heating at 60 °C for 24 h. The reaction
mixture was allowed to warm to room temperature and a mixture of 1M HCl (5 mL) and
ice (7 g) was added. The organic layer was separated. The aqueous layer was washed with
EtOAc (20 mL). The aqueous portion was basified with 3M NaOH (50 mL), and extracted
with CH2Cl2 (3 x 25 mL). The combined organic portions were dried (Na2SO4), and
evaporated to dryness under reduced pressure to yield a solid residue (0.12 g): mp 84-87
°C (lit.261 mp 89-91 °C (EtOAc)). This was converted to the hydrochloride salt using a
saturated solution of HCl/Et2O which upon recrystallization from MeOH/EtOAc afforded
0.08 g (10%) of the product as a white crystals: mp 221-222 °C (lit.261 mp 225-227 °C
(MeOH/EtOAc)); 1H NMR (DMSO-d6) δ 1.47 (m, 1H, CH), 1.77 (m, 4H, CH2), 2.11 (m,
1H, CH), 2.97 (m, 1H, CH), 3.23 (m, 1H, CH), 4.94 (t, J = 9.8 Hz, 1H, CH), 7.62 (t, J =
7.9 Hz, 2H, ArH), 7.76 (m,1H, ArH), 8.05 (dd, J = 7.2 Hz, 2H, ArH), 9.9 (br s, 2H, NH2+,
D2O ex).
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Methyl 2-phenyl-3-(pyrrolidin-1-yl)propionate Hydrochloride (85). This compound is
reported in the literature and was synthesized according to the literature procedures.262,263
A solution of ethyl 2-phenyl-3-(pyrrolidin-1-yl)propionate (126) (3.00 g, 12 mmol) in HCl
(10N, 15 mL) was microwave (50 W, 120 °C, 2 h) irradiated. The reaction mixture was
diluted with MeOH (10 mL), and the solvent was evaporated under reduced pressure to
yield 2.10 g of a crude solid of which 1.10 g was dissolved in anhydrous MeOH (20 mL)
to which HCl gas was bubbled for 5 min and the reaction was allowed to stir at reflux for
10 h. The reaction mixture was evaporated under reduced pressure to yield a crude solid
which upon recrystallization from i-PrOH afforded 0.30 g (22%) of 85 as a buff-colored
solid: mp 192-194 °C (lit.262 mp 196 °C); 1H NMR (DMSO-d6) δ 1.83-1.95 (m, 4H, CH2),
2.90-2.92 (m, 1H, CH), 3.03-3.05 (m, 1H, CH), 3.32-3.34 (m, 1H, CH), 3.49-3.52 (m, 2H,
CH2), 3.66 (s, 3H, CH3), 3.89-3.94 (m, 1H, CH), 4.36-4.39 (m, 1H, CH), 7.36-7.43 (m, 5H,
ArH), 10.64 (br s, 1H, NH+).

1-(2-Methoxy-2-phenylethyl)pyrrolidine Oxalate (86). Et3N (0.47 mL, 4.65 mmol) was
added in a dropwise manner to a stirred solution of 128 (1.00 g, 4.65 mmol) in anhydrous
benzene (10 mL) under an N2 atmosphere. The stirred reaction mixture was heated at
reflux for 48 h. The reaction mixture was allowed to cool to room temperature followed by
removal of solvents under reduced pressure. The residue obtained was dissolved in Et2O
(15 mL) and washed with H2O (3 x 20 mL). The organic portion was separated and washed
with 2M HCl (35 mL, pH=1), and the aqueous portion was basified with 3M NaOH (30
mL, pH=14), and extracted with Et2O (2 x 25 mL). The combined organic portion was
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washed with brine (2 x 10 mL), dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield 0.39 g of the free base as a yellow oil which was converted to its oxalate
salt using a saturated oxalic acid solution in Et2O which, upon recrystallization from iPrOH, afforded 0.28 g (21%) of 86 as a buff-colored solid: mp 134-135 °C; 1H NMR
(DMSO-d6) δ 1.94 (br s, 4H, CH), 3.11 (s, 3H, CH3), 3.34-3.45 (m, 6H CH), 4.64 (dd, J =
10.5, 2.5 Hz, 1H, CH), 7.36-7.39 (m, 5H, ArH); Anal. Calcd for (C13H19N·1.4C2H2O4) C,
57.27; H, 7.17; N, 4.23. Found: C, 57.07; H, 6.43; N, 4.23.

2-Methoxy-N,N-dimethyl-2-phenylethan-1-amine Hydrochloride (87). This compound
is reported in the literature264 and was synthesized according to the literature procedure
except that the literature reported a citrate salt.265 Dimethylamine (2M in MeOH 4.65 mL,
9.30 mmol) was added in a dropwise manner to a stirred solution of 128 (1.00 g, 4.65
mmol) in anhydrous benzene (10 mL) under an N2 atmosphere. The stirred reaction
mixture was heated at reflux for 72 h and allowed to cool to room temperature. Solvents
were removed under reduced pressure and residue dissolved in Et2O (15 mL) and washed
with H2O (2 x 10 mL). The organic portion was separated and washed with 2M HCl (20
mL, to pH 1), the aqueous portion was basified with 3M NaOH (to pH 14), and extracted
with Et2O (2 x 20 mL). The combined organic portion was washed with brine (3 x 10 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield 0.23 g of the
free base as a yellow oil that was converted to its hydrochloride salt using saturated
solution of HCl/Et2O which, upon recrystallization from i-PrOH, afforded 0.10 g (11%) of
87 as a white solid: mp 228-229 °C (lit.264 mp 233 °C (EtOH/EtOAc); 1H NMR (DMSO232

d6) δ 2.81 (s, 6H, CH3), 3.16 (s, 4H, CH), 3.35 (m, 2H, CH), 4.78 (dd, J = 2.5, 10.5 Hz, 1H,
CH), 7.38-7.46 (m, 5H, ArH), 10.35 (s, 1H, NH+).

2-(Methylamino)-1-phenylpropan-1-one oxime Hydrochloride (88). A solution of 57 as
its hydrochloride salt (1.00 g, 5.0 mmol) (on hand from previous studies), hydroxylamine
hydrochloride (0.75 g, 10.5 mmol) and pyridine (4.0 mL, 50.0 mmol) in absolute EtOH (25
mL) was allowed to stir at room temperature for 18 h and then at 45 °C for 48 h. Solvent
was removed under reduced pressure. The residue was treated with a saturated solution of
gaseous NH3 in MeOH and solvent was removed under reduced pressure. The solid residue
was extracted with hot acetone (3 × 30 mL). Solvent was removed under reduced pressure.
The residue was purified by flash chromatography (silica gel; CH2Cl/MeOH saturated with
gaseous NH3; 9:1). The obtained solid was suspended in acetone, stirred overnight and
collected by filtration: mp 197–205 °C. 1H NMR spectra showed that the solid contains a
mixture of isomeric oximes (2:1). The solid was dissolved in absolute EtOH and converted
to the hydrochloride salt by adding a saturated solution of gaseous HCl in Et2O. The
precipitate (0.20 g) was collected by filtration and recrystallized three times from a mixture
of acetone/absolute EtOH to afford 0.12 g (11%) of the product as white crystals: mp 209–
213 °C (lit.266 mp 198–201 °C, EtOH/Et2O/acetone); 1H NMR (DMSO-d6) δ 1.31 and 1.57
(d, 3H, CH3), 2.56 and 2.63 (s, 3H, CH3), 4.32–4.40 (two q, 1H, CH), 7.41–7.52 (m, 3H,
ArH), 7.66–7.68 (m, 2H, ArH), 9.35 (br s, 2H, NH2+), 11.51 (s, 1H, OH). Anal. Calcd
(C10H14N2O·HCl) C, 55.95; H, 7.04; N, 13.05. Found: C, 55.69; H, 6.89; N, 12.88.
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2-Methyl-1-phenylbutan-1-one (89). This compound is known and was synthesized
according to the literature procedure.267 In a 2-neck flask fitted with a CaCl2 guard tube, a
solution of 2-methylbutyrl chloride (130) (1.00 g, 8.30 mmol) in anhydrous benzene (1
mL) was added in a dropwise manner to a suspension of AlCl3 (1.20 g, 9.13 mmol) in
anhydrous benzene (2 mL) under an N2 atmosphere at room temperature. The contents
were allowed to stir at room temperature for 4 h and quenched by the addition of ice (7 g)
and conc. HCl (6 mL). The aqueous layer was extracted with Et2O (2 x 10 mL), the
combined organic portion was washed with saturated aqueous solution of NaHCO3 (5 x 5
mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield a crude
yellow-colored oil (0.70 g) which was purified by Kugelrohr distillation (149 °C at 1 Torr)
to afford 0.33g (25%) of 89 as a colorless oil: bp 240 °C at 760 mm of Hg (lit.267 bp 133–
135 °C at 24 mm of Hg); 1H NMR (CDCl3-d6) δ 0.92 (t, J = 7.5 Hz, 3H, CH3), 1.20 (m,
3H, CH3), 1.45-1.55 (m, 1H, CH), 1.79-1.89 (m, 1H, CH), 3.36-3.44 (m, 1H, CH), 7.44 (t,
J = 7.9 Hz, 2H, ArH), 7.56 (t, J = 6.8 Hz, 1H, ArH), 7.95 (d, 2H, ArH).

Dimethyl(1-methyl-2-oxo-2-phenylethyl)sulphonium Bromide (90). This compound is
reported in the literature and was synthesized according to the literature procedure.268 In a
2-neck flask, an excess of dimethylsulfide (2 mL) was added to a solution of 2bromopropiophenone (106) (0.50 g, 2.35 mmol) under an N2 atmosphere and the reaction
mixture was heated at 65 °C for 5 h, cooled to room temperature and the precipitate formed
was collected by filtration to yield 0.15 g of the product which upon recrystallization from
MeOH/Et2O afforded 0.14 g (22%) of 90 as a buff-colored solid: mp 130-131 °C (lit.268 mp
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129 °C); 1H NMR (DMSO-d6) δ 1.69 (d, J = 7.3 Hz, 3H, CH3), 2.95 (d, J = 10.6 Hz, 6H,
CH3), 5.90 (q, J = 6.4, 17.5 Hz, 1H, CH), 7.65 (t, J = 15.6, 8.0 Hz, 2H, ArH), 7.77-7.81
(m, 1H, ArH), 8.06 (dd, J = 8.2, 0.9 Hz, 2H, ArH).

1-(Benzo[d]-1,3-dioxol-5-yl)propan-1-one (92). This compound is reported in the
literature269 and was synthesized according to the literature procedure except that SnCl4
was used in place of AlCl3.269 SnCl4 (1.80 mL, 15.36 mmol) was added in a dropwise
manner at 0-5 °C to a stirred solution of propionyl chloride (1.30 mL, 15.36 mmol) and
1,3-benzodioxole (91) (1.50 g, 12.28 mmol) in anhydrous CH2Cl2 (10 mL). The contents
were allowed to stir at 0-5 °C for 10 min under an N2 atmosphere. The reaction mixture
was quenched by the careful addition of ice (10 g) and conc HCl (8 mL). The organic
portion was separated, washed with water and dried (MgSO4). The solvent was evaporated
under reduced pressure to yield a crude dark-yellow oil which was purified by Kugelrohr
distillation followed by recrystallization from hexane/Et2O to afford 2.19 g (28%) of 92 as
a white powder: mp 35–38 °C (lit.269 mp 38–39 °C, (EtOH)); bp 165 °C, 1 Torr; IR
(Diamond, cm-1) 1666 (C=O), 1436 (CH2O), 1241(C-O); 1H NMR (CDCl3-d6) δ 1.21 (t, J
= 6.8 Hz, 3H, CH3), 2.92 (q, J = 14.6, 7.3 Hz, 2H, CH2), 6.04 (s, 2H, CH2), 6.84 (d, J =8.2
Hz, 1H, ArH), 7.44 (d, J = 1.6 Hz, 1H, ArH), 7.56 (dd, J = 8.1, 1.7 Hz, 1H, ArH).

1-(Benzo[d]-1,3-dioxol-5-yl)pentan-1-one (93). This compound is reported in the
literature and was synthesized according to the literature procedure.270 SnCl4 (3.60 mL,
30.70 mmol) was added in a dropwise manner at 0-5 °C to a stirred solution of valeroyl
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chloride (3.60 mL, 30.70 mmol) and 1,2-methylenedioxybenzene (91) (3.00 g, 24.56
mmol) in anhydrous CH2Cl2 (22 mL). The reaction mixture was allowed to stir at 0-5 °C
for 20 min under an N2 atmosphere. The reaction mixture was quenched by the careful
addition of ice (21 g) and conc. HCl (16 mL). The organic layer was separated, washed
with H2O (8 mL), and dried (MgSO4). The solvent was evaporated under reduced pressure
to yield a yellow oil which was purified by Kugelrohr distillation followed by column
chromatography (silica gel; hexane/EtOAc; 90:10) to yield 1.60 g (32%) of the product as
a pale-yellow oil: bp 171 °C, 1 Torr (lit.270 bp 120 °C, 5 mm of Hg ): 1H NMR (CDCl3-d6)
δ 0.94 (t, J = 7.2 Hz, 3H, CH3), 1.35-1.44 (m, 2H, CH2), 1.73-1.5 (m, 2H,CH2), 2.88 (t, J =
7.3 Hz, 2H, CH2), 6.03 (s, 2H, CH2O), 6.80 (d, J = 7.9 Hz, 1H, ArH), 7.43 (d, J = 1.6 Hz,
1H, ArH), 7.56 (dd, J = 8.1, 1.7, Hz, 1H, ArH).
1-(Benzo[d]-1,3-dioxol-5-yl)-2-bromopropan-1-one (94). This compound is reported in
the literature and was synthesized according to the literature procedure except that AlCl3
was used.271 Bromine (0.01mL, 0.19 mmol) was added in a dropwise manner to a stirred
solution of 92 (0.27 g, 1.51 mmol) and AlCl3 (0.01 g, 0.08 mmol) in anhydrous Et2O (10
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to stir at 0 °C for
10 min, and then allowed to warm to room temperature. When the color of the solution
changed from orange to pale yellow the remaining quantity of bromine (0.07 mL, 1.35
mmol) was added in a dropwise manner. The reaction mixture was allowed to stir at room
temperature for 10 min. The reaction mixture was quenched with a saturated solution of
NaHCO3 (15 mL). Organic portion was separated, washed with brine (1 x 10 mL) and
dried (MgSO4). Solvent was removed under reduced pressure and the residue was dried
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under high vacuum to afford 0.20 g (70%) of 94 as a sticky pale-orange solid: mp 41-43 °C
(lit.256 mp 52-53 °C (MeOH)); 1H NMR (CDCl3-d6) δ 1.81 (d, J = 6.6 Hz, 3H, CH3), 5.14
(q, J =13.2, 6.6 Hz, 1H, CH), 5.99 (s, 2H, CH2), 6.80 (d, J = 8.2 Hz, 1H, ArH), 7.42 (s, J =
1.7 Hz, 1H, ArH), 7.56 (d, J = 1.7 Hz, 1H, ArH).

1-(Benzo[d]-1,3-dioxol-5-yl)-2-bromopentan-1-one (95). This compound is reported in
the literature272 (using a 3-step procedure starting from piperonal) but was synthesized here
according to a procedure for a similar compound.273 Bromine (0.06 mL, 1.16 mmol) was
added in a dropwise manner to a stirred solution of 93 (0.80 g, 3.87 mmol) and AlCl3 (0.03
g, 0.20 mmol) in anhydrous Et2O (6 mL) at 0 °C under an N2 atmosphere. The reaction
mixture was allowed to stir at 0 °C for 10 min and then allowed to warm to room
temperature. When the color of the solution changed from orange to a pale yellow, the
remaining bromine (0.14 mL, 2.70 mmol) was added in a dropwise manner. The reaction
mixture was allowed to stir at room temperature for 10 min. The reaction mixture was
quenched with a saturated solution of NaHCO3 (20 mL). The organic portion was
separated, washed with brine (10 mL), and dried (MgSO4). The solvent was evaporated
under reduced pressure to yield a yellow oil (1.10 g) which was purified by column
chromatography (silica gel; hexane/EtOAc; 95:5) to afford 0.65 g (60%) of 95 as a paleyellow oil: 1H NMR (CDCl3-d6) δ 0.97 (t, J = 14.8, 7.4 Hz, 3H, CH3), 1.58-1.44 (m, 1H,
CH2), 2.07-2.18 (m, 2H, CH2), 5.06 (t, J = 14.3, 6.8 Hz, 1H, CH) 6.05 (s, 2H, CH2O), 6.87
(d, J = 8.2 Hz, 1H, ArH) 7.48 (d, J = 1.7 Hz, 1H, ArH), 7.82 (dd, J = 8.2, 1.7 Hz, 1H,
ArH).
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1-Phenyl-2-(pyrrolidin-1-yl)ethan-1-one Oxalate (96). The compound is reported in the
literature as its hydrochloride salt274 but the oxalate salt was made here because the
hydrochloride was extremely hygroscopic. The procedure followed was modified such that
Et3N was used.275 Pyrrolidine (0.84 mL, 10.04 mmol) was added to a stirred solution of 2bromoacetophenone (105) (2.00 g, 10.04 mmol) and Et3N (1.0 mL, 10.04 mmol) in
anhydrous benzene (15 mL) under an N2 atmosphere at room temperature. The contents
were allowed to stir at room temperature for 24 h. The reaction mixture was filtered and
solvent evaporated under reduced pressure to yield 1.8 g (96%) the crude free base, of
which 1.0 g was converted to its oxalate salt using a saturated solution of oxalic acid in
Et2O and was allowed to stir at room temperature for 48 h. The precipitate was collected
by filtration to yield a solid which was recrystallized twice from absolute MeOH (10 mL)
to afford 0.35 g (24%) of 96 as brown crystals: mp 218-220 °C, absolute MeOH; 1H NMR
(DMSO-d6) δ 1.95 (s, 4H, CH2), 3.23 (m, 4H, CH2), 4.92 (s, 2H, CH2), 7.59 (s, 2H, ArH)
7.72 (s, 1H, ArH), 7.98 (s, 2H, ArH); Anal. Calcd for (C12H15NO·C2H2O4) C, 60.21; H,
6.14; N, 5.02. Found: C, 59.97; H, 6.19; N, 5.00.

1-Phenyl-2-(pyrrolidin-1-yl)propan-1-one Hydrochloride (97). This compound is
reported in the literature and was synthesized according to the literature procedure.249
Pyrrolidine (0.76 mL, 9.20 mmol) was added to a solution of 2-bromopropiophenone
(106) (1.00 g, 4.60 mmol) in anhydrous benzene (10 mL) under an N2 atmosphere at room
temperature. The reaction mixture was allowed to stir at room temperature for 14 h
followed by heating at reflux for 8 h. The reaction mixture was diluted with Et2O (30 mL)
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and washed with H2O (2 x 15 mL). The organic layer was separated and acidified with 2M
HCl (to pH 1), and extracted with Et2O (2 x 20 mL). The aqueous portion was basified
with 3M NaOH (to pH 14) and extracted with Et2O (2 x 25 mL). The combined organic
portion was washed with brine (3 x 15 mL), dried (Na2SO4), and evaporated under reduced
pressure to yield a brownish-colored oil that was converted to its hydrochloride salt using a
saturated solution of HCl/Et2O and upon two recrystallizations from absolute EtOH/Et2O
afforded 0.70 g (22%) of 97 as a cream-colored solid: mp 202-203 °C (lit.249 mp 197 °C);
1

H NMR (DMSO-d6) δ 1.51 (d, J = 7.1 Hz, 3H, CH3), 1.93 (br s, 4H, CH2), 3.20–3.08 (m,

2H CH2), 3.53–3.61 (m, 2H, CH2), 7.63 (m, 2H, ArH) 7.77 (t, J = 7.4 Hz, 1H, ArH), 8.04
(m, 2H, ArH), 10.68 (s, 1H, NH+).

1-Phenyl-2-(1-piperidinyl)-1-propanone Hydrochloride (103). This compound is
reported in the literature and was synthesized according to the literature.276 Piperidine (0.90
ml, 9.20 mmol) was added to a stirred solution of 2-bromopropiophenone (106) (1.00 g,
4.60 mmol) in anhydrous benzene (10 mL) under an N2 atmosphere at room temperature.
The reaction mixture was allowed to stir at room temperature for 3 h followed by 24 h of
reflux. The reaction mixture was cooled to room temperature and the solvent removed
under reduced pressure to yield a brown residue. The residue was dissolved in Et2O (20
mL) and washed with water (5 x 5 mL), dried (MgSO4), and solvent was evaporated under
reduced pressure to yield 0.90 g of the crude product that was converted to its
hydrochloride salt using a saturated solution of HCl/Et2O and upon recrystallization from
absolute EtOH afforded 0.50 g (43%) of 103 as a white solid: mp 212-213 °C (lit.276 mp
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212-214 °C ); 1H NMR (DMSO-d6) δ 1.51 (d, J = 7.2 Hz, 3H, CH3), 1.77 (br s, 4H, CH2),
2.99 (br s, 2H, CH2), 3.12–3.50 (m, 2H, CH2), 4.04 (m, 2H, CH2), 5.34 (q, J = 6.6 Hz, 1H,
CH), 7.63 (t, J = 7.6 Hz, 2H, ArH) 7.78 (t, J = 7.4 Hz, 1H, ArH), 8.07 (t, J = 8.4 Hz, 2H,
ArH), 10.06 (s, 1H, NH+).

2-Bromo-1-(4-fluorophenyl)-1-propanone (108). This compound is reported in the
literature and was synthesized according to the literature procedure except with the
addition of AlCl3.258 Bromine (0.05 mL, 1.09 mmol) was added in a dropwise manner to a
stirred solution of 4’-fluoropropiophenone (107) (1.00 g, 6.50 mmol) and AlCl3 (0.05 g,
0.17 mmol) in anhydrous CH2Cl2 (25 mL) at 0 °C under an N2 atmosphere. The reaction
mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room
temperature. When the color of the solution changed from orange to pale yellow the
remaining bromine (0.25 mL, 10.53 mmol) was added in a dropwise manner. The reaction
mixture was allowed to stir at room temperature for 14 h. The reaction mixture was
quenched with a saturated solution of NaHCO3 (15 mL). The organic portion was
separated, washed with H2O (10 mL) and dried (MgSO4). Solvent was removed under
reduced pressure and the residue was dried under high vacuum to afford 1.43 g (100%) of
108 as a colorless oil: 1H NMR (CDCl3-d6) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 5.23 (q, J =
13.2, 6.6 Hz, 1H, CH), 7.16 (t, J = 8.5 Hz, 2H, ArH), 8.06 (dd, J = 5.4, 2.1 Hz, 2H, ArH).
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6-(2-Nitroprop-1-en-1-yl)-2,3-dihydrobenzo[b]-1,4-dioxine (110). Ammonium acetate
(1.00 g, 13.13 mmol) was added to a solution of 1,4-benzodioxan-6-carboxaldehyde (109)
(1.00 g, 6.70 mmol) in nitroethane (20 mL), and the reaction mixture was heated at reflux
for 5 h under an N2 atmosphere. The nitroethane was evaporated under reduced pressure,
the resultant yellow residue was dissolved in CHC13 (5 mL), the organic layer was washed
with H2O (3 x 5 mL). The aqueous portion was extracted with CHC13 (3 x 5 mL), and the
organic portions were combined, dried (Na2SO4) and evaporated to yield a crude yellow oil
that was recrystallized from MeOH to yield 1.00 g (75%) of 110 as a yellow crystals: mp
97-98 °C (MeOH), (lit.277 mp 97-98 °C (MeOH)).
1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)propan-2-amine Hydrochloride (111). This
compound is reported in the literature and was synthesized according to the literature
procedure.277 A solution of 110 (1.00 g, 4.50 mmol) in anhydrous THF (18 mL) was added
in a dropwise manner to a stirred suspension of LiAlH4 (0.29 g, 7.52 mmol) in anhydrous
THF (12 mL) at 0 °C under an N2 atmosphere. After completion of the addition, the
reaction mixture was heated at reflux for 5 h, and then quenched at 0 °C by the dropwise
addition of Et2O (50 mL), H2O (3 mL) and 15% NaOH (1.7 mL). The mixture was stirred,
filtered and the filtrate was dried (Na2SO4). The solvent was evaporated under reduced
pressure to give a yellow oily residue, which was converted to its hydrochloride salt using
a saturated solution of HCl/Et2O to afford 0.16 g (64%) of 111 as a white solid: mp 163166 °C (lit.277 mp 167-170 °C). Compound was used without any further purification.
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Ethyl (1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)propan-2-yl)carbamate (112). Et3N in
anhydrous Et2O (0.4 mL) and ethyl chloroformate (0.14 mL) in Et2O (1 mL) were added to
a suspension of 111 (0.35 g) in anhydrous Et2O (10 mL) and stirred at room temperature
for 1 h under an N2 atmosphere. The reaction mixture was filtered and solvent was
removed under reduced pressure to afford 0.30 g (79%) of 112 as a yellow oil: IR
(Diamond, cm-1) 3066 (NH), 1754 (N-CO-O-), 1577 (CH2 CH2O), 1274(C-O). The
compound was used without further characterization for the preparation of 51.

1-(2,3-Dihydrobenzo[b]-1,4-dioxin-6-yl)propan-1-one (114). This compound is reported
in the literature AlCl3269 was synthesized according to the literature procedure except that
SnCl4 was used instead of AlCl3.269 SnCl4 (2.14 mL, 18.32 mmol) was added in a dropwise
manner at 0-5 °C to a stirred solution of propionyl chloride (1.60 mL, 18.32 mmol) and
1,4-benzodioxane (113) (2.00 g, 14.64 mmol) in anhydrous CH2Cl2 (20 mL). The reaction
mixture was allowed to stir at 0-5 °C for 20 min under an N2 atmosphere. The reaction
mixture was quenched by the careful addition of ice (16 g) and conc. HCl (11 mL). The
organic layer was separated, washed with H2O (3 x 5 mL), and dried (Na2SO4). The
solvent was evaporated under reduced pressure to yield 2.15 g (76%) of 114 as a yellow
oil: 1H NMR (CDCl3-d6) δ 1.20 (t, J = 7.2 Hz, 3H, CH3), 2.91 (d, J = 7.3 Hz, 2H, CH2),
4.27-4.31 (m, 4H, CH2), 6.90 (d, J = 9.08 Hz, 1H, ArH), 7.50 (s, 2H, ArH). NoteCompound has been reported as a low melting solid, mp 39-40 °C.278

242

2-Bromo-1-(2,3-dihydrobenzo[b]-1,4-dioxin-6-yl)propan-1-one (115). This compound
is known and was synthesized according to the literature procedure except that AlCl3 was
used.271 Bromine (0.15 mL, 2.96 mmol) was added in a dropwise manner to a stirred
solution of 114 (2.15 g, 11.80 mmol) and AlCl3 (0.06 g, 0.60 mmol) in anhydrous Et2O (18
mL) at 0 °C under an N2 atmosphere. The reaction mixture was allowed to stir at 0 °C for
10 min and then allowed to warm to room temperature. When the color of the solution
changed from orange to a pale yellow, the remaining bromine (0.45 mL, 8.88 mmol) was
added in a dropwise manner. The reaction mixture was allowed to stir at room temperature
for 20 min. The reaction mixture was quenched with a saturated solution of NaHCO3 (40
mL). The organic portion was separated, washed with brine (3 x 5 mL), and dried
(Na2SO4). The solvent was evaporated under reduced pressure to yield a yellow oil (3.00 g)
which was purified by column chromatography (silica gel; hexane/EtOAc; 89:11) to afford
0.88 g (30%) of 115 as a white solid: mp 77-78 °C (lit.271 bp 180-182 °C at 1.5 mm of Hg);
1

H NMR (CDCl3-d6) δ 2.09 (m, 3H, CH3), 4.46 (br s, 4H, CH2O), 5.38-5.24 (m, 1H, CH)

7.48 (m, J = 1.7 Hz, 1H, ArH), 7.82 (m, J = 8.2, 1.7 Hz, 2H, ArH).
(1-Methyl-4-(2-nitroprop-1-en-1-yl)benzene (117). Ammonium acetate (12.60 g, 163.11
mmol) was added to a solution of p-tolualdehyde (116) (10.00 g, 163.11 mmol) in
nitroethane (30 mL), and the reaction mixture was heated at reflux for 2.5 h under an N2
atmosphere. The nitroethane was evaporated under reduced pressure, the resultant yellow
residue was dissolved in CHC13 (20 mL), the organic layer was washed with H2O (3 x 10
mL), the organic portions were combined, and dried (Na2SO4). The solvent was evaporated
under reduced pressure to yield a crude residue which was purified by column
243

chromatography (silica gel; hexane:EtOAc; 100:0) to afford 4.07 g of yellow powder, that
was recrystallized from hexane to yield 4.00 g (28%) of 117 as a yellow crystals: mp 53-55
°C, (lit.279 mp 51.5-52.5 °C).
1-(p-Tolyl)propan-2-amine Hydrochloride (118). Compound is reported in the
literature280,281 and was synthesized according to the literature procedure.280 In a 3-necked
flask equipped with a CaCl2 guard tube a solution of 117 (2.00 g, 11.29 mmol) in
anhydrous THF (30 mL) was added in a dropwise manner to a stirred suspension of
LiAlH4 (1.70 g, 45.15 mmol) in anhydrous THF (40 mL) at 0 °C under an N2 atmosphere.
After completion of the addition, the reaction mixture was heated at reflux for 2.5 h, and
then quenched at 0 °C by diluting with Et2O (50 mL), and then by the dropwise addition of
H2O (2 mL), 15% NaOH (2 mL) and H2O (6 mL). The mixture was stirred, filtered and the
filtrate was washed with water (2 x 10 mL), and dried (Na2SO4). The solvent was
evaporated under reduced pressure to give a 1.40 g of a yellow oily residue, which was
converted to its hydrochloride salt using a saturated solution of HCl/Et2O to yield 0.90 g
(45%) of 118 as a white solid: mp 150-151°C (lit.281 mp 158-159 °C (EtOAc, EtOH, Et2O).

N-(1-(p-Tolyl)propan-2-yl)acetamide (119). Acetyl chloride (0.4 mL, 4.96 mmol) was
added in a dropwise manner at 0 °C to a stirred solution of 118 (0.90 g, 4.85 mmol), Et3N
(1.35 mL, 9.70 mmol) in anhydrous CH2Cl2 (25 mL) under an N2 atmosphere. The reaction
mixture was allowed to stir at room temperature for 16 h. Reaction was washed with 2M
HCl (2 x10 mL), organic layer was separated and washed with water (2 x 5 mL), and dried
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(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue
(1.01 g) which was purified by column chromatography (silica gel; hexane/EtOAc; 40:60)
to afford 0.62 g (67%) of 119 as a white solid: mp 82-83 °C.

N-(1-(p-Tolyl)propan-2-yl)propionamide (120). Propionyl chloride

(0.35 mL, 3.96

mmol) was added in a dropwise manner at 0 °C to a stirred solution of 118 (0.72 g, 3.88
mmol), Et3N (1.08 mL, 7.75 mmol) in anhydrous CH2Cl2 (10 mL) under an N2
atmosphere. The reaction mixture was allowed to stir at room temperature for 17 h.
Reaction was washed with 2M HCl (2 x10 mL), organic layer was separated and dried
(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue
(0.58 g) which was purified by column chromatography (silica gel; hexane/EtOAc; 30:70)
to afford 0.42 g (53%) of 120 as a yellow oil: 1H NMR (CDCl3-d6) δ 1.09-1.13 (m, 6H,
CH3), 2.14 (q, J = 15.1, 7.6 Hz, 2H, CH3), 2.32 (s, 3H, CH3), 2.81-2.66 (m, 2H CH2), 4.284.21 (m, 1H, CH), 7.08 (m, 4H, ArH).

1-(4-Methylphenyl)-2-propanone (121). The compound is reported in the literature and
was synthesized according to the literature procedure.282 Compound 117 (12.00 g, 67.70
mmol) was added portionwise to a solution of iron powder (45.00 g, 812.60 mmol) in 80
mL of 90% aqueous acetic acid which was heated at 70 °C for 20 minutes. After heating
for an additional 1 h at 70 °C, the mixture was poured into H2O (200 mL) and CH2Cl2 (100
mL), and the mixture was stirred for an additional 30 min and filtered through Celite. The
filter cake was washed with CH2Cl2. The organic phase was separated and washed with
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brine (30 mL), dried (Na2SO4), and evaporated under reduced pressure to yield 5.90 g
(59%) 121 as a yellow oil: 1H NMR (CDCl3-d6) δ 2.03 (s, 3H, CH3), 2.28 (s, 3H, CH3),
3.57 (s, 2H, CH2), 7.00 (d, J = 8.0 Hz, ArH), 7.06 (d, J = 8.0 Hz, 2H, ArH).

Ethyl 2-phenylacrylate (125). This compound is reported in the literature and was
synthesized according to the literature procedure.263 Formalin (37%, 7.40 mL, 91.00
mmol) was added to a mixture of ethyl phenylacetate (124) (10.00 g, 61.00 mmol), DMF
(60 mL) and K2CO3 (8.40 g, 61.00 mmol) and the reaction mixture was allowed to stir at
110 °C (oil bath) for 5 h, cooled to room temperature, quenched by addition of H2O (250
mL), and extracted with Et2O (3 x 100 mL). The combined organic portion was washed
with H2O (3 x 100 mL), aqueous LiCl (5%, 50 mL), brine (50 mL), dried (Na2SO4), and
solvent was evaporated under reduced pressure to yield 6.00 g (56%) of 125 as a crude,
yellow-colored oil: 1H NMR (CDCl3-d6) δ 1.25 (t, 3H, CH3), 3.96 (q, 2H, CH2), 5.79 (d, J
= 1.2 Hz, 1H, CH), 6.26 (d, J = 1.2 Hz, 1H, CH), 7.15-7.22 (m, 5H, Ar). The compound
was used without further characterization for the preparation of 126.

Ethyl 2-phenyl-3-(pyrrolidin-1-yl)propionate (126). This compound is reported in the
literature and was synthesized according to a procedure for the same compound.262
Pyrrolidine (6.50 g, 91.00 mmol) was added to a solution of ethyl 2-phenylacrylate (125)
(4.00 g, 23.00 mmol) in anhydrous DMF (8 mL) under an N2 atmosphere. The reaction
mixture was allowed to stir at room temperature for 1 h, diluted with Et2O (100 mL), and
washed with H2O (3 x 100 mL), dried (Na2SO4), and evaporated under reduced pressure to
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yield 3.80 g (68%) of the free base of 126 as a yellow-colored oil which was used for
further reaction without purification.

(2-Bromo-1-methoxyethyl)benzene

(128).

This

compound

is

reported

in

the

literature283,284 and was synthesized according to the literature procedure.283 Conc. H2SO4
(2.56 mL, 48 mmol) was added in a dropwise manner at 5 °C to a stirred solution of
styrene (127) (5.52 mL, 48 mmol) in anhydrous MeOH (50 mL). Portions of KBr (4.11 g,
34.57 mmol) and KBrO3 (2.89 g, 17.28 mmol) were added over a period of 30 min, and the
reaction was stirred at 5 °C for 2 h. The solvent was removed under reduced pressure, the
residue was dissolved in H2O (50 mL) and extracted with CH2Cl2 (3 x 25 mL). The
combined organic portions were washed with Na2S2O3 (50 mL), dilute NaHCO3 (50 mL),
brine (25 mL), and dried (Na2SO4). Solvent was evaporated under reduced pressure to
yield 4.50 g of crude product as yellow-colored oil. 3.40 g of the crude product was
purified by Kugelrohr distillation to yield 2.30 g (33%) of 128 as a yellow-colored oil; bp
142 °C, 1 Torr (lit.284 bp 50 °C, 0.5 Torr); 1H NMR (CDCl3-d6) δ 3.24 (s, 3H, CH3), 3.373.49 (m, 2H, CH2), 4.31 (dd, J = 4.3, 8.2 Hz, 1H, CH), 7.31-7.24 (m, 5H, ArH).

2-Methoxy-N-methyl-2-phenylethan-1-amine Hydrochloride (129). Methylamine (33%
in EtOH, 4.67 mL, 34.87 mmol) was added in a dropwise manner to a stirred solution of
128 (3.00 g, 13.95 mmol) in anhydrous benzene (10 mL) at 0 °C in an ice bath under an N2
atmosphere. The reaction mixture was stirred at room temperature for 72 h, followed by
the removal of solvents under reduced pressure. The residue obtained was dissolved in
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Et2O (20 mL) and washed with H2O (3 x 20 mL). The organic portion was separated and
washed with 2M HCl (50 mL, pH=1), and the aqueous portion was basified with 3M
NaOH (to pH 14), extracted with Et2O (5 x 25 mL) and dried (Na2SO4). Solvent was
removed under reduced pressure to yield 0.27 g of the free base as a yellow oil which was
converted into its hydrochloride salt using a saturated solution of HCl/Et2O which upon
recrystallization from acetone afforded 0.08 g (3%) of 129 as a white solid: mp 158-160
°C; 1H NMR (DMSO-d6) δ 2.58 (s, 3H, CH3), 3.05-3.19 (m, 2H, CH2), 3.19 (s, 3H, CH3),
4.60 (dd, J = 10.1, 3.2 Hz, 1H, CH), 7.35-7.46 (m, 5H, ArH), 8.90-9.13 (br s, 2H, NH2+);
Anal. Calcd for (C10H15NO·HCl.0.3H2O) C, 57.99; H, 8.08; N, 6.76. Found: C, 57.85; H,
7.74; N, 6.74.

1-(3,4-Dichlorophenyl)-2-methylbutan-1-one (132). Sec-butyl magnesium chloride (161)
(2M in Et2O, 12.10 mL) was added in a dropwise manner at 0°C to a stirred solution of
3,4-dichlorobenzonitrile (162) (3.50 g, 20.34 mmol) in anhydrous THF (12 mL) under an
N2 atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h,
cooled to 0°C, quenched by addition of 3N HCl (30 mL, pH=1), and allowed to stir at
room temperature for 30 min. The reaction mixture was basified with NH4OH solution (50
mL (1:1), to pH 14 and extracted with CH2Cl2 (5 x 25 mL). The combined organic portion
was washed with water (3 x 20 mL), dried (Na2SO4). The solvent was evaporated under
reduced pressure to yield 3.40 g as a brown-colored crude oil which was purified by
column chromatography (silica gel; hexane/EtOAc; 90:10) to afford 1.00 g of a yellowcolored oil. This was further purified using Kugelrohr distillation to afford 0.80 g (17%) of
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132 as a colorless oil: bp 210 °C, 2 Torr; 1H NMR (CDCl3-d6) δ 0.91 (t, J = 7.4 Hz, 3H,
CH3), 1.19 (d, J = 6.8 Hz, 2H, CH3), 1.46-1.50 (m, 1H, CH), 1.76-1.87 (m, 1H, CH), 3.273.34 (m, 1H, CH), 7.55 (d, J = 8.4 Hz, 1H, ArH), 7.76 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 8.02
(d, J = 2.0 Hz, 1H, ArH); Anal. Calcd for (C11H12) C, 57.17; H, 5.23. Found: C, 57.47; H,
5.30.

2-(Adamantan-1-yl)-2-(methylamino)-1-phenylethan-1-one

Hydrochloride

(137).

Excess of methylamine (2 mL of a 40% solution of methylamine in water) was added to
stirred solution of K2CO3 (0.56 g, 4.05 mmol), KI (0.68 g, 4.05 mmol) and 142 (0.45 g,
1.35 mmol) in anhydrous DMF (4 mL) in a sealed tube. The reaction mixture was heated at
85 °C for 18 h and 120 °C for an additional 24 h. The reaction mixture was then transferred
to a round-bottom flask and the solvents were evaporated under reduced pressure and the
residue was dissolved in Et2O (10 mL) and the organic layer was washed with H2O (3 x 5
mL) and separated. The organic layer was acidified with 1M HCl (25 mL, pH=1), and then
aqueous portion was separated and basified with 1M NaOH (35 mL, to pH=14) and
extracted with Et2O (3 x 10 mL). The organic portions were combined, dried (Na2SO4),
and evaporated under reduced pressure to yield the free base which was converted into the
hydrochloride salt using a saturated solution of HCl/Et2O which upon recrystallization
from i-PrOH/Et2O afforded 0.03 g (25%) of 137 as a buff-colored solid: mp 272 °C; 1H
NMR (DMSO-d6) δ 1.69-1.53 (m, 12H, CH), 1.91 (s, 3H, CH), 2.32 (s, 2H, CH3), 5.71 (s,
1H, CH), 7.50-7.43 (m, 5H, ArH). Anal. Calcd for (C12H15N·HCl) C, 71.34; H, 8.19; N,
4.38. Found: C, 71.08; H, 8.18; N, 4.33.
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1-Adamantyl acetyl chloride (140). This compound is reported in the literature and was
synthesized according to the literature procedure.285 Thionyl chloride (5.25 mL) was added
in a dropwise manner to 1-adamantyl acetic acid (139) (3.50 g, 18.01 mmol), and the
reaction mixture was heated at reflux for 2 h. Excess of thionyl chloride was evaporated
under reduced pressure and a few drops of benzene were added to form an azeotrope to
yield 3.50 g (93%) of 140 as a yellow oil; IR (Diamond, cm-1) 1788.50 (COCl).

2-(Adamantan-1-yl)-1-phenylethan-1-one (141). In a 3-neck flask, AlCl3 (2.50 g, 18.74
mmol) was added to a solution of 140 (3.50 g, 16.45 mmol) in anhydrous benzene (40 mL)
under an N2 atmosphere at room temperature, and the reaction mixture was heated at 50 °C
for 2 h. Reaction mixture was cooled to room temperature and quenched by the careful
addition of ice/H2O (15 mL), followed by CH2Cl2 (2 x 25 mL). The organic layer was
separated and washed with saturated NaHCO3 (2 x 20 mL), brine (2 x 10 mL), dried
(Na2SO4), and evaporated to dryness under reduced pressure to yield 3.70 g of the crude
residue which was purified by column chromatography (silica gel; hexane/EtOAc; 86:14)
to afford 1.20 g (29%) of 141 as a white solid: mp 70-71 °C (lit.246 mp 66-67 °C); 1H NMR
(CDCl3-d6) δ 1.70-1.62 (m, 12H, CH), 1.95 (s, 3H, CH), 2.72 (s, 2H, CH2), 7.47-7.43 (m,
2H, ArH), 7.56-7.52 (s, 1H, ArH), 7.95-7.93 (m, 2H, ArH).

2-(Adamantan-1-yl)-2-bromo-1-phenylethan-1-one (142). Bromine (0.04 mL, 0.78
mmol) was added in a dropwise manner to a stirred solution of 141 (0.71 g, 2.79 mmol)
and AlCl3 (0.02 g, 0.14 mmol) in anhydrous Et2O (10 mL) at 0 °C under an N2 atmosphere.
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The reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to
room temperature. When the color of the solution changed from orange to pale yellow the
remaining quantity of bromine (0.10 mL, 1.99 mmol) was added in a dropwise manner.
The reaction mixture was allowed to stir at room temperature for 30 min. The reaction
mixture was quenched with a saturated solution of NaHCO3 (pH=7). The organic portion
was separated, washed with brine (10 mL) and dried (Na2SO4). Solvent was removed
under reduced pressure and the residue was dried under high vacuum to afford 0.78 g
(84%) of 142 as a white solid: mp 81–83 °C; 1H NMR (CDCl3-d6) δ 1.71-1.65 (m, 9H,
CH), 2.00-1.95 (s, 6H, CH), 4.99 (s, 1H, CH), 7.46-7.50 (m, 2H, ArH), 7.61-7.57 (m, 1H,
ArH), 7.96 (dd, J = 8.6, 1.4 Hz, 2H, ArH).

1-(4-(tert-Butyl)phenyl)-2-(methylamino)propan-1-one

Hydrochloride

(143).

Methylamine (33% in EtOH, 1.34 mL, 10.82 mmol) was added to a stirred solution of 149
(1.45 g, 5.40 mmol) in anhydrous benzene (5 mL) in a sealed tube at 0-5 °C. Reaction
mixture was allowed to warm to room temperature and stirred at room temperature for 18
h. The residue was filtered and the filtrate was evaporated under reduced pressure. The
residue was dissolved in Et2O (20 mL) and the organic layer was washed with H2O (2 x 5
mL). The organic portions were combined and acidified with 1M HCl (30 mL, pH=1). The
aqueous portion was basified with 1M NaOH (40 mL, pH=14), and extracted with Et2O (5
x 5 mL). The combined organic portions were combined, dried (Na2SO4), and evaporated
to dryness under reduced pressure to yield 0.60 g of a crude yellow oil which was
converted to its hydrochloride salt (0.39 g) which upon recrystallization from i-PrOH/Et2O
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afforded 0.10 g (7%) of 143 as a white powder: mp 210-213 °C; 1H NMR (DMSO-d6) δ
1.24 (s, 9H, CH3), 1.38 (d, J = 7.1 Hz, 3H, CH3), 2.42 (d, J = 1.6 Hz, 1.7H, CH), 3.26 (s,
1.6H, CH), 5.06 (q, J = 14.2, 7 Hz, 1H, CH), 7.55 (d, J = 8.5 Hz, 2H, ArH), 7.91 (d, J =
8.5 Hz, 2H, ArH), 9.35 (br s, 2H, NH2+); Anal. Calcd for (C14H21N·) C, 65.74; H, 8.67; N,
5.48. Found: C, 65.46; H, 8.79; N, 5.33.

1-(4-Benzylphenyl)-2-(methylamino)propan-1-one Hydrochloride (144). Methylamine
(33% in EtOH, 0.68 mL, 5.47 mmol) was added to a stirred solution of 150 (0.83 g, 2.70
mmol) in anhydrous benzene (5 mL) in a sealed tube at 0-5 °C. Reaction mixture was
allowed to warm to room temperature and stirred at room temperature for 15 h and 45 °C
for 4 h. The residue was filtered and the filtrate was evaporated under reduced pressure.
The residue was dissolved in Et2O (20 mL) and the organic layer was washed with H2O (3
x 5 mL). The organic portions were combined and acidified with 1M HCl (20 mL, pH=1).
The aqueous portion was basified with 1M NaOH (35 mL, pH=14), and extracted with
Et2O (3 x 15 mL). The combined organic portions were washed with brine (2 x 10 mL),
dried (Na2SO4), and evaporated to dryness under reduced pressure to yield 0.15 g of a
crude yellow oil which was converted to its hydrochloride salt using a saturated solution of
HCl/Et2O and upon recrystallization from i-PrOH/Et2O afforded 0.50 g (7%) of 144 as a
white powder: mp 185-187 °C; 1H NMR (DMSO-d6) δ 1.43 (d, J = 7.2 Hz, 3H, CH3), 2.57
(s, 3H, CH3), 4.06 (s, 2H, CH2), 5.11 (q, J = 14.3, 7.1 Hz, 1H, CH), 7.32-7.22 (m, 5H,
ArH), 7.47 (d, J = 8.3 Hz, 2H, ArH), 7.99 (d, J = 8.3 Hz, 2H, ArH), 9.29 (br s, 2H, NH2+);
Anal. Calcd for (C17H19NO) C, 70.46; H, 6.96; N, 4.83. Found: C, 70.15; H, 6.86; N, 4.69.
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1-(4-(tert-Butyl)phenyl)propan-1-one (147). This compound is reported in the
literature286,287 and was synthesized according to the literature procedure.287 In a 3-neck
flask equipped with a CaCl2 guard-tube, propionyl chloride (3.25 mL, 37.25 mmol) was
added to a solution of t-butylbenzene (145) (5.00 g, 37.25 mmol) in anhydrous CH2Cl2 (5
mL) under an N2 atmosphere at room temperature. Reaction mixture was cooled to 0 °C
and AlCl3 (5.00 g, 37.25 mmol) was added slowly over a period of 10 minutes. Reaction
mixture was then stirred at room temperature for 5 h. Reaction mixture was poured into an
ice and conc. HCl mixture (10 mL) and stirred for 30 min. The organic layer was separated
and washed with brine (2 x 5 mL), dried (Na2SO4), and evaporated to dryness under
reduced pressure to yield 5.20 g of the crude product which was purified by column
chromatography (silica gel; Hexane/EtOAc; 90:10) and Kugelrohr distillation to afford
1.85 g (26%) of 147 as a colorless oil: bp (178 °C, 0.5 Torr) (lit.286 bp 162 °C, 5 Torr) 1H
NMR (CDCl3-d6) δ 1.24 (t, J = 4 Hz, 3H, CH3), 1.35 (s, 9H, CH3), 2.98 (q, 2H, J = 14.5,
7.3 Hz, CH2), 7.47 (dd, J = 6.8, 1.8 Hz, 2H, ArH), 7.91 (d, J = 8.5 Hz, 2H, ArH).

1-(4-Benzylphenyl)propan-1-one (148). In a 3-neck flask equipped with a CaCl2 guardtube, propionyl chloride (2.60 mL, 29.72 mmol) was added to a solution of
diphenylmethane (146) (5.00 g, 29.72 mmol) in anhydrous CH2Cl2 (5 mL) under an N2
atmosphere at room temperature. Reaction mixture was cooled to 0 °C and AlCl3 (4.00 g,
29.72 mmol) was added slowly over a period of 10 min. Reaction mixture was heated to
reflux for 2 h. Reaction mixture was poured into an ice and conc. HCl mixture (8 mL) and
stirred for 30 min. The organic layer was separated and the aqueous layer was washed with
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CH2Cl2 (3 x 10 mL). Organic fractions were combined and dried (Na2SO4), and evaporated
to dryness under reduced pressure to yield 6.30 g of the crude product which was purified
by column chromatography (silica gel; Hexane/EtOAc; 88:12) and Kugelrohr distillation
(210 °C, 0.7 Torr) to afford 2.80 g (42%) of 148 as a white solid: mp 42-43 °C (lit.288 mp
41.8-43.2 °C); 1H NMR (CDCl3-d6) δ 1.19 (t, J = 7.24 Hz, 3H, CH3), 2.95 (q, 2H, J = 14.5,
7.2 Hz, CH2), 4.01 (s, 2H, CH2), 7.24-7.16 (m, 3H, ArH), 7.32-7.26 (m, 4H, ArH), 7.87 (d,
J = 8.3 Hz, 2H, ArH).

2-Bromo-1-(4-(tert-butyl)phenyl)propan-1-one (149). Bromine (0.17 mL, 3.30 mmol)
was added in a dropwise manner to a stirred solution of 147 (1.85 g, 9.72 mmol) and AlCl3
(0.49 g, 0.05 mmol) in anhydrous Et2O (5 mL) at 0 °C under an N2 atmosphere. The
reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room
temperature. When the color of the solution changed from orange to pale yellow the
remaining quantity of bromine (0.33 mL, 6.42 mmol) was added in a dropwise manner.
The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture
was quenched with a saturated solution of NaHCO3 (30 mL). The organic portion was
separated, washed with brine (2 x 5 mL) and dried (Na2SO4). Solvent was removed under
reduced pressure and the residue was dried under high vacuum to afford 2.14 g of the
crude product which was purified by column chromatography (silica gel; hexane; 100) and
then by Kugelrohr distillation to afford 1.45 g (56%) of 149 as a yellow oil: bp 224 °C, 1
Torr; 1H NMR (CDCl3-d6) δ 1.35 (s, 9H, CH3), 1.90 (d, J = 6.6 Hz, 3H, CH3), 5.29 (q, J =
13.3, 6.6 Hz, 1H, CH), 7.50 (t, J = 1.8 Hz, 2H, ArH), 7.98 (dd, J = 6.8, 1.8 Hz, 2H, ArH).
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1-(4-Benzylphenyl)-2-bromopropan-1-one (150). Bromine (0.10 mL, 1.94 mmol) was
added in a dropwise manner to a stirred solution of 148 (1.45 g, 6.46 mmol) and AlCl3
(0.006 g, 0.05 mmol) in anhydrous Et2O (5 mL) at 0 °C under an N2 atmosphere. The
reaction mixture was allowed to stir at 0 °C for 10 min, and then allowed to warm to room
temperature. When the color of the solution changed from orange to pale yellow the
remaining quantity of bromine (0.23 mL, 4.46 mmol) was added in a dropwise manner.
The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture
was quenched with a saturated solution of NaHCO3 (50 mL). The organic portion was
separated, washed with brine (2 x 5 mL) and dried (Na2SO4). Solvent was removed under
reduced pressure and the residue was dried under high vacuum to afford 1.30 g of the
crude product which was purified by Kugelrohr distillation to afford 0.83 g (42%) of 150
as a yellow oil: bp 240 °C, 1 Torr; 1H NMR (CDCl3-d6) δ 1.89 (d, J = 6.6 Hz, 3H, CH3),
4.04 (s, 2H, CH2), 5.26 (q, J = 6.4, 13.3 Hz, 1H, CH), 7.32-7.16 (m, 6H, ArH), 7.95 (q, J =
8.3, 6.4 Hz, 3H, ArH).

1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)propan-1-one

Hydrochloride

(151).

This

compound is reported in the literature and was synthesized according to the literature
procedure.249 Pyrrolidine (2.78 mL, 33.24 mmol) was added to a stirred solution of 153
(4.04 g, 16.62 mmol) in anhydrous benzene (20 mL) at room temperature under an N2
atmosphere. The reaction mixture was allowed to stir at room temperature for 18 h. Et2O
(50 mL) was added and the organic layer was washed with H2O (2 x 10 mL). The organic
portions were combined and acidified with 1M HCl (50 mL, pH=1). The aqueous portion
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was basified with 1M NaOH (75 mL, pH=14), and extracted with Et2O (3 x 20 mL). The
combined organic portions were dried (Na2SO4), and evaporated to dryness under reduced
pressure to yield a crude yellow oil which was converted to its hydrochloride salt using a
saturated solution of HCl/Et2O and upon recrystallization from absolute EtOH/Et2O
afforded 0.66 g (15%) of 151 as a white powder: mp 206-207 °C (lit.249 mp 197-199 °C
with decomposition); 1H NMR (DMSO-d6) δ 1.49 (d, J = 7.1 Hz, 3H, CH3), 1.91-2.06 (m,
4H, CH2), 2.42 (s, 3H, OCH3), 3.04-3.21 (m, 4H, CH2), 5.42 (t, J = 7.1 Hz, 1H, CH), 7.44
(d, J = 7.8 Hz, 2H, ArH), 7.94 (d, J = 8.3 Hz, 2H, ArH), 10.58 (s, 1H, NH+).

2-Bromo-1-(4-methoxyphenyl)propan-1-one (153). This compound is reported in the
literature 289,290 and was synthesized according to the literature procedure except that AlCl3
was used.290 Bromine (0.10 mL, 1.94 mmol) was added in a dropwise manner to a stirred
solution of 4’-methoxypropiophenone (152) (5.00 g, 30.45 mmol) and AlCl3 (0.20 g, 1.52
mmol) in anhydrous Et2O (20 mL) at 0 °C under an N2 atmosphere. The reaction mixture
was allowed to stir at 0 °C for 10 min, and then allowed to warm to room temperature.
When the color of the solution changed from orange to pale yellow the remaining quantity
of bromine (1.50 mL, 28.32 mmol) was added in a dropwise manner. The reaction mixture
was allowed to stir at room temperature for 30 min. The reaction mixture was quenched
with a saturated solution of NaHCO3 (50 mL). The organic portion was separated, washed
again with saturated NaHCO3 (15 mL), brine (15 mL), water (15 mL) and dried (Na2SO4).
Solvent was removed under reduced pressure and the residue was dried under high vacuum
to afford 5.20 g of a cream-colored solid which was purified by recrystallization using
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absolute EtOH to afford 4.00 g (55%) of 153 as a white solid: mp 72-73 °C (lit.289 mp 6667 °C); 1H NMR (CDCl3-d6) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 2.43 (s, 3H, OCH3), 5.28 (q,
J = 13.3, 6.6 Hz, 1H, CH), 7.29 (d, J = 9.2 Hz, 2H, ArH), 7.93 (d, J = 8.3 Hz, 2H, ArH).

1-(1-Phenylpropan-2-yl)pyrrolidine Hydrochloride (154). The compound is reported in
literature and was synthesized according to the literature procedure.250 A solution of 155
(0.67 g, 5.39 mmol) in anhydrous Et2O (2 mL) was added in a dropwise manner with
stirring to a solution of benzylmagnesium chloride, and the reaction mixture was heated at
reflux for 1.5 h, cooled to room temperature and quenched by the careful addition of ice
(12 g) conc HCl (10 mL). The organic layer is separated and the aqueous portion was
basified with NaHCO3 (20 mL) and extracted with Et2O (3 x 15 mL). The combined
organic portion was dried (Na2SO4) and evaporated to dryness under reduced pressure to
yield 0.27 g of the free base which was converted into its hydrochloride salt using a
saturated solution of HCl/Et2O which upon recrystallization absolute EtOH/Et2O afforded
0.05 g (5%) of the product as white solid: mp 155-157 °C (lit.250 mp 151-152 °C); 1H
NMR (DMSO-d6) δ 1.07 (d, J = 7.2 Hz, 3H, CH3), 1.92 (s, 4H, CH2), 2.60 (t, J = 23.9,
12.8 Hz, 1H, CH), 3.19 (d, J = 13.2 Hz, 1H, CH), 3.29 (s, 3H, CH), 3.47 (d, J = 6.7, 5.8
Hz, 1H, CH), 7.24 (t, J = 13.6, 7.5 Hz, 3H, ArH), 7.31 (d, J = 7.2 Hz, 2H, ArH), 10.97 (s,
1H, NH+, D2O ex).
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2-(pyrrolidin-1-yl)propanenitrile (155). The compound is reported in the literature250,291
and was synthetized according to the literature procedure.250,291 Pyrrolidine (1.42 g, 20.00
mmol) was acidified by 2M HCl; this was added to a solution of KCN (1.30 g, 20.00
mmol) in H2O (10 mL). This mixture was added in a dropwise manner at 0 °C to a stirred
solution of acetaldehyde (0.88 g, 20.00 mmol) in anhydrous Et2O (10 mL) under an N2
atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h. The
organic portion was separated, washed with brine (2 x 5 mL) and H2O (2 x 5 mL), dried
(Na2SO4) and evaporated to dryness under reduced pressure to yield a crude yellowcolored liquid (0.90 g), which was purified by Kugelrohr distillation to afford 0.670 g
(73%) of the product as a colorless liquid: bp 40 °C, 0.5 Torr (lit.250 bp 78-80°C, 10 Torr);
1

H NMR (CDCl3-d6) δ 1.48 (d, J = 7.2 Hz, 3H, CH3), 1.84 (s, 4H, CH2), 2.62-2.74 (m, 4H,

CH2), 3.87 (q, J = 7.2, 14.4 Hz, 1H, CH).

2-Methylamino-1-phenylethan-1-one Hydrochloride (156). AlCl3 (2.74 g, 20.54 mmol)
was added in a portionwise manner to a stirred solution of 160 (3.70 g, 18.17 mmol) in
anhydrous benzene (40 mL) under an N2 atmosphere. The stirred reaction mixture was
heated at reflux for 4 h, allowed to cool to room temperature, quenched by addition of
conc. HCl (12 mL) and ice (10 g). The organic layer was separated, washed with saturated
NaHCO3 (3 x 15 mL) and brine (2 x 10 mL), dried (Na2SO4), and evaporated under
reduced pressure to yield 0.80 g (18%) of the intermediate as brownish-orange oil. This
intermediate was then dissolved in conc. HCl (50 mL) and i-PrOH (75 mL) and stirred at
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40 °C for 48 h. The solvent was evaporated to yield 0.50 g of residue, which was
recrystallized twice from absolute EtOH to yield 0.08 g (19%) of 156 as white crystals: mp
205-207 °C (lit.142 mp 219 °C, EtOH); 1H NMR (DMSO-d6) δ 2.63 (s, 3H, CH3), 4.75 (s,
2H, CH2), 7.61 (t, J = 7.7 Hz, 2H, ArH), 7.75 (t, J = 7.8 Hz, 1H, ArH), 7.99 (t, J = 7.2 Hz,
2H, ArH), 9.32 (s, 2H, NH2+); Anal. Calcd for (C9H11N·HCl) C, 58.23; H, 6.51; N, 7.54.
Found: C, 57.96; H, 6.57; N, 7.40.

N-Trifluoroacetyl sarcosine (159). This compound is reported in the literature

292,293

and

was synthesized according to the literature procedure.292 Trifluroacetic anhydride (8.60
mL, 61.78 mmol) was added in a dropwise manner at 0 °C to a stirred suspension of
sarcosine (158) (5.00 g, 56.16 mmol) in anhydrous CH2Cl2 (14 mL) under an N2
atmosphere. The reaction mixture was allowed to stir at room temperature for 2 h. The
solvent was evaporated under reduced pressure to yield 10.38 g (87%) of 159 as a viscous
yellow oil, which solidifies upon cooling: mp 55-58 °C (lit.293 mp 54.5-55.5 °C); IR
(Diamond, cm-1) 1662 (CONH), 1778 (CO), 3000 (OH). Compound was used without
further purification.

N-Trifluoroacetyl sarcosinyl chloride (160). Oxalyl chloride (2.10 mL, 23.76 mmol) was
added in a dropwise manner over 5 min to a stirred solution of 159 (4.00 g, 21.60 mmol)
and pyridine (3 drops) in anhydrous benzene (22 mL) under an N2 atmosphere. The stirred
reaction mixture was heated at reflux for 1 h, allowed to cooled to room temperature and
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solvents were removed reduced pressure to yield 4.17 g (95%) of the 160 as a browncolored liquid; IR (Diamond, cm-1) 1682 (CONH), 1788 (COCl).
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